WO2007022980A1 - Use of azabicyclo hexane derivatives - Google Patents

Use of azabicyclo hexane derivatives Download PDF

Info

Publication number
WO2007022980A1
WO2007022980A1 PCT/EP2006/008314 EP2006008314W WO2007022980A1 WO 2007022980 A1 WO2007022980 A1 WO 2007022980A1 EP 2006008314 W EP2006008314 W EP 2006008314W WO 2007022980 A1 WO2007022980 A1 WO 2007022980A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
azabicyclo
phenyl
thio
triazol
Prior art date
Application number
PCT/EP2006/008314
Other languages
French (fr)
Inventor
Dieter Hamprecht
Christian Heidbreder
Sergio Melotto
Fabrizio Micheli
Tadataka Yamada
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2008527394A priority Critical patent/JP5166267B2/en
Priority to CN2006800389371A priority patent/CN101291669B/en
Priority to EA200800655A priority patent/EA016084B1/en
Priority to BRPI0614929-4A priority patent/BRPI0614929A2/en
Priority to DE602006020589T priority patent/DE602006020589D1/en
Priority to EP06777058A priority patent/EP1917013B1/en
Priority to MX2008002564A priority patent/MX2008002564A/en
Priority to AT06777058T priority patent/ATE500826T1/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to CA002620090A priority patent/CA2620090A1/en
Priority to AU2006284077A priority patent/AU2006284077B2/en
Priority to US12/064,119 priority patent/US20090036461A1/en
Priority to KR1020087006993A priority patent/KR101363090B1/en
Publication of WO2007022980A1 publication Critical patent/WO2007022980A1/en
Priority to PE2007001117A priority patent/PE20080609A1/en
Priority to US11/841,015 priority patent/US20080058398A1/en
Priority to EA200970211A priority patent/EA017917B1/en
Priority to CL200702422A priority patent/CL2007002422A1/en
Priority to TW096130644A priority patent/TW200825074A/en
Priority to EP07788490A priority patent/EP2054054A1/en
Priority to PCT/EP2007/058636 priority patent/WO2008022994A1/en
Priority to KR1020097003484A priority patent/KR101495362B1/en
Priority to CA002661437A priority patent/CA2661437A1/en
Priority to MX2009001941A priority patent/MX2009001941A/en
Priority to AU2007287527A priority patent/AU2007287527B2/en
Priority to CN2007800392082A priority patent/CN101528221B/en
Priority to BRPI0716454-8A2A priority patent/BRPI0716454A2/en
Priority to ARP070103715A priority patent/AR062471A1/en
Priority to ZA2008/01352A priority patent/ZA200801352B/en
Priority to IL189435A priority patent/IL189435A0/en
Priority to NO20081314A priority patent/NO20081314L/en
Priority to ZA2009/00886A priority patent/ZA200900886B/en
Priority to IL196976A priority patent/IL196976A0/en
Priority to CO09017330A priority patent/CO6150139A2/en
Priority to NO20090834A priority patent/NO20090834L/en
Priority to CR10638A priority patent/CR10638A/en
Priority to MA31673A priority patent/MA30672B1/en
Priority to US13/432,359 priority patent/US20120196910A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention provides a new use of a D3 antagonist of formula (I), as disclosed in the International Patent Application WO 2005/08032, in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome
  • a somatoform disorder such as body dysmorph
  • the DSM-IV sets forth two indicia of compulsion.
  • the person has repetitive behaviors or mental acts that the person feels driven to perform in response to an obsession or according to rules that must be applied rigidly. Repetitive behaviors include hand washing, ordering and checking, while mental acts include voting, counting and repeating words silently.
  • the behaviors or mental acts are aimed at preventing some dreaded event or situation; however, these behaviors or mental acts either are not connected in a realistic way to what they are designed to neutralize or prevent, or are clearly excessive.
  • Y-BOCS Yale-Brown Obsessive-Compulsive Scale
  • Obsessive-compulsive spectrum disorders include somatoform disorders including body dysmorphic disorder and hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, and movement disorders, including Tourette's syndrome.
  • Somatoform disorders include body dysmorphic disorder (BDD) and hyperchondriasis.
  • Body dysmorphic disorder (BDD) is a preoccupation with an imagined slight defect in appearance that causes significant distress or impairment in functioning.
  • Individuals suffering from BDD have preoccupations similar to OCD obsessions in that they have repetitive intrusive thoughts, often perform time-consuming, repetitive and sometimes ritualistic behaviours.
  • Hypochondriasis is a preoccupation with the fear of having, or the idea that one has, a serious disease based on the person's misinterpretation of bodily signs or symptoms.
  • Hypochondriacal preoccupations resemble OCD obsessions in that they are often experienced as intrusive and persistent, and the individuals often display repetitive checking behaviours.
  • the DSM-IV defines anorexia nervosa as a refusal to maintain a minimally normal body weight; intensive fear of gaining weight or becoming fat even though underweight; significant disturbance in perception of body shape or size; and, in females, amenorrhea.
  • the DSM- IV defines bulimia nervosa as recurrent episodes of binge eating followed by inappropriate compensatory behaviours designed to prevent a weight gain.
  • BED is characterized by recurrent episodes of binge eating in the absence of regular use of inappropriate compensatory behaviours.
  • all three disorders are characterized by a core preoccupation with food and body weight. Individuals suffering from these disorders often perform specific rituals, and have an abnormal preoccupation with food and weight.
  • NPSAs nonparaphilic sexual addictions
  • Tourette's syndrome is a chronic neuropsychiatric disorder characterized by motor tics and one or more vocal tics beginning before the age of 18 years.
  • the DSM-IV defines a tic as a sudden, rapid, recurrent, nonrhythmic, stereotyped motor movement or vocalization.
  • Tourette's syndrome patients may be able to suppress tics for varying lengths of time, but eventually experience them as irresistible and perform them.
  • Tourette's patients exhibit obsessions resembling OCD obsessions, for example, they often feel the need to perform tics until they are felt to be "just right.”
  • Autism is characterized by difficulties with social interaction, speech and communication, and by a compulsive core. Autistic individuals often display compulsive, repetitive behaviors.
  • the present invention provides a new use of a D3 antagonist in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervo
  • a D3 antagonist for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
  • this invention provides a method of treating a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; or premature ejaculation, comprising administering to a mammal in need thereof an effective amount of a D3 antagonist.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; or premature ejaculation
  • the present invention provides a new use of a D3 antagonist in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervo
  • a D3 antagonist for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
  • this invention provides a method of treating a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and a method of treating premature ejaculation, comprising administering to a mammal in need thereof an effective amount of a D3 antagonist.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome.
  • Treatment includes prophylaxis, where this is appropriate for the relevant condition(s).
  • the present invention provides a new use of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof:
  • G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R 1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloCi. 4 alkyl, C 1 ⁇ aIkOXy, haloC ⁇ alkoxy, C ⁇ alkanoyl; or corresponds to a group R 5 ; R 2 is hydrogen or C 1-4 alkyl;
  • R 3 is C 1-4 alkyl
  • R 4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl;
  • R 5 is a moiety selected from the group consisting of: isoxazolyl, -CH 2 -N- pyrrolyl, 1 ,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2- pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, d ⁇ alkyl, haloC 1-4 alkyl, C 1- 4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R 1 corresponds to R 5 , p is 1 ; in the manufacture of a medicament for the treatment of of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervo
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above or premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I) as herein defined or a salt thereof.
  • a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
  • the somatoform disorder is binge eating.
  • Treatment includes prophylaxis, where this is appropriate for the relevant condition(s).
  • G 1 p, R 1 , R 2 , R 3 , R 4 , and R 5 are defined as above for compounds of formula (I), in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above; and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I)' as herein defined or a salt thereof.
  • the somatoform disorder is binge eating.
  • G, p, R 1 , R 2 , R 3 , R 4 , and R 5 are defined as above for compounds of formula (I)' or a salt thereof, in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IA) as herein defined or a salt thereof.
  • the somatoform disorder is binge eating.
  • stereochemical isomers enriched in configuration (1 S.5R) or (1 R.5R) of formula (IA) correspond in one embodiment to at least 90% e.e. In another embodiment the isomers correspond to at least 95% e.e. In another embodiment the isomers correspond to at least 99% e.e.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions,
  • a still further aspect of the invention provides a method of treating a somatoform disoder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound from the list cited above or a salt thereof.
  • a mammal e.g. human
  • the somatoform disorder is binge eating.
  • 5- or 6-membered heteroaromatic group refers to a monocyclic 5- or 6- membered heterocyclic group containing 1 , 2, 3 or 4 heteroatoms, for example from 1 to 3 heteroatoms, selected from O, N and S. When the group contains 2-4 heteroatoms, one may be selected from O, N and S and the remaining heteroatoms may be N.
  • Examples of 5 and 6-membered heteroaromatic groups include pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, furyl, thienyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
  • d ⁇ alkyl refers to an alkyl group having from one to four carbon atoms, in all isomeric forms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert- butyl.
  • n-C 1-4 alkyl refers to the unbranched alkyls as defined above.
  • C 1 ⁇ aIkOXy refers to a straight chain or branched chain alkoxy (or “alkyloxy”) group having from one to four carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.
  • halogen and its abbreviation “halo” refer to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). Where the term “halo” is used before another group, it indicates that the group is substituted by one, two or three halogen atoms.
  • haloC 1-4 alkyl refers to groups such as trifluoromethyl, bromoethyl, trifluoropropyl, and other groups derived from refers to groups such as trifluoromethoxy, bromoethoxy, trifluoropropoxy, and other groups derived from C 1-4 alkoxy groups as defined above.
  • 8- to 11 -membered bicyclic group refers to a bicyclic ring system containing a total of 8, 9, 10 or 11 carbon atoms, wherein 1 , 2, 3 or 4 or 5 of the carbon atoms are optionally replaced by a heteroatom independently selected from O, S and N.
  • the term includes bicyclic systems wherein both rings are aromatic, as well as bicyclic ring systems wherein one of the rings is partially or fully saturated. Examples of 8- to 1 1- membered bicyclic groups wherein both rings are aromatic include indenyl, naphthyl and azulenyl.
  • Examples of 8- to 11-membered bicyclic groups having 1 , 2, 3, 4 or 5 heteroatoms, in which both rings are aromatic include: 6H-thieno[2,3-b]pyrrolyl, imidazo[2,1- b][1 ,3]thiazolyl, imidazo[5,1-b][1 ,3]thiazolyl, [1 ,3]thiazolo[3,2-b][1 ,2,4]triazolyl, indolyl, isoindolyl, indazolyl, benzimidazolyl e.g. benzimidazol-2-yl, benzoxazolyl e.g.
  • benzoxazol- 2-yl benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzothienyl, benzofuranyl, naphthridinyl, quinolyl, quinoxalinyl, quinazolinyl, cinnolinyl and isoquinolyl.
  • Examples of 8- to 11 -membered bicyclic groups having 1 , 2, 3 , 4 or 5 heteroatoms, in which one of the rings is partially or fully saturated includes dihydrobenzofuranyl, indanyl, tetrahydronaphthyl, indolinyi, isoindolinyl, tetrahydroisoquinolinyl, tetrahydroquinolyl, benzoxazinyl and benzoazepinyl.
  • heterocyclyl refers to a 5 or 6-membered monocyclic or 8 to 1 1 -membered bicyclic group wherein 1 , 2, 3, 4 or 5 of the carbon atoms are replaced by a heteroatom independently selected from O, S and N and which is partially or fully saturated.
  • heterocyclyl which are fully saturated 5 or 6-membered monocyclic rings include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, isothiazolyl, thiazolyl, tetrahydrofuranyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl, dioxanyl, tetrahydro-2H-pyranyl and dithianyl.
  • heterocyclyl groups which are partially saturated 5 or 6-membered monocyclic rings include oxazolinyl, isoaxazolinyl, imidazolinyl, pyrazolinyl, 1 ,2,3,6-tetrahydropyridyl and 3,6-dihydro-2H-pyranyl.
  • heterocyclyl groups which are fully saturated 8 to 11 -membered bicyclic rings include decahydroquinolinyl, octahydro-2H-1 ,4-benzoxazinyl and octahydro-IH-cyclopenta- [6]pyridinyl.
  • heterocyclyl groups which are partially saturated 8 to 11- membered bicyclic rings include 2,3-dihydro-1 H-indolyl, 1 ,2,3,4-tetrahydroquinolinyl, 1 ,2,3,4-tetrahydroisoquinolinyl and 2,3,4, 5-tetrahydro-1 H-3-benzazepinyl.
  • Any of these groups may be attached to the rest of the molecule at any suitable position.
  • salt refers to any salt of a compound according to the present invention prepared from an inorganic or organic acid or base, quaternary ammonium salts and internally formed salts.
  • Physiologically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent compounds. Such salts must clearly have a physiologically acceptable anion or cation.
  • physiologically acceptable salts of the compounds of the present invention include acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic and arylsulfonic, for example benzenesul, in
  • R 1 is halogen, cyano, acetyl, trifluoromethyl, trifluoromethoxy.
  • R 2 is hydrogen. In another embodiment, R 2 is C 1-4 alkyl (e.g. methyl).
  • R 5 is a group selected from: isoxazolyl, 2-pyrrolidinonyl, 1 ,1-dioxido- 2-isothiazolidinyl which is optionally substituted by one or two substituents selected from: halogen, cyano, C 1-2 alkyl (e.g. methyl), haloC ⁇ alkyl (e.g. trifluoromethyl), C 1-2 alkoxy (e.g. methoxy), C 1-3 alkanoyl (e.g. acetyl).
  • R 1 is bromo, fluoro, trifluoromethoxy, cyano, hydroxy, chloro, methoxy, tert-butyl, trifluoromethyl.
  • R 5 is isoxazolyl, 2-pyrrolidinonyl, -CH 2 -N-pyrrolyl, 1 ,1-dioxido-2-isothiazolidinyl, 2-thienyl, 2-pyridyl, 2-thiazolyl.
  • p is 1 or 2.
  • R 4 may be optionally substituted phenyl (e.g. phenyl, 4- trifluoromethyl-phenyl, 3,4-difluorophenyl), an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline, 8-fluoro-2-methylquinoline), an optionally substituted pyranyl (e.g. 4-tetrahydro-2H-pyranyl), an optionally substituted pyridinyl (e.g. 3-methyl-2- pyridinyl, 2-methyl-3-pyridinyl, 3-pyridinyl, 2-methyl-6-trifluoromethyl-3-pyridinyl), an optionally substituted pyrazolyl (e.g.
  • phenyl e.g. phenyl, 4- trifluoromethyl-phenyl, 3,4-difluorophenyl
  • an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline, 8-flu
  • pyrimidyl e.g. 5-pyrimidinyl
  • an optionally substituted pyridazinyl e.g. 4-pyridazinyl
  • an optionally substituted pyrazinyl e.g. 5-methyl-2-pyrazinyl
  • oxazolyl e.g. 4-methyl-1 ,3-oxazol-5-yl
  • 2-methyl-5-trifluoromethyl-1 ,3-oxazol-4-yl 2-methyl-5-trifluoromethyl-1 ,3-oxazol-4-yl
  • an optionally substituted isoxazolyl e.g. 3- methyl-5-isoxazolyl
  • an optionally substituted thiazolyl e.g. 2,4-dimethyl-1 ,3-thiazol-5-yl
  • an optionally substituted triazolyl e.g. 1 -methyl-1 H-1 ,2,3-triazol-4-yl.
  • R 3 is methyl
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IB) as herein defined or a salt thereof.
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C ⁇ alkanoyl; and when R 1 is chlorine and p is 1 , such Ri is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • R 4 examples include an optionally substituted phenyl (e.g. phenyl, 4-trifluoromethyl- phenyl, 3,4-difluorophenyl), an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline, 8-fluoro-2-methylquinoline), an optionally substituted pyranyl (e.g. 4- tetrahydro-2H-pyranyl), an optionally substituted pyridinyl (e.g. 3-methyl-2-pyridinyl, 2- methyl-3-pyridinyl, 3-pyridinyl, 2-methyl-6-trifluoromethyl-3-pyridinyl), an optionally substituted pyrazolyl (e.g.
  • phenyl e.g. phenyl, 4-trifluoromethyl- phenyl, 3,4-difluorophenyl
  • an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IC) as herein defined or a salt thereof.
  • a mammal e.g. human
  • IC formula
  • a compound of formula (IC) or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C 1-4 alkyl, fluoroC 1-4 alkyl, C 1-4 alkoxy, fluoroC 1-4 alkoxy, and when Ri is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • Examples of R 4 include those defined previously for compounds (IB).
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (ID) as herein defined or a salt thereof.
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C 1-4 alkyl, fluoroC 1-4 alkyl, d -4 alkoxy, fluoroC 1-4 alkoxy, C 1-4 alkanoyl; and when Ri is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • Examples of R 4 include those defined previously for compounds (IB).
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IE) as herein defined or a salt thereof. Also provided is a compound of formula (IE) or a salt thereof for use in the treatment of a somatoform disorder and premature ejaculation.
  • a mammal e.g. human
  • G corresponds to 2-pyridyl (Compounds (IEi)) and in another embodiment to 3-pyridyl (Compounds (IE 2 )), as illustrated below:
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C 1-4 alkyl, fluoroC 1-4 alkyl, C 1- 4 alkoxy, fluoroC ⁇ alkoxy, C 1-4 alkanoyl; and when Ri is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • R 4 examples include those defined previously for compounds (IB).
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IF) as herein defined or a salt thereof.
  • a mammal e.g. human
  • an effective amount of a compound of formula (IF) as herein defined or a salt thereof comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IF) as herein defined or a salt thereof.
  • a compound of formula (IF) or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C ⁇ alkyl, fluoroC ⁇ alkyl, C 1-4 alkoxy, fluoroC ⁇ alkoxy, C ⁇ alkanoyl; and when Ri is chlorine and p is 1 , such Ri is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • R 4 examples include those defined previously for compounds (IB).
  • Compounds of formula (IE)' correspond to the stereochemical isomers of compounds of formula (IE) as above defined, enriched in configuration (1 R, 5R) or (1 R, 5S) depending on the presence of a 2-pyridine ring.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IB)' as herein defined or a salt thereof.
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 1 1-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, d ⁇ alkyl, fluoroC ⁇ alkyl, C 1-4 alkoxy, fluoroC 1-4 alkoxy, C 1 . 4 alkanoyl; and when Ri is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • R 4 examples include optionally substituted phenyl (e.g. phenyl, 4-trifluoromethyl-phenyl, 3,4-difluorophenyl), an optionally substituted bicyclic group such as quinolinyl (e.g. 2- methylquinoline, 8-fluoro-2-methylquinoline), an optionally substituted pyranyl (e.g. 4- tetrahydro-2H-pyranyl), an optionally substituted pyridinyl (e.g. 3-methyl-2-pyridinyl, 2- methyl-3-pyridinyl, 3-pyridinyl, 2-methyl-6-trifluoromethyl-3-pyridinyl), an optionally substituted pyrazolyl (e.g.
  • phenyl e.g. phenyl, 4-trifluoromethyl-phenyl, 3,4-difluorophenyl
  • an optionally substituted bicyclic group such as quinolinyl (e.g. 2- methylquinoline,
  • 5-chloro-2- thienyl an optionally substituted oxazolyl (e.g. 4-methyl-1 ,3-oxazol-5-yl, 2-methyl-5- trifluoromethyl-1 ,3-oxazol-4-yl), an optionally substituted isoxazolyl (e.g. 3-methyl-5- isoxazolyl), an optionally substituted thiazolyl (e.g. 2,4-dimethyl-1 ,3-thiazol-5-yl), an optionally substituted triazolyl (e.g. 1-methyl-1 H-1 ,2,3-triazol-4-yl).
  • oxazolyl e.g. 4-methyl-1 ,3-oxazol-5-yl, 2-methyl-5- trifluoromethyl-1 ,3-oxazol-4-yl
  • isoxazolyl e.g. 3-methyl-5- isoxazolyl
  • an optionally substituted thiazolyl e.g. 2,4-d
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IC)' as herein defined or a salt thereof.
  • a compound of formula (IC)' or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 1 1-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, d ⁇ alkyl, fluoroC ⁇ alkyl, d. 4 alkoxy, fluoroC ⁇ alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • R 4 include those defined previously for compounds (IB)'.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (ID)' as herein defined or a salt thereof.
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C ⁇ alkyl, fluoroC 1-4 alkyl, Ci -4 alkoxy, fluoroC 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • Examples of R 4 include those defined previously for compounds (IB)'.
  • a new use of a stereochemical isomer enriched in the (1 S,5R) configuration or (1 R.5R) configuration of formula (IE)' or a salt thereof is provided, wherein G is 2-pyridyl or 3-pyridyl and R 1 , p, R 3 and R 4 are as defined for formula (I):
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IE)' as herein defined or a salt thereof.
  • a mammal e.g. human
  • IE formula
  • IE formula (IE)' or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
  • G corresponds to 2-pyridyl (Compounds (IE 1 )') and in another embodiment to 3-pyridyl (Compounds (IE 2 )'), as illustrated below:
  • the configuration will then change depending on the type of pyridine ring, as mentioned above.
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, d ⁇ alkyl, fluoroC 1-4 alkyl, C 1 .
  • R 4 alkoxy, fluoroC 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such Ri is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • R 4 include those defined previously for compounds (IB)'.
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IF)' as herein defined or a salt thereof.
  • a mammal e.g. human
  • an effective amount of a compound of formula (IF)' as herein defined or a salt thereof.
  • R 3 is methyl.
  • R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 1 1-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C ⁇ alkyl, fluoroC ⁇ alkyl, C 1-4 alkoxy, fluoroC 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
  • R 4 include those defined previously for compounds (IB)'.
  • Certain of the compounds of the invention may be used as acid addition salts with less than one, or one or more equivalents of the acid.
  • the present invention includes within its scope the use of all possible stoichiometric and non-stoichiometric forms.
  • Salts may also be prepared from other salts of the compound of formula (I) using conventional methods.
  • formulations used in the invention are applied in pharmaceutically acceptable amounts and in pharmaceutically acceptable compositions.
  • Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic ingredients.
  • an effective amount means that amount necessary to delay the onset of, inhibit the progression of, halt altogether the onset or progression of or diagnose the particular condition being treated.
  • an effective amount for treating an obsessive compulsive spectrum disorder will be that amount necessary to inhibit mammalian symptoms of the particular obsessive compulsive spectrum disorder in-situ.
  • effective amounts will depend, of course, on the particular condition being treated; the severity of the condition; individual patient parameters including age, physical condition, size and weight; concurrent treatment; frequency of treatment; and the mode of administration. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
  • a minimum dose be used, that is, the lowest safe dosage that provides appropriate relief of symptoms. Dosage may be adjusted appropriately to achieve desired drug levels, locally or systemically.
  • a variety of administration routes are available. The particular mode selected will depend of course, upon the particular drug selected, the severity of the disease state(s) being treated and the dosage required for therapeutic efficacy.
  • the methods of this invention may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects.
  • modes of administration include oral, rectal, sublingual, topical, nasal, transdermal or parenteral routes.
  • parenteral includes subcutaneous, intravenous, intramuscular, or infusion. Intravenous routes are preferred.
  • compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
  • compositions suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active compound.
  • Other compositions include suspensions in aqueous liquors or nonaqueous liquids such as a syrup, an elixir, or an emulsion.
  • Other delivery systems can include time- release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the active compounds of the invention, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art.
  • the present invention provides a new use of a compound of formula (I) selected from the following group consisting of:
  • a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I) selected from the list of compounds above or a salt thereof. Also provided is a compound of formula (I) selected from the list of compounds above cited or a salt thereof for use in the treatment of a somatorm disorder as defined above and premature ejaculation.
  • Sydeham's chorea torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculationin a mammal.
  • a still further aspect of the invention provides a method of treating of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions,
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions,
  • Sydeham's chorea torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I) selected from the list of compounds above and salts thereof.
  • a compound of formula (I) selected from the list of compounds above, and salts thereof, for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation.
  • a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation.
  • a somatoform disorder is binge eating.
  • VCD Experimental vibrational circular dichroism
  • NBS N-bromosuccinimide
  • Vitride "Red-AI®”
  • HOBt 1-hydroxybenzotriazole
  • EtOAc ethyl acetate
  • Et 2 O dietyl ether
  • DMF N,N'-dimethylformamide
  • MeOH methanol
  • TFA trifluoroacetic acid
  • tetrahydrofuran tetrahydrofuran
  • IPA isopropanol
  • TEA triethylamine
  • DCC 1 ,3- dicyclohexylcarbodiimide
  • SCX strong cation exchanger
  • TIc refers to thin layer chromatography on silica plates
  • dried refers to a solution dried over anhydrous sodium sulphate
  • r.t. (RT) refers to room temperature
  • Rt retention time
  • DMSO dimethyl sulfoxide.
  • Triflouroacetic anhydride (0.21 mL) was added to a solution of 4-[3-azabicyclo[3.1.0]hex- 1-yl]benzonitrile (280 mg, prepared in analogy to the method described in Preparation 5), and triethylamine (0.25 mL) in dichloromethane (15 mL) at O 0 C.
  • the reaction mixture was allowed to warm to room temperature over 2h, then washed with saturated NaHCO 3 , the organic layer dried and evaporated to give 269 mg of the title compound.
  • Ethyl-2-chloroacetoacetate (1 wt; 1 eq., 1000 g) was aged with formamide (0.68 vol; ca. 2.8 eq.) and the resulting solution was heated to 120 0 C. After 5 hours the mixture was allowed to cool to room temperature and allowed to age under nitrogen over night. The mixture was treated with NaOH (3 M, 6 vol, reaction moderately exothermic) and stirred at room temperature for 4 hours. Ethyl acetate (6 vol) was added and the phases allowed to separae. The organic layer was discarded while the aqueous was acidified with cone. (32%) aqueous HCI to pH 2 (ca. 2.0 vol). A precipitate started to form.
  • the cake was suspended in 1 M aqueous NaOH (13 vol) and heated to 70 0 C for 30 min. After this time, the mixture was cooled to 25 ⁇ 2 0 C and a solid was removed by filtration. The cake was washed with 1 M aqueous NaOH (10 vol). The combined mother liquors were cooled to 0 0 C and acidified to ca. pH 5 with HCI (aqueous, 16%; NOTE: keep temperature while adding HCI below +10 0 C). The suspended product was isolated by filtration washing with water (2x3 vol).
  • Milled sodium hydroxide (40 g) was added in small portions to a stirred solution of trimethylsulfoxonium iodide (219 g) in DMSO (anhydrous, 2 I). The resulting mixture was allowed to stir at room temperature for 1.5 h.
  • the configuration of the title compound was assigned by comparing its experimental VCD spectrum and observed specific rotation to the data observed for (1 S,5R)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane (see Preparation 48) as the reference sample.
  • the assignment of the absolute configuration of the title compound was confirmed by a single crystal X-ray structure obtained from a crystal of (1 S,5R)-1-[4- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane, (S)-(+)-mandelic acid salt.
  • UV wavelengh range 200-400 nm Analysis time 25 min ret. time (min) % a/a
  • the title compound was prepared in 160 mg yield from commercially available methyl 4-fluorophenylacetate (1 g, 6 mmol) following the methods described in preparations 1 , 2, 3, 4, 6.
  • the title compound was prepared in 1.25g yield from commercially available methyl 3-chlorophenylacetate (5 g, 27 mmol) following the methods described in preparations 1 , 2, 3, 4, 5.
  • the title compound was prepared in 1.2 g yield from commercially available methyl 3-methoxyphenylacetate (5 g, 27.7 mmol) following the methods described in preparations 1 , 2, 3, 4, 5.
  • the absolute configuration of the optical isomers was assigned as described for Preparation 18.
  • the assignment of the absolute configuration of the title compound was confirmed by a single crystal X-ray structure obtained from a crystal of (1 S,5f?)-1-(4-bromophenyl)-3- azabicyclo[3.1.0]hexane, (S)-(+)-O-acetyl mandelic acid salt.
  • Both, analysis based on the known configuration of the (S)(+)-acetyl mandelic acid and on the basis of anomalous dispersion effects confirmed the assignment of the title compound as being (1 S,5R)-1-(4- bromophenyl)-3-azabicyclo[3.1.Ojhexane.
  • UV wavelength 285 nm, band width 130 nm
  • a DMSO (140 mL) solution of this crude product was added dropwise to a preformed solution of trimethylsulfoxonium iodide (2 eq with respect to component A plus 2 eq with respect to component B) in anhydrous DMSO (412 mL) to which NaH (3 eq with respect to component A plus 2 eq with respect to component B) had been added portionwise.
  • the reaction mixture was stirred for 30 min and AcOH (2 eq) was added followed by water.
  • the reaction mixture was extracted with Et 2 O and then with EtOAc, the combined organic layers were washed with saturated aqueous NaCI and dried over Na 2 SO 4 .
  • the solution was filtered and the filtrate was concentrated in vacuo.
  • the crude product obtained was triturated with water and then with cyclohexanes to give the title compound as light brown solid (5.98 g).
  • This material was recrystallised 2 times from CH 3 CN (25 mL per g solid) to give 1.57 g of a white solid. This material was then suspended in sodium hydroxide (1 M solution, 1.1 eq) and dichloromethane (100 ml_) and allowed to stir at room temperature until complete dissolution. After separation of the two phases, the aqueous layer was extracted again with dichloromethane. The combined organic layers were washed with sodium hydroxide and then dried over Na 2 SO 4 . Evaporation of solvent in vacuo gave the title compound (874 mg) as colorless liquid.
  • the title compound was separated to give the separated enantiomers by preparative chromatography using a chiral column chiralcel AD 10 um, 250 x 21 mm, eluent A: n- hexane; B: isopropanol + 0.1 % isopropyl amine, gradient isocratic 2% B, flow rate 7 mL/min, detection UV at 200-400 nm.
  • Retention times given were obtained using an analytical HPLC using a chiral column chiralcel AD 5 um, 250 x 4.6 mm, eluent A: n- hexane; B: isopropanol +0.1% Isopropyl amine, gradient isocratic 2% B, flow rate 1.2 mL/min, detection UV at 200-400 nm.
  • Diisopinocampheylborane was prepared following the procedure reported in J. Org. Chem. 1984, 49, 945-947.
  • 2-[(1Z)-3-Chloro-1-(chloromethyl)-1-propen-1-yl]-4,4,5,5- tetramethyl-1 ,3,2-dioxaborolane (previously described in Tetrahedron Lett. 1993, 34, 4827-4828) was prepared following the general procedure reported in Tetrahedron Lett. 1989, 30, 2929, using 1 ,4-dichloro-2-butyne. The material thus obtained was further converted following the procedure reported in Synlett 2002, 5, 829-831.
  • the title compound was prepared in 480 mg yield (84%) as a colorless oil from 5- [(I R.SS/I S. ⁇ RS ⁇ S-azabicyclotS.I .Olhex-i-yl ⁇ -methyl-I .S-benzothiazole (374 mg) in analogy to the method described in Preparation 40.
  • the reaction mixture was heated at 80 0 C for 4 h and the solvent evaporated under vacuum.
  • the crude product was treated with diethyl ether and saturated aqueous ammonium chloride solution, the organic phase was washed with brine, dried over sodium sulphate and concentrated under vacuum.
  • the crude product was purified by chromatography over silica gel (cyclohexane/ETOAC 8/1 ). The purified product was then dissolved in CH 2 CI 2 (10 ml_) and trifluoroacetic acid was added (4 ml_). After 2 h the reaction mixture was treated with solid sodium carbonate and the solvent evaporated. The residue was treated with water and extracted with CH 2 CI 2 , the organic phase washed with brine, dried over sodium sulphate and evaporated to give the title compound (0.1g, 34%).
  • the reaction mixture was heated at 88 0 C for 2 h, and the solvents evaporated under vacuum.
  • the crude product was treated with diethyl ether and water, the organic phase washed with brine, dried over sodium sulphate, concentrated under vacuum and extracted twice with ether.
  • the solvent was evaporated and the crude product purified by chromatography over silica gel (cyclohexane/ETOAC 8/1 ).
  • the recovered product was then dissolved in CH 2 CI 2 (10 mL) and trifluoroacetic acid was added (4 mL). After 3 h the reaction mixture was treated with solid sodium carbonate and the solvent evaporated.
  • the residue was treated with water and extracted with CH 2 CI 2 , the organic phase washed with brine, dried over sodium sulphate and evaporated to give the title compound (0.12 g, 45%).
  • Example 1 S-IS-US-KIR.SS/IS.SRJ-i ⁇ -MethoxyphenyO-S-azabicyclotS.I.Olhex-S- yl]propyl ⁇ thio)-4-methyl-4H-1,2,4-triazol-3-yl]-2-methylquinoline hydrochloride
  • Example 1 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 2.1 cm, eluent CO 2 containing 20% (ethanol + 0.1% isopropanol), flow rate 25 mL/min, P 194 bar, T 35 0 C, detection UV at 220 nm, loop 1 ml_.
  • Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 20% (ethanol + 0.1 % isopropanol), flow rate 2.5 mUmin, P 194 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 2 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel OJ-H, 25 x 2.1 cm, eluent CO 2 containing 12% (ethanol + 0.1 % isopropylamine), flow rate 2.5 mL/min, P 196 bar, T 36 0 C, detection UV at 220 nm, loop 1 ml_.
  • Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be 5-[5-( ⁇ 3-[(1R,5S)-1-(4- bromophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl ⁇ thio)-4-methyl-4H-1 ,2,4-triazol-3-yl]-2- methylquinoline.
  • (1S.5R)- 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane (see Preparation 48) was used as the reference.
  • Enantiomer 2 was assigned as described for Enantiomer 1 to be ⁇ -fS- ⁇ S-KI S.SRJ-i ⁇ -bromophenyO-S-azabicyclolS.I .Olhex-S-yllpropylJthioH- methyl-4/-/-1 ,2,4-triazol-3-yl]-2-methylquinoline.
  • Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
  • Example 3 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chiralcel OD 10 ⁇ m, 250 x 20 mm, eluent A: n-hexane; B: isopropanol, gradient isocratic 35% B, flow rate 7 mLVmin, detection UV at 200-400 nm, CD 230 nm. Retention times given were obtained using an analytical HPLC using a chiral column Chiralcel OD 5 ⁇ m, 250 x 4.6 mm, eluent A: n-hexane; B: isopropanol, gradient isocratic 25% B, flow rate 1 mL/min, detection UV at 200-400 nm.
  • Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
  • Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be 5-[5-( ⁇ 3-[(1 S,5ft)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl ⁇ thio)-4-methyl-4/-/-1 ,2,4-triazol-3-yl]-2- methylquinoline.
  • Enantiomer 2 was assigned as described for Enantiomer 1 to be 5-[5-( ⁇ 3-[(1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl ⁇ thio)-4- methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline.
  • Enantiomer 1 showed fpKi (D3) > 0.6 log-unit higher than Enantiomer 2.
  • Example 5 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) as described in Example 1 but applying a pressure of 200 bar instead of 194 bar.
  • Enantiomer 2 showed fpKi (D3) > 0.9 log-unit higher than Enantiomer 1.
  • Example 6 4-[(1 R.5S/1 S,5R)-3-(3- ⁇ [4-Methyl-5-(2-methylquinolin-5-yl)-4tf-1 ,2,4-triazol-3- yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hex-1-yl]benzonitrile hydrochloride
  • Example 7 4-[(1 R.5S/1 S,5R)-3-(3- ⁇ [4-Methyl-5-(2-methylquinolin-5-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenol hydrochloride
  • Example 8 (1 R.5S/1 S,5/?)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 9 (1 /?,5S/1 S,5/?)-1 -(4-Bromophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol- 5-yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 9 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel AS-H, 25 x 2.1 cm, eluent CO 2 containing 11% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0 C, detection UV at 220 nm, loop 2 ml_.
  • Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 10% (ethanol + 0.1 % isopropyilamine), flow rate 2.5 mL/min, P 199 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be (IS, 5 R)-I -(4- bromophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane. (7R,5S)-1-(4-Bromophenyl)-3- azabicyclo[3.1.0]hexane (compare Preparation 32) was used as the reference.
  • Enantiomer 2 was assigned as described for Enantiomer 1 to be (1R,5S)-1-(4-bromophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4- triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 10 (1 R.5S/1 S,5R)-1 -(4-fert-Butylphenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 11 (1 /?,5S/1 S, 5/?)-1 -(3,4-Dichlorophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 11 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 8% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 194 bar, T 36 0 C, detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 8% (ethanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 190 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 0.5 log-units higher than Enantiomer 2.
  • Example 12 (1R.5S/1 S,5R)-1-(4-methoxyphenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1, 3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 12 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 9% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0 C, detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 8% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 190 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 13 (1 /?,5S/1 S,5R)-1 -[4-(5-methyl-3-isoxazolyl)phenyl]-3-(3- ⁇ [4-methyl-5-(4- methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 15 (1 S,5/?)-3-(3- ⁇ [4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4/7-1 ,2,4-triazol-3- yl]thio ⁇ propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 16 (1 R.5S/1 S,5R)-1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3- ⁇ [4-methyl-5- (4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]- hexane hydrochloride
  • Example 16 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chiralpak AD 10 ⁇ m, 250 x 21 mm, eluent A: n-hexane; B: isopropanol + 0.1% isopropyl amine, gradient isocratic 9% B, flow rate 7 mL/min, detection UV at 200-400 nm.
  • Retention times given were obtained using an analytical HPLC using a chiral column Chiralpak AD-H 5 ⁇ m, 250 x 4.6 mm, eluent A: n-hexane; B: isopropanol, gradient isocratic 15% B, flow rate 0.8 mL/min, detection UV at 200-400 nm.
  • Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
  • Example 17 (1 R,5S ⁇ S,5fl)-3-(3- ⁇ [4-Methyl-5-(4-methyM ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-1-[3-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 17 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 10% (ethanol + 0.1 % isopropanol), flow rate 2.5 mL/min, P 180 bar, T 35 0 C, detection UV at 220 nm, loop 1 mL.
  • Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 10% (ethanol + 0.1% isopropanol), flow rate 22 mL/min, P 190 bar, T 36 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 18 (1 R.5S/1 S,5R)-1 -[4-Fluoro-3-(trifluoromethyl)phenyl]-3-(3- ⁇ [4-methyl-5- (4-methyl-1 ,3-oxazol-5-yl)-4W-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]- hexane hydrochloride
  • Example 19 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 196 bar, T 36 0 C, detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 190 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 20 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 15% (ethanol + 0.1 % isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0 C 1 detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 2.5 mL ⁇ in, P 190 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be (1S,5f?)-1-(4- chlorophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane.
  • Enantiomer 2 was assigned as described for Enantiomer 1 to be (1 f?,5S)-1 -(4-chlorophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4tf-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 21 ⁇ 1S.5R/1 /?,5S)-1-(4-Fluorophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4W-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 21 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 7% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 196 bar, T 36 0 C, detection UV at 220 nm, loop 1 ml_.
  • Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 6% (ethanol + 0.1% isopropylamine), flow rate 2.5 r ⁇ Umin, P 190 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 22 ( ⁇ S,5R/f/?,5S)-1-(3-Chlorophenyl)-5-methyl-3-(3- ⁇ [4-methyl-5-(4-methyl- 1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.OJhexane hydrochloride
  • Example 22 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 15% (ethanol + 0.1 % isopropylamine), flow rate 22 ml_/min, P 192 bar, T 36 0 C, detection UV at 220 nm, loop 1 ml_.
  • Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 180 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 23 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 7% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0 C, detection UV at 220 nm, loop 1 ml_.
  • Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 6% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 190 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 24 (1 S,5fl/f K,5S)-3-(3- ⁇ [4-methyl-5-(4-methyM ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-S-yllthiolpropylJ-i-ia-tmethyloxyJphenyll-S-azabicyclo ⁇ .i .Olhexane hydrochloride
  • Example 24 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel OJ-H, 25 x 2.1 cm, eluent CO 2 containing 13% (2-propanol + 0.1% isopropylamine), flow rate 22 mL/min, P 200 bar, T 36 0 C, detection UV at 220 nm.
  • Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralcel OJ-H, 25 x 0.46 cm, eluent CO 2 containing 13% (2-propanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 180 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 29 ⁇ -IS-KS- ⁇ IS.SR/tR.SSJ-i ⁇ -ChlorophenyO-S-azabicycloIS.I .Olhex-S- yl]propyl ⁇ thio)-4-methyl-4H-1,2,4-triazol-3-yl]-2-methylquinoline hydrochloride
  • Example 29 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 25% (ethanol + 0.1 % isopropylamine), flow rate 22 mL/min, P 199 bar, T 36 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 30 (1S,5R/1 K,5S)-3-(3- ⁇ [4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 , 2,4- triazol-3-yl]thio ⁇ propyl)-1- ⁇ 4-[(trifluoromethyl)oxy]phenyl ⁇ -3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 30 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chirapak AS-H, 25 x 2 cm, eluent A: n-hexane; B: isopropanol, gradient isocratic 15% B v/v, flow rate 7 mL/min, detection UV at 220 nm. Retention times given were obtained using chiral column Chiracel OD, 25 x 0.46 cm, eluent A: n-hexane; B: isopropanol, gradient isocratic 10% B v/v, flow rate 1 mL/min, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 33 (1 S.5R/1 R,5S)-3-(3- ⁇ [4-Methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-1- ⁇ 4-[(trifluoromethyl)oxy]phenyl ⁇ -3-azabicyclo[3.1. OJhexane hydrochloride
  • Example 33 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 8% (2-propanol + 0.1% isopropylamine), flow rate 22 mL/min, P 200 bar, T 36 0 C, detection UV at 220 nm.
  • Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 8% (2-propanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 180 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
  • Example 34 (1 f?,5S/1 S,5f?)-1-(3-Bromophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5- yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
  • the title compound was prepared in 23 mg yield as a white slightly hygroscopic solid from (1R,5S/1 S,5R)-1-(3-bromophenyl)-3-azabicyclo[3.1.0]hexane (140 mg) in analogy to the method described in Example 1 and purifying the free base of the title compound by preparative HPLC using a column X Terra MS C18 5 ⁇ m, 100 x19 mm, eluent A: H 2 O+0.1% TFA; B: CH 3 CN+0.1 % TFA, gradient 10% (B) for 1 min, from 10% (B) to 35% (B) in 12 min, flow rate 17 mL/min, detection UV at 200-400 nm.
  • Example 35 was separated to give the separated diastereoisomers by semi-preparative HPLC using a chiral column Chirapak AD, 25 x 2 cm, eluent A: n-hexane; B: ethanol ⁇ 0.1% isopropylamine, gradient isocratic 15% B v/v, flow rate 7 ml_/min, UV wavelength range 220-400 nm. Retention times given were obtained using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent A: n-hexane; B: ethanol ⁇ 0.1% isopropylamine, gradient isocratic 17% B v/v, flow rate 1 mL/min, UV wavelength range 200-400 nm.
  • Example 36 (1 R.5S/1 S,5R)-1 -[2-Fluoro-5-(trifluoromethyl)phenyl]-3-(3- ⁇ [4-methyl-5-
  • Example 36 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chirapak AS-H, 25 x 2 cm, eluent A: n-hexane; B: isopropanol + 0.1 % isopropylamine, gradient isocratic 10% B v/v, flow rate 7 mL/min, detection UV at 220 nm.
  • Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 7% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 180 bar, T 35 0 C, detection UV at 220 nm.
  • Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
  • Example 37 1 -[4-[(1 K.5S/1 S,5/?)-3-(3- ⁇ [4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hex-1-yl]-2- (methyloxy)phenyl]ethanone hydrochloride
  • Example 38 1-[4-[(1R,5S/1S,5R)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-(methyloxy)phenyl]-1 - propanone hydrochloride
  • Example 39 (1 R.5S/1 S,5R)-3-(3- ⁇ [4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-1-[2-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
  • Example 40 (1 S,5R)-1 -[2-Fluoro-4-(trif luoromethyl)phenyl]-3-(3- ⁇ [4-methyl-5-(4- methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-a2abicyclo[3.1.0]hexane hydrochloride

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention provides a new use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof, wherein: G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxyl, cyano, C1-4alkyl, haloC1-4alkyl, C1-4 alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4 alkyl; R3 I s C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.

Description

USE OF AZABICYCLO HEXANE DERIVATIVES
The present invention provides a new use of a D3 antagonist of formula (I), as disclosed in the International Patent Application WO 2005/08032, in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.
The DSM-IV sets forth two indicia of compulsion. First, the person has repetitive behaviors or mental acts that the person feels driven to perform in response to an obsession or according to rules that must be applied rigidly. Repetitive behaviors include hand washing, ordering and checking, while mental acts include praying, counting and repeating words silently. Second, the behaviors or mental acts are aimed at preventing some dreaded event or situation; however, these behaviors or mental acts either are not connected in a realistic way to what they are designed to neutralize or prevent, or are clearly excessive.
Individuals who meet the DSM-IV criteria for OCD can be scored using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Y-BOCS scores range from 0 to 40. Generally, 0 to 7 is considered a subclinical syndrome, 8- 15 is considered mild, 16-23 is considered moderate, 24-31 is considered severe, and 32-40 is considered extremely severe.
A wide range of psychiatric and neuropsychiatric disorders appear to be related to OCD and form a family of related disorders referred to as obsessive-compulsive (OC) spectrum disorders. Obsessive-compulsive spectrum disorders include somatoform disorders including body dysmorphic disorder and hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, and movement disorders, including Tourette's syndrome.
Somatoform disorders include body dysmorphic disorder (BDD) and hyperchondriasis. Body dysmorphic disorder (BDD) is a preoccupation with an imagined slight defect in appearance that causes significant distress or impairment in functioning. Individuals suffering from BDD have preoccupations similar to OCD obsessions in that they have repetitive intrusive thoughts, often perform time-consuming, repetitive and sometimes ritualistic behaviours. Hypochondriasis is a preoccupation with the fear of having, or the idea that one has, a serious disease based on the person's misinterpretation of bodily signs or symptoms. Hypochondriacal preoccupations resemble OCD obsessions in that they are often experienced as intrusive and persistent, and the individuals often display repetitive checking behaviours.
The DSM-IV defines anorexia nervosa as a refusal to maintain a minimally normal body weight; intensive fear of gaining weight or becoming fat even though underweight; significant disturbance in perception of body shape or size; and, in females, amenorrhea. The DSM- IV defines bulimia nervosa as recurrent episodes of binge eating followed by inappropriate compensatory behaviours designed to prevent a weight gain. BED is characterized by recurrent episodes of binge eating in the absence of regular use of inappropriate compensatory behaviours. There is some overlap among anorexia nervosa, bulimia nervosa, and BED. However, all three disorders are characterized by a core preoccupation with food and body weight. Individuals suffering from these disorders often perform specific rituals, and have an abnormal preoccupation with food and weight.
Individuals suffering from paraphilias and nonparaphilic sexual addictions (NPSAs) experience similar increasing senses of tension or arousal before committing the act, then pleasure, gratification or relief at the time of committing the act.
Tourette's syndrome is a chronic neuropsychiatric disorder characterized by motor tics and one or more vocal tics beginning before the age of 18 years. The DSM-IV defines a tic as a sudden, rapid, recurrent, nonrhythmic, stereotyped motor movement or vocalization. Tourette's syndrome patients may be able to suppress tics for varying lengths of time, but eventually experience them as irresistible and perform them. Tourette's patients exhibit obsessions resembling OCD obsessions, for example, they often feel the need to perform tics until they are felt to be "just right."
Autism is characterized by difficulties with social interaction, speech and communication, and by a compulsive core. Autistic individuals often display compulsive, repetitive behaviors.
Thus there is a need for a therapeutic agent for the treatment of patients suffering from the somatoform disorders as defined above.
The present invention provides a new use of a D3 antagonist in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.
Also provided is a D3 antagonist for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
In another aspect this invention provides a method of treating a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; or premature ejaculation, comprising administering to a mammal in need thereof an effective amount of a D3 antagonist.
The present invention provides a new use of a D3 antagonist in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.
Also provided is a D3 antagonist for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
In another aspect, this invention provides a method of treating a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and a method of treating premature ejaculation, comprising administering to a mammal in need thereof an effective amount of a D3 antagonist.
"Treatment" includes prophylaxis, where this is appropriate for the relevant condition(s).
In one embodiment, the present invention provides a new use of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof:
Figure imgf000004_0001
wherein:
G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloCi.4alkyl, C1^aIkOXy, haloC^alkoxy, C^alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl;
R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl;
R5 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N- pyrrolyl, 1 ,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2- pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, d^alkyl, haloC1-4alkyl, C1- 4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1 , such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1 ; in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above or premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I) as herein defined or a salt thereof.
Also provided is a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
In one embodiment, the somatoform disorder is binge eating.
"Treatment" includes prophylaxis, where this is appropriate for the relevant condition(s).
Because of the presence of the fused cyclopropane compounds of formula (I) are believed to have a "cis" disposition of the substituents (both groups linked to the bicyclic ring system are on the same face of this bicyclic ring system). In another embodiment of the present invention a new use is provided for compounds of formula (I)' and salts thereof which correspond to the compounds of formula (I) having "cis" disposition, represented by the bold highlight of the bonds:
Figure imgf000006_0001
wherein G1 p, R1, R2, R3, R4, and R5 are defined as above for compounds of formula (I), in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above; and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I)' as herein defined or a salt thereof.
Also provided is a compound of formula (I)' or a salt thereof for use in the treatment of a somatoform disorder and premature ejaculation.
In one embodiment, the somatoform disorder is binge eating.
In a further embodiment of the present invention a new use is provided for compounds of formula (IA) that correspond to stereochemical isomers of compounds of formula (I)', enriched in configuration (1 S.5R) (or (1 R.5R) when G is 2-pyridyl);
Figure imgf000006_0002
wherein G, p, R1, R2, R3, R4, and R5 are defined as above for compounds of formula (I)' or a salt thereof, in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IA) as herein defined or a salt thereof.
Also provided is a compound of formula (IA) or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculaiton.
In one embodiment, the somatoform disorder is binge eating.
It is intended in the context of the present invention that stereochemical isomers enriched in configuration (1 S.5R) or (1 R.5R) of formula (IA) correspond in one embodiment to at least 90% e.e. In another embodiment the isomers correspond to at least 95% e.e. In another embodiment the isomers correspond to at least 99% e.e.
In another embodiment of the present invention a new use is provided of the following stereochemical isomers enriched in configuration (1 R, 5S):
5-[5-({3-[(1 R,5S)-1 -(4-Methoxyphenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl-
4H-1 ,2,4-triazol-3-yl]-2-methylquinoline, Enantiomer 2; 5-[5-({3-[(tR,5S)-1-(4-Bromophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl-4H-
1 ,2,4-triazol-3-yl]-2-methylquinoline, Enantiomer 1;
5-[5-({3-[(1 R,5S)-1-(4-tert-Butylphenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl-
4H-1 ,2,4-triazol-3-yl]-2-methylquinoline, Enantiomer 1 ;
(1R,5S)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-[3-
(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane, Enantiomer 2; (7f?,5S)-1-(3-Chlorophenyl)-5-methyl-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-
1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane, Enantiomer 2;
1 -[5-[(1 R,5S)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}- propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-(methyloxy)phenyl]-1 -propanone, Enantiomer 2;
2-Methyl-5-[(1 f?,5S)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-1 ,3-benzothiazole, Enantiomer 2;
or a salt thereof in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions,
Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal. Thus, a still further aspect of the invention provides a method of treating a somatoform disoder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound from the list cited above or a salt thereof.
Also provided is a compound from the list cited above or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
In one embodiment, the somatoform disorder is binge eating.
The term "5- or 6-membered heteroaromatic group" refers to a monocyclic 5- or 6- membered heterocyclic group containing 1 , 2, 3 or 4 heteroatoms, for example from 1 to 3 heteroatoms, selected from O, N and S. When the group contains 2-4 heteroatoms, one may be selected from O, N and S and the remaining heteroatoms may be N. Examples of 5 and 6-membered heteroaromatic groups include pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, furyl, thienyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
The term "d^alkyl" refers to an alkyl group having from one to four carbon atoms, in all isomeric forms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert- butyl. The term "n-C1-4alkyl" refers to the unbranched alkyls as defined above.
The term "C1^aIkOXy" refers to a straight chain or branched chain alkoxy (or "alkyloxy") group having from one to four carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.
The term "halogen" and its abbreviation "halo" refer to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). Where the term "halo" is used before another group, it indicates that the group is substituted by one, two or three halogen atoms. For example, "haloC1-4alkyl" refers to groups such as trifluoromethyl, bromoethyl, trifluoropropyl, and other groups derived from
Figure imgf000008_0001
refers to groups such as trifluoromethoxy, bromoethoxy, trifluoropropoxy, and other groups derived from C1-4alkoxy groups as defined above.
The term "8- to 11 -membered bicyclic group" refers to a bicyclic ring system containing a total of 8, 9, 10 or 11 carbon atoms, wherein 1 , 2, 3 or 4 or 5 of the carbon atoms are optionally replaced by a heteroatom independently selected from O, S and N. The term includes bicyclic systems wherein both rings are aromatic, as well as bicyclic ring systems wherein one of the rings is partially or fully saturated. Examples of 8- to 1 1- membered bicyclic groups wherein both rings are aromatic include indenyl, naphthyl and azulenyl.
Examples of 8- to 11-membered bicyclic groups having 1 , 2, 3, 4 or 5 heteroatoms, in which both rings are aromatic, include: 6H-thieno[2,3-b]pyrrolyl, imidazo[2,1- b][1 ,3]thiazolyl, imidazo[5,1-b][1 ,3]thiazolyl, [1 ,3]thiazolo[3,2-b][1 ,2,4]triazolyl, indolyl, isoindolyl, indazolyl, benzimidazolyl e.g. benzimidazol-2-yl, benzoxazolyl e.g. benzoxazol- 2-yl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzothienyl, benzofuranyl, naphthridinyl, quinolyl, quinoxalinyl, quinazolinyl, cinnolinyl and isoquinolyl. Examples of 8- to 11 -membered bicyclic groups having 1 , 2, 3 , 4 or 5 heteroatoms, in which one of the rings is partially or fully saturated includes dihydrobenzofuranyl, indanyl, tetrahydronaphthyl, indolinyi, isoindolinyl, tetrahydroisoquinolinyl, tetrahydroquinolyl, benzoxazinyl and benzoazepinyl.
The term "heterocyclyl" refers to a 5 or 6-membered monocyclic or 8 to 1 1 -membered bicyclic group wherein 1 , 2, 3, 4 or 5 of the carbon atoms are replaced by a heteroatom independently selected from O, S and N and which is partially or fully saturated. Examples of "heterocyclyl" which are fully saturated 5 or 6-membered monocyclic rings include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, isothiazolyl, thiazolyl, tetrahydrofuranyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl, dioxanyl, tetrahydro-2H-pyranyl and dithianyl. Examples of "heterocyclyl" groups which are partially saturated 5 or 6-membered monocyclic rings include oxazolinyl, isoaxazolinyl, imidazolinyl, pyrazolinyl, 1 ,2,3,6-tetrahydropyridyl and 3,6-dihydro-2H-pyranyl. Examples of "heterocyclyl" groups which are fully saturated 8 to 11 -membered bicyclic rings include decahydroquinolinyl, octahydro-2H-1 ,4-benzoxazinyl and octahydro-IH-cyclopenta- [6]pyridinyl. Examples of "heterocyclyl" groups which are partially saturated 8 to 11- membered bicyclic rings include 2,3-dihydro-1 H-indolyl, 1 ,2,3,4-tetrahydroquinolinyl, 1 ,2,3,4-tetrahydroisoquinolinyl and 2,3,4, 5-tetrahydro-1 H-3-benzazepinyl.
Any of these groups may be attached to the rest of the molecule at any suitable position.
As used herein, the term "salt" refers to any salt of a compound according to the present invention prepared from an inorganic or organic acid or base, quaternary ammonium salts and internally formed salts. Physiologically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent compounds. Such salts must clearly have a physiologically acceptable anion or cation. Suitably physiologically acceptable salts of the compounds of the present invention include acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic and arylsulfonic, for example benzenesulfonic and p-toluenesulfonic, acids; base addition salts formed with alkali metals and alkaline earth metals and organic bases such as N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumaine (N-methylglucamine), lysine and procaine; and internally formed salts. Salts having a non-physiologically acceptable anion or cation are within the scope of the invention as useful intermediates for the preparation of physiologically acceptable salts and/or for use in non-therapeutic, for example, in vitro, situations.
In one embodiment, R1 is halogen, cyano, acetyl, trifluoromethyl, trifluoromethoxy.
In one embodiment, R2 is hydrogen. In another embodiment R2 is C1-4alkyl (e.g. methyl).
In one embodiment, R5 is a group selected from: isoxazolyl, 2-pyrrolidinonyl, 1 ,1-dioxido- 2-isothiazolidinyl which is optionally substituted by one or two substituents selected from: halogen, cyano, C1-2alkyl (e.g. methyl), haloC^alkyl (e.g. trifluoromethyl), C1-2alkoxy (e.g. methoxy), C1-3alkanoyl (e.g. acetyl).
Suitably, R1 is bromo, fluoro, trifluoromethoxy, cyano, hydroxy, chloro, methoxy, tert-butyl, trifluoromethyl.
Suitably, R5 is isoxazolyl, 2-pyrrolidinonyl, -CH2-N-pyrrolyl, 1 ,1-dioxido-2-isothiazolidinyl, 2-thienyl, 2-pyridyl, 2-thiazolyl.
In one embodiment, p is 1 or 2.
In another embodiment p is 0.
In one embodiment, R4 may be optionally substituted phenyl (e.g. phenyl, 4- trifluoromethyl-phenyl, 3,4-difluorophenyl), an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline, 8-fluoro-2-methylquinoline), an optionally substituted pyranyl (e.g. 4-tetrahydro-2H-pyranyl), an optionally substituted pyridinyl (e.g. 3-methyl-2- pyridinyl, 2-methyl-3-pyridinyl, 3-pyridinyl, 2-methyl-6-trifluoromethyl-3-pyridinyl), an optionally substituted pyrazolyl (e.g. 5-chloro-1-methyl-1 H-pyrazol-4-yl, 1-methyl-3- trifluoromethyl-1 H-pyrazol-4-yl 1 ,5-dimethyl-1 H-pyrazoly-4-yl), an optionally substituted pyrimidyl (e.g. 5-pyrimidinyl), an optionally substituted pyridazinyl (e.g. 4-pyridazinyl), an optionally substituted pyrazinyl (e.g. 5-methyl-2-pyrazinyl), an optionally substituted furanyl (e.g. 3-methyl-2-furanyl, 2,5-dimethyl-3-furanyl), an optionally substituted thienyl
(e.g. 5-chloro-2-thienyl), an optionally substituted oxazolyl (e.g. 4-methyl-1 ,3-oxazol-5-yl,
2-methyl-5-trifluoromethyl-1 ,3-oxazol-4-yl), an optionally substituted isoxazolyl (e.g. 3- methyl-5-isoxazolyl), an optionally substituted thiazolyl (e.g. 2,4-dimethyl-1 ,3-thiazol-5-yl), an optionally substituted triazolyl (e.g. 1 -methyl-1 H-1 ,2,3-triazol-4-yl).
In one embodiment, R3 is methyl.
In one embodiment a new use of a compound of formula (IB) or a salt thereof is provided, wherein R1, p, R3 and R4 are as defined for formula (I):
Figure imgf000011_0001
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IB) as herein defined or a salt thereof.
Also provided is a compound of formula (IB) or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
In Formula (IB), in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro,
Figure imgf000011_0002
C^alkanoyl; and when R1 is chlorine and p is 1 , such Ri is not present in the ortho position with respect to the linking bond to the rest of the molecule.
Examples of R4 include an optionally substituted phenyl (e.g. phenyl, 4-trifluoromethyl- phenyl, 3,4-difluorophenyl), an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline, 8-fluoro-2-methylquinoline), an optionally substituted pyranyl (e.g. 4- tetrahydro-2H-pyranyl), an optionally substituted pyridinyl (e.g. 3-methyl-2-pyridinyl, 2- methyl-3-pyridinyl, 3-pyridinyl, 2-methyl-6-trifluoromethyl-3-pyridinyl), an optionally substituted pyrazolyl (e.g. 5-chloro-1-methyl-1 H-pyrazol-4-yl, 1 -methyl-3-trifluoromethyl- 1 H-pyrazol-4-yl 1 ,5-dimethyl-1 H-pyrazoly-4-yl), an optionally substituted pyrimidyl (e.g. 5- pyrimidinyl), an optionally substituted pyridazinyl (e.g. 4-pyridazinyl), an optionally substituted pyrazinyl (e.g. 5-methyl-2-pyrazinyl), an optionally substituted furanyl (e.g. 3- methyl-2-furanyl, 2,5-dimethyl-3-furanyl), an optionally substituted thienyl (e.g. 5-chloro-2- thienyl), an optionally substituted oxazolyl (e.g. 4-methyl-1 ,3-oxazol-5-yl, 2-methyl-5- trifluoromethyl-1,3-oxazol-4-yl), an optionally substituted isoxazolyl (e.g. 3-methyl-5- isoxazolyl), an optionally substituted thiazolyl (e.g. 2,4-dimethyl-1 ,3-thiazol-5-yl), an optionally substituted triazolyl (e.g. 1-methyl-1 H-1 ,2,3-triazol-4-yl). In another embodiment, a new use of a compound of formula (IC) or a salt thereof is provided, wherein R1, p, R3 and R4 are as defined for formula (I):
Figure imgf000012_0001
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IC) as herein defined or a salt thereof.
Also provided is a compound of formula (IC) or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
In Formula (IC), in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C1-4alkyl, fluoroC1-4alkyl, C1-4alkoxy, fluoroC1-4alkoxy,
Figure imgf000012_0002
and when Ri is chlorine and p is 1 , such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule. Examples of R4 include those defined previously for compounds (IB).
In another embodiment, a new use of a compound of formula (ID) or a salt thereof is provided, wherein R1, p, R3 and R4 are as defined for formula (I):
Figure imgf000012_0003
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (ID) as herein defined or a salt thereof.
Also provided is a compound of formula (ID) or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
In Formula (ID), in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C1-4alkyl, fluoroC1-4alkyl, d-4alkoxy, fluoroC1-4alkoxy, C1-4alkanoyl; and when Ri is chlorine and p is 1 , such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule. Examples of R4 include those defined previously for compounds (IB).
In another embodiment, a new use of a compound of formula (IE) or a salt thereof is provided, wherein G is 2-pyridyl or 3-pyridyl and R1, p, R3 and R4 are as defined for formula (I):
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IE) as herein defined or a salt thereof. Also provided is a compound of formula (IE) or a salt thereof for use in the treatment of a somatoform disorder and premature ejaculation.
In Formula (IE), in one embodiment, G corresponds to 2-pyridyl (Compounds (IEi)) and in another embodiment to 3-pyridyl (Compounds (IE2)), as illustrated below:
Figure imgf000014_0001
In Formulae (IE), (IE1) and (IE2), in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C1-4alkyl, fluoroC1-4alkyl, C1- 4alkoxy, fluoroC^alkoxy, C1-4alkanoyl; and when Ri is chlorine and p is 1 , such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
Examples of R4 include those defined previously for compounds (IB).
In another embodiment, a new use of a compound of formula (IF) or a salt thereof is provided, wherein R1, p, R3 and R4 are as defined for formula (I):
Figure imgf000014_0002
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IF) as herein defined or a salt thereof.
Also provided is a compound of formula (IF) or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
In Formula (IF), in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C^alkyl, fluoroC^alkyl, C1-4alkoxy, fluoroC^alkoxy, C^alkanoyl; and when Ri is chlorine and p is 1 , such Ri is not present in the ortho position with respect to the linking bond to the rest of the molecule.
Examples of R4 include those defined previously for compounds (IB).
Further embodiment of the present invention is the new use of compounds of formula (IB)', (IC)1, (ID)', and (IF)' which, respectively, correspond to the stereochemical isomers of compounds of formula (IB), (IC), (ID) and (IF) as defined above enriched in configuration (1S, 5R).
Compounds of formula (IE)' correspond to the stereochemical isomers of compounds of formula (IE) as above defined, enriched in configuration (1 R, 5R) or (1 R, 5S) depending on the presence of a 2-pyridine ring.
In one embodiment, a new use of stereochemical isomer enriched in the (1 S.5R) configuration of formula (IB)' or a salt thereof is provided, wherein R1, p, R3 and R4 are as defined for formula (I):
Figure imgf000015_0001
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IB)' as herein defined or a salt thereof.
Also provided is a compound of formula (IB)' or a salt thereof for use in the treatment of a somatoform disorder and premature ejaculation.
In Formula (IB)', in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 1 1-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, d^alkyl, fluoroC^alkyl, C1-4alkoxy, fluoroC1-4alkoxy, C1.4alkanoyl; and when Ri is chlorine and p is 1 , such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
Examples of R4 include optionally substituted phenyl (e.g. phenyl, 4-trifluoromethyl-phenyl, 3,4-difluorophenyl), an optionally substituted bicyclic group such as quinolinyl (e.g. 2- methylquinoline, 8-fluoro-2-methylquinoline), an optionally substituted pyranyl (e.g. 4- tetrahydro-2H-pyranyl), an optionally substituted pyridinyl (e.g. 3-methyl-2-pyridinyl, 2- methyl-3-pyridinyl, 3-pyridinyl, 2-methyl-6-trifluoromethyl-3-pyridinyl), an optionally substituted pyrazolyl (e.g. 5-chloro-1-methyl-1 H-pyrazol-4-yl, 1-methyl-3-trifluoromethyl- 1 H-pyrazol-4-yl 1 ,5-dimethyl-1 H-pyrazoly-4-yl), an optionally substituted pyrimidyl (e.g. 5- pyrimidinyl), an optionally substituted pyridazinyl (e.g. 4-pyridazinyl), an optionally substituted pyrazinyl (e.g. 5-methyl-2-pyrazinyl), an optionally substituted furanyl (e.g. 3- methyl-2-furanyl, 2,5-dimethyl-3-furanyl), an optionally substituted thienyl (e.g. 5-chloro-2- thienyl), an optionally substituted oxazolyl (e.g. 4-methyl-1 ,3-oxazol-5-yl, 2-methyl-5- trifluoromethyl-1 ,3-oxazol-4-yl), an optionally substituted isoxazolyl (e.g. 3-methyl-5- isoxazolyl), an optionally substituted thiazolyl (e.g. 2,4-dimethyl-1 ,3-thiazol-5-yl), an optionally substituted triazolyl (e.g. 1-methyl-1 H-1 ,2,3-triazol-4-yl).
In another embodiment, a new use of a stereochemical isomer enriched in the (1 S.5R) configuration of formula (IC)' or a salt thereof is provided, wherein R1, p, R3 and R4 are as defined for formula (I):
Figure imgf000016_0001
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IC)' as herein defined or a salt thereof.
Also provided is a compound of formula (IC)' or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
In Formula (IC)', in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 1 1-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, d^alkyl, fluoroC^alkyl, d.4alkoxy, fluoroC^alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1 , such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule. Examples of R4 include those defined previously for compounds (IB)'.
In another embodiment, a new use of a stereochemical isomer enriched in the (1 S.5R) configuration of formula (ID)' or a salt thereof is provided, wherein R1, p, R3 and R4 are as defined for formula (I):
Figure imgf000017_0001
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (ID)' as herein defined or a salt thereof.
Also provided is a compound of formula (ID)' or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
In Formula (ID)', in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C^alkyl, fluoroC1-4alkyl, Ci-4alkoxy, fluoroC1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1 , such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule. Examples of R4 include those defined previously for compounds (IB)'.
In another embodiment, a new use of a stereochemical isomer enriched in the (1 S,5R) configuration or (1 R.5R) configuration of formula (IE)' or a salt thereof is provided, wherein G is 2-pyridyl or 3-pyridyl and R1, p, R3 and R4 are as defined for formula (I):
Figure imgf000018_0001
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IE)' as herein defined or a salt thereof.
Also provided is a compound of formula (IE)' or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
In Formula (IE)', in one embodiment, G corresponds to 2-pyridyl (Compounds (IE1)') and in another embodiment to 3-pyridyl (Compounds (IE2)'), as illustrated below:
Figure imgf000019_0001
The configuration will then change depending on the type of pyridine ring, as mentioned above.
In Formulae (IE)', (IE1)1 and (IE2)', in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, d^alkyl, fluoroC1-4alkyl, C1. 4alkoxy, fluoroC1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1 , such Ri is not present in the ortho position with respect to the linking bond to the rest of the molecule. Examples of R4 include those defined previously for compounds (IB)'.
In another embodiment, a new use of a stereochemical isomer enriched in the (1 S.5R) configuration of formula (IF)' or a salt thereof is provided, wherein R1, p, R3 and R4 are as defined for formula (I):
(lF).
Figure imgf000019_0002
in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal. Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IF)' as herein defined or a salt thereof.
Also provided is a compound of formula (IF)' or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
In Formula (IF)', in one embodiment, R3 is methyl. R4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 1 1-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C^alkyl, fluoroC^alkyl, C1-4alkoxy, fluoroC1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1 , such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule. Examples of R4 include those defined previously for compounds (IB)'.
Certain of the compounds of the invention may be used as acid addition salts with less than one, or one or more equivalents of the acid. The present invention includes within its scope the use of all possible stoichiometric and non-stoichiometric forms.
Salts may also be prepared from other salts of the compound of formula (I) using conventional methods.
When administered, the formulations used in the invention are applied in pharmaceutically acceptable amounts and in pharmaceutically acceptable compositions. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic ingredients.
In the present invention, compounds of formula (I) are administered in safe and effective amounts. An effective amount means that amount necessary to delay the onset of, inhibit the progression of, halt altogether the onset or progression of or diagnose the particular condition being treated. In general, an effective amount for treating an obsessive compulsive spectrum disorder will be that amount necessary to inhibit mammalian symptoms of the particular obsessive compulsive spectrum disorder in-situ. When administered to a subject, effective amounts will depend, of course, on the particular condition being treated; the severity of the condition; individual patient parameters including age, physical condition, size and weight; concurrent treatment; frequency of treatment; and the mode of administration. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
It is preferred generally that a minimum dose be used, that is, the lowest safe dosage that provides appropriate relief of symptoms. Dosage may be adjusted appropriately to achieve desired drug levels, locally or systemically.
A variety of administration routes are available. The particular mode selected will depend of course, upon the particular drug selected, the severity of the disease state(s) being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, sublingual, topical, nasal, transdermal or parenteral routes. The term
"parenteral" includes subcutaneous, intravenous, intramuscular, or infusion. Intravenous routes are preferred.
The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
Compositions suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquors or nonaqueous liquids such as a syrup, an elixir, or an emulsion. Other delivery systems can include time- release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the active compounds of the invention, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art.
In one embodiment the present invention provides a new use of a compound of formula (I) selected from the following group consisting of:
5-[5-({3-[(rR,5S/tS,5f?)-1-(4-Methoxyphenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4- methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline;
5-[5-({3-[(tS,5f?)-1-(4-Methoxyphenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl- 4H-1 ,2,4-triazol-3-yl]-2-methylquinoline, Enantiomer 1 ;
5-[5-({3-[(-/R,5S/)S,5R)-1-(4-Bromophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4- methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline;
5-[5-({3-[(1S,5R)-1-(4-Bromophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl-4H-
1 ,2,4-triazol-3-yl]-2-methylquinoline, Enantiomer 2;
2-Methyl-5-[4-methyl-5-({3-[( 1 R, 5S/1S, 5R)- 1 -phenyl-3-azabicyclo[3.1.0]hex-3- yl]propyl}thio)-4H-1 ,2,4-triazol-3-yl]quinoline; 2-Methyl-5-[4-methyl-5-({3-[(^S,5R)-1-phenyl-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4H-
1 ,2,4-triazol-3-yl]quinoline, Enantiomer 2;
5-[5-({3-[(7R,5S/7S,5R)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4- methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline;
5-[5-({3-[(rS,5/?)-1-(3,4-Dichloropheny])-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl- 4H-1 ,2,4-triazol-3-yl]-2-methylquinoline, Enantiomer 1 ;
5-[5-({3-[(1 R,5S/1S,5R)-1-(4-tert-Butylphenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4- methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline;
5-[5-({3-[(1 S,5R)-1-(4-tert-Butylphenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl-
4H-1 ,2,4-triazol-3-yl]-2-methylquinoline, Enantiomer 2;
4-[(1 R.5S/1 S,5R)-3-(3-{[4-Methyl-5-(2-methylquinolin-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]benzonitrile;
4-[(1 R.5S/1 S,5R)-3-(3-{[4-Methyl-5-(2-methylquinolin-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]phenol;
(1 R.5S/1 S,5R)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1 -phenyl-3-azabicyclo[3.1.0]hexane;
(1 R,5S/1 S,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-
3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane, Enantiomer 1 ;
(1 R.5S/1 S,5R)-1 -(4-tert-Butylphenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-
1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 R,5S/1S,5R)-1-(3,4-Dichlorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-1 -(3,4-Dichlorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane, Enantiomer 2;
(1 R.5S/1 S,5R)-1-(4-methoxyphenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-
1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-1 -(4-methoxyphenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane,_Ej^njiθQτeL2;
(1 R,5S/1S,5R)-1-[4-(5-methyl-3-isoxazolyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-
5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 S,5f?)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-[4-
(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; (1 S,5R)-3-(3-{[4-Methyl-5-(4-methyl-
1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1 -[4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane; (1 f?,5S/1 S,5f?)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4- methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]- hexane;
(1R,5S/1 S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1 -[3-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(1 R.5S/1 S,5R)-1-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane; 1-[5-[(7S,5R/f/?f5S)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-(methyloxy)phenyl]ethanone;
1-[5-[(7S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-2-(methyloxy)phenyl]ethanone, Enantiomer 1 ;
( 7S,5/^7ft,5S)-1-(4-Chlorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.Ojhexane;
(7S,5f?)-1-(4-Chlorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-
3-yl]thio}propyl)-3-azabicyclo[3.1.Ojhexane, Enantiomer 1 ;
(7S,5R/ϊR,5S)-1-(4-Fluorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-y!]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(rS,5/?)-1-(4-Fluorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hexane, Enantiomer 1 ;
(tSI5/V7R,5S)-1-(3-Chlorophenyl)-5-methyl-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-
4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(tS,5R)-1-(3-Chlorophenyl)-5-methyl-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-
1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane, Enantiomer 1 ;
(rS,5R/tR5S)-1-(3-Fluorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2)4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(tS,5R)-1-(3-Fluorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.Ojhexane, Enantiomer 1 ;
(ϊS,5f?/tR,5S)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1 -[3-(methyloxy)phenyl]-3-azabicyclo[3.1.Ojhexane;
(tS,5f?)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-[3- (methyloxy)phenylJ-3-azabicyclo[3.1.Ojhexane, Enantiomer 1 ;
(tS,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(tetrahydro-2H-pyran-4-yl)-4/-/-1 ,2,4-triazol-
3-yl]thio}propyl)-3-azabicyclo[3.1.Ojhexane;
(7S,5f?)-1-(4-Bromophenyl)-3-[3-({4-methyl-5-[4-(trifluoromethyl)phenyl]-4H-1 ,2,4-triazol-
3-yl}thio)propyl]-3-azabicyclo[3.1.Ojhexane;
(tS.S^-i^-BromophenyO-S-CS-iμ-methyl-S-CS-pyridinyO^H-I ^Λ-triazol-S-ylJthio}- propyl)-3-azabicyclo[3.1.Ojhexane,
(ϊS,5«)-1-(4-Bromophenyl)-3-(3-{[5-(3,4-difluorophenyl)-4-methyl-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.Ojhexane;
5-[5-({3-[(tS,5R/tR,5S)-1-(4-Chlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4- methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline;
5-[5-({3-[(tS,5R/tR,5S)-1-(4-Chlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4- methyl-4/-/-1 ,2,4-triazol-3-yl]-2-methylquinoline, Enantiomer 1 ;
(fS,5f?/tf?,5S)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yljthio}propyl)-1 -{4-[(trifluoromethyl)oxyJphenyl}-3-azabicyclo[3.1.Ojhexane;
(7S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-{4-
[(trifluoromethyl)oxy]phenyl}-3-azabicyclo[3.1.Ojhexane, Enantiomer 1
(tS,5R/tR,5S)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-ylJ- thioJpropyO-i-^-methyl^-CtrifluoromethyOphenylJ-S-azabicyclo^.i. Ojhexane; (tSf5AVf/?f5S)-3-(3-{[4-Methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1 ,2,4-triazol-3- ylJthioJpropyO-i^-fCtrifluoromethyOoxyJphenylJ-S-azabicyclofS.I .Ojhexane;
(fS,5f?)-3-(3-{[4-Methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-
{4-[(trifluoromethyl)oxy]phenyl}-3-azabicyclo[3.1.0]hexane, Enantiomer 2;
(1 R5S/1 S,5/?)-1 -(3-Bromophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyi)-3-azabicyclo[3.1.0]hexane;
(7S)5f?)-3-(1-Methyl-3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(fS,5R)-3-(1-Methyl-3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1 -[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane, Diastereoisomer 1 ;
( 1S,5R)-3-(1 -Methyl-3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4W-1 ,2,4-triazol-3- yl]thio}propyl)-1 -^(trifluoromethyOphenyll-S-azabicycloβ.1.0]hexane, Diastereoisomer 2;
(1 R.5S/1 S,5R)-1-[2-Fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane;
(1 S,5f?)-1-[2-Fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-
4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane, Enantiomer 2;
1-[4-[(1/?,5S/1S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-(methyloxy)phenyl]ethanonei
1 -[4-[(1 R.5S/1 S,5R)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-(methyloxy)phenyl]-1 -propanone;
(1 R5S/1 S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1-[2-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)- 4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1S,5R)-3-(3-{[4-Methyl-5-(2-methyl-3-pyridinyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-[4-
(trifluoromethyl)phenyl]-3-azabicyclo[3.1.OJhexane;
(1 S,5R)-3-(3-{[4-Methyl-5-(4-pyridazinyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1 -[4-
(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-3-(3-{[5-(1 ,5-Dimethyl-1 H-pyrazol-4-yl)-4-methyl-4H-1 ,2,4-triazol-3-yl]thio}propyl)- 1 -^-(trifluoromethyOphenyll-S-azabicycloβ.1.0]hexane;
(1 S,5R)-3-(3-{[4-Methyl-5-(5-pyrimidinyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-[4-
(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-3-(3-{[4-Methyl-5-(3-methyl-2-furanyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-[4-
(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(IS.SRJ-S-CS-p-Methyl-δ-Ce-methyl-S-pyridinylHH-I ^Λ-triazol-S-yllthioJpropyO-i-μ- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-3-(3-{[5-(2,4-Dimethyl-1 ,3-thiazol-5-yl)-4-methyl-4H-1 ,2,4-triazol-3-yl]thio}propyl)-
1 -[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-3-(3-{[4-Methyl-5-(5-methyl-2-pyrazinyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-[4-
(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(I S.SRJ-S^S-^-Methyl-δ-Ctetrahydro^H-pyran^-ylHH-i ^^-triazol-S-yOthioJpropyO-i-μ- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; 2-Methyl-6-{4-methyl-5-[(3-{(1 S,5R)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hex-3- yl}propyl)thio]-4H-1 ,2,4-triazol-3-yl}quinoline;
8-Fluoro-2-methyl-5-{4-methyl-5-[(3-{(1S,5R)-1-[4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hex-3-yl}propyl)thio]-4H-1 ,2,4-triazol-3-yl}quinoline;
2-Methyl-5-{4-methyl-5-[(3-{(1 S,5R)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hex-3- yl}propyl)thio]-4H-1 ,2,4-triazol-3-yl}quinoline;
(1S,5R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(2-methyl-3-pyridinyl)-4H-
1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane;
(1S,5R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-pyridazinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1S,5R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(5-pyrimidinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1S,5R)-3-(3-{[5-(2,4-Dimethyl-1 ,3-thiazol-5-yl)-4-methyl-4H-1 ,2,4-triazol-3-yl]thio}propyl)-
1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; (1 S,5R)-1-[2-Fluoro-4-
(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(5-methyl-2-pyrazinyl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(I S.SRJ-i-^-Fluoro^-CtrifluoronnethyOphenyll-S-tS-^-methyl-S-μ-CtrifluoromethyOphenyl]- 4H-1 ,2,4-triazol-3-yl}thio)propyl]-3-azabicyclo[3.1.OJhexane;
1 -{4-[(1 R.5S/1 S,5R)-3-(3-{[4-Methyl-5-(2-methyl-5-quinolinyl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenyl}-2-pyrrolidinone;
5-{5-[(3-{(1 f?,5S/1 S,5f?)-1-[4-(1 ,1-Dioxido-2-isothiazolidinyl)phenyl]-3-azabicycle-
[3.1.0]hex-3-yl}propyl)thio]-4-methyl-4/-M ,2,4-triazol-3-yl}-2-methylquinoline;
(1 S,5R)-1-[3-Fluoro-4-(trifluoromethyl)phenyl]-5-methyl-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane Enantiomer 1;
1-(2-(Methyloxy)-5-{(1R,5S/7S,5R)-3-[3-({4-methyl-5-[4-(trifluoromethyl)phenyl]-4H-1 ,2,4- triazol-3-yl}thio)propyl]-3-azabicyclo[3.1.0]hex-1 -yl}phenyl)ethanone;
1-[5-[(1f?,5S/^S,5R)-3-(3-{[5-(3,4-Difluorophenyl)-4-methyl-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-(methyloxy)phenyl]ethanonei
1-{2-(Methyloxy)-5-[(1R,5S/7S,5R)-3-(3-{[4-methyl-5-(3-pyridinyl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenyl}ethanone;
1-[5-[(1 f?,5S/tS,5f?)-3-(3-{[4-Methyl-5-(2-methyl-5-quinolinyl)-4H-1 ,2,4-triazol-3- yllthioJpropyO-S-azabicyclo^.i .Olhex-i-yll^-CmethyloxyJphenyllethanone;
1 -{2-(Methyloxy)-5-[(1 f?,5S/^S,5R)-3-(3-{[4-methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenyl}ethanone;
1-(2-Hydroxy-5-{(1R,5S/rS,5R)-3-[3-({4-methyl-5-[4-(trifluoromethyl)phenyl]-4H-1 ,2,4- triazol-3-yl}thio)propyl]-3-azabicyclo[3.1.0]hex-1 -yl}phenyl)ethanone;
1-{5-[(1R,5S/7S,5R)-3-(3-{[5-(3,4-Difluorophenyl)-4-methyl-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-hydroxyphenyl}ethanone;
1 -{2-Hydroxy-5-[(1 R,5S/7S,5R)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenyl}ethanone;
1-{2-Hydroxy-5-[(1f?,5S/tS,5R)-3-(3-{[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1 ,2,4-triazol- 3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenyl}ethanone; 1-[5-[(1 R5S/ySI5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-2-(methyloxy)phenyl]-1-propanone;
1-[5-[(7S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}- propvl)-3-azabicyclor3.1.01hex-1-yll-2-(methyloxv)phenvll-1-propanone Enantiomer 1 ;
2-Methyl-5-[(1R5S/7S,5/?)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-1 ,3-benzothiazole;
2-Methyl-5-[(7S,5/:?)-3-(3-{[4-methyl-5-(4-methyl-1 l3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-1 ,3-benzothiazole, Enantiomer 1 ;
2-Methyl-6-[(1R,5S/7S,5R)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-1 ,3-benzothiazole;
1-Methyl-5-[(1/?,5S/rS,5/?)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-1 H-indazole;
1-Methyl-5-[(ϊS,5R)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-1/-/-indazole, Enantiomer 1 ;
(1 R,5S/7S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1 -[θ-ttrifluoromethyO-S-pyridinylJ-S-azabicycloβ.1.0]hexane;
(1/?,5S/yS,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(2-methyl-3-pyridinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane;
(1 R,5S/tS,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(4-pyridazinyl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.Ojhexane;
(1 R,5S/ϊS,5f?)-1-(4-Bromophenyl)-3-(3-{[5-(5-chloro-1-methyl-1 H-pyrazol-4-yl)-4-methyl-
4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 R,5S/7S,5f?)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(1-methyl-1 H-1 ,2,3-triazol-4-yl)-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 R,5S/7S,5R)-1-(4-Bromophenyl)-3-(3-{[5-(1 ,5-dimethyl-1 H-pyrazol-4-yl)-4-methyl-4H-
1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 f?,5S/tS,5f?)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(5-pyrimidinyl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 R,5S/ϊS,5R)-1-(4-Bromophenyl)-3-[3-({4-methyl-5-[1-methyl-3-(trifluoromethyl)-1 H- pyrazol-4-yl]-4H-1 ^^-triazol-S-yllthioJpropylJ-S-azabicyclotS.1.0]hexane;
(1 R,5S/7S,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(3-methyl-2-furanyl)-4H-1 ,2,4-triazol-
3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1f?,5S/ϊS,5f?)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(3-methyl-5-isoxazolyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 R,5S/tS,5f?)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(6-methyl-3-pyridinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 R,5S/fS,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(1-methyl-1 H-pyrazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 R,5S/tS,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(5-methyl-3-pyridinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 R,5S/ϊS,5f?)-1-(4-Bromophenyl)-3-[3-({4-methyl-5-[2-methyl-5-(trifluoromethyl)-1 ,3- oxazol-4-yl]-4H-1 ^^-triazol-S-ylJthioJpropyll-S-azabicyclo^.1.0]hexane; (1 R,5S/7S,5f?)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(3-methyl-2-pyridinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane;
(1 f?,5S/tS,5R)-1-(4-Bromophenyl)-3-(3-{[5-(2,4-dimethyl-1 ,3-thiazol-5-yl)-4-methyl-4H-
1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1/?,5S/7S,5/?)-1-(4-Bromophenyl)-3-(3-{[5-(2,5-dimethyl-3-furanyl)-4-methyl-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane;
(1 R,5S/7S,5R)-1-(4-Bromophenyl)-3-(3-{-[ 5-(5-chloro-2-thienyl)-4-methyl-4H-1 ,2,4-triazol-
3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1R,5S/ϊS,5R)-1-(4-Bromophenyl)-3-(3-{[4-ethyl-5-(3-pyridinyl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1/?,5S/yS,5f?)-1-(4-Bromophenyl)-3-[3-({4-methyl-5-[2-methyl-6-(trifluoromethyl)-3- pyridinyl]-4H-1 ,2,4-triazol-3-yl}thio)propyl]-3-azabicyclo[3.1.0]hexane.
5-[5-({3-[(1f?,5S/7S,5R)-1-(4-Bromophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4- methyl-4H-1 ,2,4-triazol-3-yl]-1-methyl-3-(trifluoromethyl)-1 H-thieno[2,3-c]pyrazole;
3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-
(I R.SR/fS^S^I-^-CtrifluoromethyO^-pyridinyll-S-azabicyclotS.I .Olhexane;
3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-(1/?,5f?)-1-[5- (trifluoromethyl)-2-pyridinyl]-3-azabicyclo[3.1.0]hexane, Enantiomer 2;
3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-
(IR.SR/fS.SSJ-i-tβ-CtrifluoromethyO^-pyridinylJ-S-azabicyclo^.i .Olhexane;
(1R,5S/tS,5R)-1-[3-Fluoro-4-(1 H-pyrrol-1-ylmethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-
1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 S.5R/1 R,5S)-3-(3-{[4-Methyl-5-(5-methyl-2-pyrazinyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1 - [e-CtrifluoromethyO-S-pyridinyll-S-azabicycloβ.1.0]hexane;
(1 S.5R/1 R,5S)-3-(3-{[4-Methyl-5-(6-methyl-3-pyridinyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1 -
[e-CtrifluoromethyO-S-pyridinylJ-S-azabicyclotS.1.0]hexane;
(1 S.5R/1 R,5S)-3-(3-{[4-Methyl-5-(2-methyl-3-pyridinyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1 -
[6-(trifluoromethyl)-3-pyridinyl]-3-azabicyclo[3.1.OJhexane;
(1 S,5R/1 R,5S)-3-{3-[(4-Methyl-5-phenyl-4H-1 ,2,4-triazol-3-yl)thio]propyl}-1-[6- (trifluoromethyl)-3-pyridinyl]-3-azabicyclo[3.1.0]hexane;
(1 S.5R/1 R,5S)-3-(3-{[5-(2,4-Dimethyl-1 ,3-thiazol-5-yl)-4-methyl-4H-1 ,2,4-triazol-3- yOthioJpropyO-i-ie-^rifluoromethyO-S-pyridinyll-S-azabicycloIS.I .Olhexane;
(1 S.5R/1 R,5S)-3-[3-({4-Methyl-5-[4-(trifluoromethyl)phenyl]-4H-1 ,2,4-triazol-3- yl}thio)propyl]-1 -[θ-^rifluoromethyO-S-pyridinylJ-S-azabicyclotS.1.0]hexane;
(1 S.5R/1 R,5S)-2-Methyl-5-[3-(3-{[4-methyl-5-(5-methyl-2-pyrazinyl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-1 ,3-benzothiazole;
(1 S.5R/1 R,5S)-2-Methyl-5-[3-(3-{[4-methyl-5-(6-methyl-3-pyridinyl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-1 ,3-benzothiazole;
(1 S.5R/1 R,5S)-2-Methyl-5-(3-{3-[(4-methyl-5-phenyl-4H-1 ,2,4-triazol-3-yl)thio]propyl}-3- azabicyclo[3.1.0]hex-1 -yl)-1 ,3-benzothiazole;
(1 S.5R/1 R,5S)-5-[3-(3-{[5-(2,4-Dimethyl-1 ,3-thiazol-5-yl)-4-methyl-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-methyl-1 ,3-benzothiazole; (1 S.5R/1 R,5S)-2-Methyl-5-{3-[3-({4-methyl-5-[4-(trifluoromethyl)phenyl]-4H-1 ,2,4-triazol-3- yl}thio)propyl]-3-azabicyclo[3.1.0]hex-1 -yl}-1 ,3-benzothiazole;
(1f?,5S/1 S,5R)-1-[3-Fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-S-yO^H-I ^Λ-triazol-S-yljthioJpropyO-azabicyclotS.I .Olhexane;
(1 S,5/?)-1-[3-Fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)- 4H- 1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.0]hexane, Enantiomer 1 ;
(1 R.5S/1 S,5R)-1 -[2-Fluoro-3-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.OJhexane;
(1 S,5f?)-1-[2-Fluoro-3-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-
4H- 1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.0]hexane, Enantiomer 2;
(1/?,5S/1S,5/?)-1-[4-(Methyloxy)-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1,3- oxazol-5-yl)-4H-1 ^^-triazol-S-yljthiolpropyO-azabicycloβ.1.0]hexane;
(1R,5S/1 S,5f?)-1-[4-(4-Chloro-2-fluorophenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-
4H- 1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo [3.1.OJhexane;
(1R,5S/1 S,5R)-1-[3-(2-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1 -{3-[(trifluoromethyl)oxy]phenyl}-3-azabicyclo[3.1.0]hexane;
(1R,5S/1 S,5f?)- 1-(2-Chloro-4-methylphenyl)-3-(2-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)- 4/-/-1 ,2,4-triazol-3-yl]thio}piOpyl)-3-azabicyclo[3.1.0]hexane;
(1R,5S/1 S,5R)-1-[3-Chloro-4-(methyloxy)phenyl]-3-(2-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5- yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane;
(1R,5S/1 S,5R)-1-[4-(2,4-Dimethyl-1 ,3-thiazol-5-yl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 R.5S/1 S,5R)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1 ^-[θ-CtrifluoromethyO^-pyridinyOphenylJ-S-azabicycIo^.1.0]hexane;
(1R,5S/1 S,5R)-1-[3-(2,4-dimethyl-1 ,3-thiazol-5-yl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ^^-triazol-S-ylJthiolpropyO-S-azabicyclo^.1.0]hexane;
(1 R.5S/1 S,5f?)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1 -[S-CS-methyl^-thienyOphenyll-S-azabicyclo^.1.0]hexane;
(1 R.5S/1 S,5R)-1-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1S,5R)-3-(3-{[5-(2,4-Dimethyl-1 ,3-oxazol-5-yl)-4-methyl-4H-1 ,2,4-triazol-3-yl]thio}propyl)- i-^-fluoro^-CtrifluoromethyOphenyll-S-azabicyclotS.I .Olhexane; and salts thereof, in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
Thus, a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I) selected from the list of compounds above or a salt thereof. Also provided is a compound of formula (I) selected from the list of compounds above cited or a salt thereof for use in the treatment of a somatorm disorder as defined above and premature ejaculation.
In a further embodiment of the present invention a new use is provided of a compound selected from the group consisting of:
(1R.5S/1 S,5/?)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- ylJthioJpropylJ-i-β-CtrifluoromethyOphenylJ-S-azabicycloβ.i . OJhexane;
(1 S,5R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-
4/-/-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane; (tS,5R)-3-(3-{[4-Methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-
{4-[(trifluoromethyl)oxy]phenyl}-3-azabicyclo[3.1.0]hexane, Enantiomer 1 ;
(1S,5R)-3-(3-{[4-Methyl-5-(2-methyl-3-pyridinyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1-[4-
(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-3-(3-{[4-Methyl-5-(4-pyridazinyl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-1 -[4-
(trifluoromethyl)phenyl]-3-azabicyclo[3.1.OJhexane; (1 S,5R)-3-(3-{[5-(2,4-Dimethyl-1 ,3-thiazol-5-yl)-4-methyl-4H-1 ,2,4-triazol-3-yl]thio}propyl)-
1 -[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.OJhexane;
(1S,5R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-pyridazinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane;
(1 S,5R)-3-(3-{[5-(2,4-Dimethyl-1 ,3-thiazol-5-yl)-4-methyl-4H-1 ,2,4-thazol-3-yl]thio}propyl)-
1 -^-fluoro^-CtrifluoromethyOphenylJ-S-azabicyclofS.1.OJhexane; (1 S,5R)-1 -[3-Fluoro-4-(trifluoromethyl)phenylJ-5-methyl-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4/-/-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane Enantiomer 1 ;
(1 R5S/ϊS,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(6-methyl-3-pyridinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane;
3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-(1 f?,5f?)-1-[5-
(trifluoromethyl)-2-pyridinyl]-3-azabicyclo[3.1.OJhexane, Enantiomer 2; (1 S,5R)-1 -[3-Fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-
4H-1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.OJhexane, Enantiomer 1 ;
(1 S,5R)-3-(3-{[5-(2,4-Dimethyl-1 ,3-oxazol-5-yl)-4-methyl-4H-1 ,2,4-triazol-3-yl]thio}propyl)-
1 -β-fluoro^trifluoromethyOphenylJ-S-azabicycloβ.1.OJhexane; and salts thereof, in the manufacture of a medicament for the treatment of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions,
Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculationin a mammal.
Thus, a still further aspect of the invention provides a method of treating of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions,
Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I) selected from the list of compounds above and salts thereof.
Also provided is a compound of formula (I) selected from the list of compounds above, and salts thereof, for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation.
In a further aspect, a somatoform disorder is binge eating.
It is intended that reference to particular compounds herein be interpreted to mean that the salts, solvates and prodrugs of those compounds may also be employed.
Examples
The invention is further illustrated by the following non-limiting examples. Preparations 1 to 5 were carried out in analogy to the synthetic route described in J.Med.Chem. 1981 , 24, 481-490.
All temperatures refer to 0C. Infrared spectra were measured on a FT-IR instrument. Compounds were analysed by direct infusion of the sample dissolved in acetonitrile into a mass spectra operated in positive electro spray (ES+) ionisation mode. Proton Magnetic Resonance (1H-NMR) spectra were recorded at 400 MHz, chemical shifts are reported in ppm downfield (d) from Me4Si, used as internal standard, and are assigned as singlets (s), broad singlets (bs), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or multiplets (m).
Experimental vibrational circular dichroism (VCD) spectra were measured using a ChirallRTM VCD spectrometer operating in the 2000-800 cm-1 frequency range. Spectra were measured at room temperature (23o C) using a sealed transmission cell with barium fluoride windows and a path length of 100 microns. (Scan times varied from 60 to 120 minutes per isomer.) Sample solutions were typically prepared by dissolving 10 milligrams of each enantiomer in 100 microliters of deutero-chloroform (CDCI3). For ab initio assignments, VCD and unpolarized IR spectra were calculated using the Gaussian 98 software package.1.
Optical rotations were measured using a (Perkin Elmer Model 241 ) polarimeter operating at 589 nm (Sodium source). Measurements were made using a 1 decimeter microcell thermostated at 23o C. Concentrations were typically 10 mg/ml (c=0.01). For ab initio OR assignments, the Dalton Quantum Chemistry Program was used. Column chromathography was carried out over silica gel (Merck AG Darmstaadt, Germany). The following abbreviations are used in the text: NBS = N-bromosuccinimide, Vitride = "Red-AI®", HOBt = 1-hydroxybenzotriazole EtOAc = ethyl acetate, Et2O = dietyl ether, DMF = N,N'-dimethylformamide, MeOH = methanol, TFA = trifluoroacetic acid, tetrahydrofuran = tetrahydrofuran, IPA = isopropanol, TEA = triethylamine, DCC = 1 ,3- dicyclohexylcarbodiimide, SCX = strong cation exchanger, TIc refers to thin layer chromatography on silica plates, and dried refers to a solution dried over anhydrous sodium sulphate, r.t. (RT) refers to room temperature, Rt = retention time, DMSO = dimethyl sulfoxide.
Preparation 1 : Methyl bromo(4-methoxyphenyl)acetate
Figure imgf000031_0001
To a mixture of methyl 4-methoxyphenylacetate (20 g, 0.11 mol) and NBS (0.11 mol) in CCI4 (0.2 I) were added 3 drops of 48% HBr and this mixture was heated to reflux for 8 h. The cooled solution was filtered through a pad of silica gel and the filtrate was evaporated in vacuo to give 29 g of the title compound as pale yellow oil, which was used in the subsequent step without further purification.
NMR (1H, CDCI3): δ 7.3 (d, 2H), 6.8 (d, 2H), 5.1 (s, 1 H), 3.8 (s, 3H), 3.5 (s, 3H).
Preparation 2: Dimethyl i-^-methoxyphenylH ^-cyclopropanedicarboxylate
Figure imgf000031_0002
COOMe
To a stirred slurry of of NaH (4.4 g , 60% in mineral oil) in anhydrous Et2O (0.3 I )was added methanol (10.3 mL) followed by a solution of bromo ester obtained in Prep. 1 methyl bromo(4-methoxyphenyl)acetate (29 g) in methyl acrylate (19.8 mL) (for examples starting from an ethyl phenylacetate derivative ethanol and ethyl acrylate were used, respectively) and methanol (3 mL) at 0 0C, over a 30 min.. The mixture was stirred at 25 0C for 24 h and then unreacted NaH was decomposed with 3 mL methanol. Water was added (75 mL), the organic phase separated, dried over Na2SO4 and filtered. Volatiles were evaporated in vacuo to give 31.5 g of the title compound as an oil, which was used in the subsequent step without further purification.
NMR (1H1 CDCI3): δ 7.3 (d, 2H), 6.8 (d, 2H), 3.77 (s, 3H), 3.73 (s, 3H), 3.64 (s, 3H), 2.18 (dd, 1 H), 2.05 (dd, 1 H), 1.46 (dd, 1 H). MS (mlz): 265.4[MH]+. Preparation 3: 1-(4-Methoxyphenyl)-1,2-cyclopropanedicarboxylic acid
Figure imgf000032_0001
A mixture of diester obtained in Prep. 2 (31.5 g) and KOH (13.5 g) in 1 :1 EtOH:H2O (240 ml.) was heated at reflux for 6 h and then concentrated to half the original volume. The aqueous solution was extracted with Et2O, chilled in ice, and then made acidic with 25 ml_ of 12N HCI. White crystalline product was collected by filtration and dried under vacuo to give 12.8 of the title compound (overall yield from methyl bromo(4- methoxyphenyl)acetate: 50%).
NMR (1H1 DMSO): δ 12.5 (bs,2H), 7.25 (d, 2H), 6.85 (d, 2H), 3.7 (s, 3H), 2.0 (dd, 1 H), 1.85 (dd, 1 H), 1.38 (dd, 1 H). MS (m/z): 235.0[M-H]".
Preparation 4: (1 /?,5S/1 S,5R)-1 -[4-(Methoxy)phenyl]-3-azabicyclo[3.1.0]hexane-2,4- dione
Figure imgf000032_0002
A mixture of 12.8 g of the diacid obtained in Preparation 3 and 6.5 g of urea in 300 ml_ of m-xylene was heated at reflux for 8 h and then concentrated to dryness in vacuo. The crude was purified by column chromatography (AcOEt:cyclohexane=1 (?):10 to 4:6) to give 5.5 g of the title compound (y= 46%).
MS (m/z): 218.1 [MH]+.
Preparation 5: (1 f?,5S/1S,5f?)-1-[4-(Methoxy)phenyl]-3-azabicyclo[3.1.0]hexane
Figure imgf000032_0003
To a stirred slurry of 5.5 g of the imide obtained in Preparation 4 in 170 ml_ of toluene was slowly added 45 ml_ of Vitride (3.4 M in toluene) under N2. This solution was stirred at reflux for 2 h. To the cooled solution was cautiously added aqueous NaOH (10 M, 40 ml.) and the organic layer was washed with two portions of water and dried over Na2SO4. This solution was filtered, and the filtrate was evaporated in vacuo to give 4.8 g of the title compound (y= 100%).
NMR (1H, CDCI3): δ 7.10 (d, 2H), 6.82 (d, 2H), 3.77 (s, 3H), 3.35-2.98 (m, 4H), 2.58 (dd, 1 H), 0.87 (dd, 1H), 0.78 (dd, 1 H), NH not observed. MS (m/z): 190.1[MH]+.
Preparation 6: (1 R.5S/1 S,5R)-1 -(4-Bromophenyl)-3-azabicyclo[3.1.0]hexane
Figure imgf000033_0001
To 20 ml. of 1M BH3-tetrahydrofuran, stirred at 0 0C under N2, was slowly added a solution of 1.32 g (5 mmol) of (1R,5S/1 S,5R)-1-(4-bromophenyl)-3-azabicyclo[3.1.0]hexane-2,4- dione, prepared in analogy to Preparation 4, in 2OmL of dry tetrahydrofuran. This solution was stirred at room temperature for 15 min and then warmed on a steam bath for 1 h. The solution was then cooled in an ice bath, 2.5 mL of 6 M HCI was added cautiously, and the solvent was removed in vacuo. The residual material was combined with 12.5 mL of 5 M
NaOH and the mixture was extracted with ether. The ether extract was washed twice with water, dried over Na2SO4 and filtered to give 1.19 g of the title compound (y= 100%).
NMR (1H, CDCI3): δ 7.35 (d, 2H), 7.02 (d, 2H), 3.25-2.96 (m, 4H), 1.63 (dd, 1 H), 1.55 (dd, 1 H), 1.30 (dd, 1 H), NH not observed. MS (m/z): 238.1[MH]M Br.
Preparation 7: (1A?,5S/1S,5/?j- 4-[3-(Trifluoroacetyl)-3-azabicyclo[3.1.0]hex-1- yljbenzonitrile
Figure imgf000033_0002
Triflouroacetic anhydride (0.21 mL) was added to a solution of 4-[3-azabicyclo[3.1.0]hex- 1-yl]benzonitrile (280 mg, prepared in analogy to the method described in Preparation 5), and triethylamine (0.25 mL) in dichloromethane (15 mL) at O0C. The reaction mixture was allowed to warm to room temperature over 2h, then washed with saturated NaHCO3, the organic layer dried and evaporated to give 269 mg of the title compound.
MS (mlz): 281.2[MH]+.
Preparation 8: (1R,5S/1S,5R)- 4-[3-(Trifluoroacetyl)-3-azabicyclo[3.1.0]hex-1- yl]benzaldehyde
Figure imgf000034_0001
A mixture of 4-[3-(trifluoroacetyl)-azabicyclo[3.1.0]hex-1-yl]benzonitrile (283 mg), Ni-Al alloy (450 mg) , formic acid (3.9 ml.) and water (1.1 ml_) was stirred at 80 0C for 3h. The reaction mixture was cooled to room temperature and filtered. The filtrate was extracted with ethyl acetate and the organic phase washed with NaHCO3, dried over Na2SO4 and evaporated in vacuo to give 195 mg of the title compound as yellow oil. .
MS (m/z): 284.2[MH]+.
Preparation 9: (1R,5S/1S,5R)- ^-(TrifluoroacetyO-S-azabicycloβ.i.Olhex-i- yl]benzaldehyde oxime
Figure imgf000034_0002
To a solution of 4-[3-(trifluoroacetyl)-3-azabicyclo[3.1.0]hex-1-yl]benzaldehyde (195 mg) in 5 mL of pyridine was added hydroxylamine hydrochloride (57.5 mg) and the mixture was stirred for 3 h at room temperature. The solvent was evaporated, the crude dissolved in ethyl acetate and the organic phase washed with 10% aqueous Na2CO3 and brine, dried over Na2SO4 and evaporated in vacuo to give 225 mg of the title compound as yellow oil. .
MS (m/z): 299.2[MH]+.
Preparation 10: (1R,5S/1S,5/?j- 4-[3-(Trifluoroacetyl)-3-azabicyclo[3.1.0]hex-1-yl]-Λ/- hydroxybenzenecarboximidoyl chloride
Figure imgf000034_0003
To a solution of 4-[3-(trifluoroacetyl)-(3-azabicyclo[3.1.0]hex-1-y]benzaldehyde oxime (0.69 mmol) in 3.5 mL of dimethylformamide was added portion wise Λ/-chlorosuccinimide (97 mg) at 0 0C. After stirring for 1.5 h at 40 0C the solvent was evaporated. The crude product was dissolved in diethyl ether / dichloromethane (4/1 ) and the organic phase washed with water, dried over Na2SO4 and concentrated in vacuo to give 243 mg of the title compound as a brown oil. Preparation 11: (1/?,5S/1S,5/?J- 1-[4-(5-Methyl-3-isoxazolyl)phenyl]-3- (trifluoroacetyl)-3-azabicyclo[3.1.0]hexane
Figure imgf000035_0001
To a solution of 4-[3-(trifluoroacetyl )3-azabicyclo[3.1.0]hex-1-yl)-Λ/- hydroxybenzenecarboximidoyl chloride (0.69 mmol) in 6 ml_ of chloroform triethylamine (0.24 ml.) and 2-chloro propene (0.29 ml.) were added and the reaction stirred for 18 h at room temperature. The solution was washed with water, dried over Na2SO4 and volatiles evaporated in vacuo . The crude was purified by column chromatography (AcOEt:cyclohexane=1 :10 to 4:6) to give 180 mg of the title compound. MS (m/z): 337.2[MH]+.
Preparation 12: (1/?,5S/1S,5f?> 1-[4-(5-Methyl-3-isoxazolyl)phenyl]-3- azabicyclo[3.1.OJhexane
Figure imgf000035_0002
A mixture of 1 -[4-(5-methyl-3-isoxazolyl)phenyl]-3-(trifluoroacetyl)-3- azabicyclo[3.1.0]hexane (0.54 mmol) and K2CO3 (296 mg )in methanol (5 mL) and water (5 mL) was stirred for 4 h at 50 0C. The solvent was evaporated in vacuo and the product treated with dichloromethane / isopropanol 1/1 and filtered. The filtrate was dried over Na2SO4 and volatiles evaporated in vacuo to give 105 mg of the title compound (y= 81%).
MS (m/z): 241.2[MH]+.
Preparation 13: 5-{5-[(3-Chloropropyl)thio]-4-methyl-4H-1,2,4-triazol-3-yl}-2- methylquinoline
Figure imgf000035_0003
To 4-methyl-5-(2-methyl-5-quinolinyl)-2,4-dihydro-3H-1 ,2,4-triazole-3-thione (3.6 g, prepared in analogy to the method described in WO200240471 ) in ethanol (60 mL) containing 1-bromo-3-chloropropane (2.0 mL) was carefully added with stirring sodium hydride (0.60 g, 60% in petrolium). The mixture was heated at reflux for 45 min. Volatiles were evaporated in vacuo and the residue submitted to column chromatography (EtOAc - acetone gradient). The material thus obtained was precipitated from hot EtOAc (20 ml_) by adding petroleum ether (40-60, 50 ml_), cooled and collected by filtration to provide the title compound as colourless crystals (2.1 g).
NMR (1H, CDCI3): δ 8.18 (d, 1 H), 8.12 (d, 1 H), 7.76 (t, 1 H), 7.55 (d, 1 H), 7.30 (d, 1 H), 3.75 (t, 2H), 3.50 (t, 2H), 3.40 (s, 3H), 2.76 (s, 3H), 2.37 (m, 2H).
Preparation 14: 3-[(3-Chloropropyl)thio]-4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazole
Figure imgf000036_0001
Ethyl-2-chloroacetoacetate (1 wt; 1 eq., 1000 g) was aged with formamide (0.68 vol; ca. 2.8 eq.) and the resulting solution was heated to 120 0C. After 5 hours the mixture was allowed to cool to room temperature and allowed to age under nitrogen over night. The mixture was treated with NaOH (3 M, 6 vol, reaction moderately exothermic) and stirred at room temperature for 4 hours. Ethyl acetate (6 vol) was added and the phases allowed to separae. The organic layer was discarded while the aqueous was acidified with cone. (32%) aqueous HCI to pH 2 (ca. 2.0 vol). A precipitate started to form. The suspension was treated with AcOEt (8 vol) and vigorously stirred until the bulk of the precipitate had dissolved. The aqueous phase was further extracted with AcOEt twice (6 vol each) and the combined organic layers distilled to low volume (again a suspension was observed at low volume). Fresh AcOEt (8 vol) was added and the mixture evaporated to dryness. The collected solid was placed in the oven at 40 0C over night under reduced pressure to give 4-methyl-1 ,3-oxazole-5-carboxylic acid (498 g, 64.5%).
This material (498 g, 1 wt) was dissolved in dry tetrahydrofuran (5 vol), under nitrogen, cooled to 0 0C. DCC (1.62 wt, 1 eq) was added portionwise followed by HOBt (1.07 wt, 1 eq). The mixture was warmed to 25±2 0C and stirred for 30 min. 4-Methyl-3- thiosemicarbazide (0.83 wt, 1 eq) was then added and the mixture further stirred for 2 h at 25±2°C. The mixture was filtered and the cake was washed with fresh tetrahydrofuran (1 vol) and dried on the filter for a few hours. The cake was suspended in 1 M aqueous NaOH (13 vol) and heated to 70 0C for 30 min. After this time, the mixture was cooled to 25±2 0C and a solid was removed by filtration. The cake was washed with 1 M aqueous NaOH (10 vol). The combined mother liquors were cooled to 0 0C and acidified to ca. pH 5 with HCI (aqueous, 16%; NOTE: keep temperature while adding HCI below +10 0C). The suspended product was isolated by filtration washing with water (2x3 vol). The cake was dried at 40 0C for 18 h in high vacuum to obtain 4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-2,4- dihydro-3H-1 ,2,4-triazole-3-thione (respectively a tautomeric form thereof; 290 g, 37%). NaOEt (21% solution in EtOH, 2.08 vol, 1.1 eq) was added to EtOH (20 vol) under nitrogen atmosphere. 4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-2,4-dihydro-3/-/-1 ,2,4-triazole- 3-thione (respectively a tautomeric form thereof; 290 g, 1 wt) was added in one portion and the resulting mixture stirred at 25±2°C until a clear solution was obtained. Then 1- bromo-3-chloropropane (0.54 vol, 1.1 eq) was added and the solution stirred at 40 'C for 24 h then cooled to 25 'C. After filtration water (20 vol) was added and the ethanolic phase was removed by vacuum distillation (internal temperature ~40 'C). The mixture was extracted with EtOAc (41 vol). The aqueous layer was removed and the organic phase was evaporated to dryness. Dichloromethane (4 vol) was added. The organic solution is purified through a short silica gel column (18 wt of silica), eluting with EtOAc (200 vol) to give the title compound as a solid foam (267.64 g, 66%).
NMR (1H, CDCI3): δ 7.90 (s, 1 H), 3.70 (s, 5H), 3.40 (t, 2H), 2.52 (s, 3H), 2.30 (m, 2H).
Preparation 15: 3-[4-(Trifluoromethyl)phenyl]-1 H-pyrrole-2,5-dione
Figure imgf000037_0001
A mixture of hydrochloric acid (37%, 285 mL) and water (190 ml.) was added to 4- (trifluoromethyl)aniline (15O g, 116 mL) at room temperature with vigorous stirring and the formed precipitate was allowed to stir for further 30 minutes. Temperature was reduced to 0 CC and sodium nitrite (70.6 g) in 180 mL of water was added dropwise to the stirred suspension. At the end of diazotisation, a clear yellow solution was obtained. Maleimide (180 g) in acetone (1.1 I) was added dropwise at 0 °C and then the pH of the solution was adjusted to 3-3.5 by adding sodium acetate. Copper (II) chloride (18.8 g) was added to the vigorously stirred mixture. After a few minutes a gas started to develop (conspicuous foaming). The reaction mixture was allowed to stir at 0 0C for 1 h and overnight at room temperature.
Acetone was removed in vacuo, the residue was filtered and dried overnight in vacuo to give the title compound (155 g) as a light brown solid (y = 63%). MS (m/z): 242.2 [MH]+.
Preparation 16: (1 R.5S/1 S,5/?)-1 -[4-(Trif luoromethyl)phenyl]-3-azabicyclo[3.1.0]- hexane-2,4-dione
Figure imgf000038_0001
Milled sodium hydroxide (40 g) was added in small portions to a stirred solution of trimethylsulfoxonium iodide (219 g) in DMSO (anhydrous, 2 I). The resulting mixture was allowed to stir at room temperature for 1.5 h.
3-[4-(Trifluoromethyl)phenyl]-1/-/-pyrrole-2,5-dione (Preparation 15, 120 g) dissolved in DMSO (anhydrous, 0.5 I) was then added dropwise and the resulting mixture was allowed to stir at room temperature for 20 minutes. Temperature was then reduced to 0 0C and NH4CI (aqueous saturated solution, 2 I) was slowly added, followed by Et2O (1 I). After separation of the two phases, the aqueous layer was repeatedly extracted with Et2O (3 x 1 I). Combined organic layers were washed with brine (2 x 1 I) and then dried over Na2SO4. Evaporation of the solvent gave a light brown solid which was suspended in 1 I of dichloromethane and 1 I of cyclohexane. The mixture was allowed to stir at room temperature for 45 minutes and then filtered to give the title compound (116 g) as white solid (y = 71%).
MS (mlz): 256.1 [MH]+.
Preparation 17: (1 R,5Sή S,5/?)-1 -[4-(Trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]- hexane
Figure imgf000038_0002
Borane (1 M in tetrahydrofuran, 1.4 I) was charged into a 5 I reactor under N2 and cooled at 0 0C. (1/?,5S/1 S,5/?)-1-[4-(Trifluoromethyl)phenyl]-3-a2abicyclo[3.1.0]hexane-2,4-dione (Preparation 16, 101 g) dissolved in tetrahydrofuran (anhydrous, 1 I) was then added dropwise with vigorous stirring whereby the temperature was constantly kept below 5 °C and gas evolution was monitored. At the end of the addition the resulting mixture was allowed to stir at 0 0C for 1 h and then at room temperature overnight.
The mixture was then cooled to 0 0C and methanol (200 ml.) followed by hydrochloric acid (6 M solution, 0.8 I) were cautiously added monitoring gas evolution, tetrahydrofuran was then removed in vacuo, the residue was cooled to 0 0C and sodium hydroxide (5 M solution) was added until pH 9-10 had been reached. The aqueous layer was extracted with Et2O (3 x 1 I). Removal of solvent in vacuo gave the title compound (140 g) as colorless oil.
MS (m/z): 228.1 [MH]+.
Preparation 18: (1S,5/?)-1-[4-(Trifiuoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane
Figure imgf000039_0001
(S) - (+) - Mandelic acid (94 g) was added in portions to a stirred solution of (1f?,5S/1 S,5f?)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (Preparation 17, 140 g) in 1.4 I of tetrahydrofuran. The resulting mixture was stirred at room temperature for 2 h until a white precipitate was formed. The mixture was then warmed up to reflux temperature, stirred for 45 minutes and then slowly cooled down to room temperature. The white solid was collected by filtration and dried in vacuo. This material was recrystallised 4 times from tetrahydrofuran (10 volumes) to give 32.5 g of a white solid. This material was then suspended in sodium hydroxide (1 M solution, 400 ml_) and Et2O (400 ml_) and allowed to stir at room temperature until complete dissolution. After separation of the two phases, the aqueous layer was extracted again with Et2O (3 x 250 ml_). Combined organic layers were washed with sodium hydroxide (1 M solution, 3 x 200 mL) and then dried over Na2SO4. Evaporation of solvent in vacuo gave the title compound (19 g) as white solid (y = 37%).
The absolute configuration of the optical isomers was assigned using comparative VCD (vibrational circular dichroism) and OR (optical rotation) analyses.
The configuration of the title compound was assigned by comparing its experimental VCD spectrum and observed specific rotation to the data observed for (1 S,5R)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane (see Preparation 48) as the reference sample. The assignment of the absolute configuration of the title compound was confirmed by a single crystal X-ray structure obtained from a crystal of (1 S,5R)-1-[4- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane, (S)-(+)-mandelic acid salt. Both, analysis based on the known configuration of the (S)(+)- mandelic acid and on the basis of anomalous dispersion effects confirmed the assignment of the title compound as being (1 S,5R)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane.
NMR (1H, CDCI3): δ 7.51 (d, 2H), 7.25 (d, 2H), 3.20 (d, 1 H), 3.0-3.1 (m, 3H), 1.69 (m, 1 H), 0.8-1.0 (m, 2H), NH not observed. MS (mlz): 228.1 [MH]+. Analytical chromatography
Column: chiralcel OD 10 um, 250 x 4.6 mm
Mobile phase: A: n-Hexane; B: lsopropanol +0.1% lsopropyl amine Gradient: isocratic 2% B Flow rate: 1 ml_/min
UV wavelengh range: 200-400 nm Analysis time 25 min ret. time (min) % a/a
16.5 0.4 (1 R,5S)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane
21.7 99.6 title compound Specific Optical Rotation: [D]0 = - 10 ° (CDCI3, T = 20 0C, c = 0.004 g/0.8 ml_).
Preparation 19: S-ftfS.S/^-i-I^TrifluoromethylJphenyll-S-azabicycloβ.i.Olhex-a- yl}-1-butanol
Figure imgf000040_0001
To a suspension of (1 S, 5R)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (Preparation 18, 100 mg) in tetrahydrofuran (1.1 ml_), 4-hydroxy-2-butanone (0.66 mmol), acetic acid (0.66 mmol) and NaBH(OAc)3 (0.88 mmol) were added. The mixture was stirred at room temperature for 2 h. After addition of NaOH (1 M), the solvent was eliminated under vacuo, the residue was dissolved in ethyl acetate and the organic layer was washed with H2O and dried over Na2SO4. This solution was concentrated in vacuo to give 130 mg of the title compound which was used without further purification. MS (m/z): 300 [MH]+.
Preparation 20: (tS,5R)-3-(3-Chloro-1-methylpropyl)-1-[4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000040_0002
To a solution of 3-{(1 S,5R)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hex-3-yl}-1- butanol (Preparation 19, 130 mg) in chloroform (4 ml_), thionyl chloride (0.87 mmol) was added and the mixture was stirred at room temperature for 6 h. After addition of NaOH (1 M), dichloromethane was added and the organic layer was washed with Brine and dried over Na2SO4. The solution was concentrated in vacuo and the crude product purified by flash chromatography (ethyl acetate: cyclohexane= 5:95) to give 106 mg of the title compound.
MS (m/z): 318 [MH]+.
Preparation 21 : 1-{5-[(fS,5ft/7R,5S)-3-Azabicyclo[3.1.0]hex-1-yl)-2- (methyloxy)phenyl}ethanone
Figure imgf000041_0001
The title compound was prepared in 32 mg yield from 1-[4-(methyloxy)phenyl]-3- (trifluoroacetyl)-3-azabicyclo[3.1.0]hexane (94 mg) as described for preparation 34.
MS (m/z): 232 [MH]+. HPLC: condition 1 , Rt= 3.393 min.
Preparation 22: (7S,5R/f R,5S)-1-(4-Chlorophenyl)-3-azabicyclo[3.1.0]hexane
Figure imgf000041_0002
The title compound was prepared in 230 mg yield from commercially available methyl 4-chlorophenylacetate (1 g, 5.5 mmol) following the methods described in preparations 1 , 2, 3, 4, 6.
MS (m/z): 194 [MH]+,.
Preparation 23: (1S.5R/1 /?,5S)-1-(4-Fluorophenyl)-3-azabicyclo[3.1.0]hexane
Figure imgf000041_0003
The title compound was prepared in 160 mg yield from commercially available methyl 4-fluorophenylacetate (1 g, 6 mmol) following the methods described in preparations 1 , 2, 3, 4, 6.
MS (m/z): 178 [MH]+. Preparation 24: (fS,5R/7 /^SSM-β-ChlorophenyO-S-azabicycloβ.i .Olhexane
Figure imgf000042_0001
The title compound was prepared in 1.25g yield from commercially available methyl 3-chlorophenylacetate (5 g, 27 mmol) following the methods described in preparations 1 , 2, 3, 4, 5.
MS {ml z): 194 [MH]+. HPLC: condition 1, Rt= 3.469 min.
Preparation 25: {1S.5R/1 R,5S)-1-(3-Fluorophenyl)-3-azabicyclo[3.1.0]hexane
Figure imgf000042_0002
The title compound was prepared in 1.97 g yield from commercially available methyl 3-fluorophenylacetate (5 g, 29.7 mmol) following the methods described in preparations 1 , 2, 3, 4, 5.
MS (m/z): 178 [MH]+.
Preparation 26: (IS.SR/IR.SSJ-i-IS^MethyloxyJphenyll-S-azabicyclo^.i .Olhexane
Figure imgf000042_0003
The title compound was prepared in 1.2 g yield from commercially available methyl 3-methoxyphenylacetate (5 g, 27.7 mmol) following the methods described in preparations 1 , 2, 3, 4, 5.
MS (m/z): 190 [MH]+. HPLC: condition 1 , Rt= 3.219 min.
Preparation 27: (1S,5R/1R,5S)^ -[2-Methyl-4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000042_0004
The title compound was prepared in 71 mg yield from commercially available 2-methyl-4-(trifluoromethyl)aniline (1 g, 5.7 mmol) following the methods described in preparations 15, 16, 17.
MS {ml z)\ 242 [MH]+.
Preparation 28: Methyl bromo{4-[(trifluoromethyl)oxy]phenyl}acetate
Figure imgf000043_0001
To a solution of 4-trifluoromethoxyphenylacetic acid (5 g, 23 mmol) in carbon tetrachloride oxalyl chloride (25 mmol) and two drops of DMF were added at O0C. After stirring the solution at room temperature for 1 h, NBS (25 mmol) and few drops of 48% HBr were added and the mixture was heated to reflux for 4 h. The solution was allowed to cool, MeOH (5 mL) was added and the mixture was stirred at room temperature for 1 h. After filtration through a pad of silica gel, the filtrate was evaporated in vacuo to give 7.2 g of the title compound as yellow foam, which was used in the subsequent step without further purification.
MS (mlz): 314 [MH]+.
Preparation 29: (fS,5R/f/?,5S)-1-{4-[(Trifluoromethyl)oxy]phenyl}-3- azabicyclo[3.1.0]hexane
Figure imgf000043_0002
The title compound was prepared in 1.2 g yield from methyl 3- triflouromethoxyphenylacetate (Preparation M, 23 mmol) following the methods described in preparations 2, 3, 4, 5.
MS {mlz): 244 [MH]+. HPLC: condition 1 , Rt= 3.942 min.
Preparation 30: (ϊS,5R/^f?,5S)-1-[3-(Trifluoromethyl)phenyl]-3-azabicyclo[3.1.OJhexane
Figure imgf000043_0003
The title compound was prepared in 1.5 g yield from commercially available 3-trifluoromethylphenylacetic acid (5 g, 24.5 mmol), following the methods described in preparations 28, 2, 3, 4, 5.
MS (m/z): 228 [MH]+. HPLC: condition 1 , Rt= 3.665 min.
Preparation 31 : {1R,5S/1S,5R)- 1-(3-Bromophenyl)-3-azabicyclo[3.1.0]hexane
Figure imgf000044_0001
The title compound was prepared in 1.6 g yield from commercially available 3-bromophenylacetic acid (5 g, 23.2 mmol), following the methods described in preparations 28, 2, 3, 4, 6.
MS (mlz): 239 [MH]+. HPLC: condition 1 , Rt= 3.528 min.
Preparation 32: (7S,5R)-1-(4-Bromophenyl)-3-azabicyclo[3.1.0]hexane
Figure imgf000044_0002
(S)(+)-Acetyl mandelic acid (3.22 g) was added in portions to a stirred solution of (1f?,5S/1 S,5R)-1-[4-bromophenyl]-3-azabicyclo[3.1.0]hexane (Preparation 6, 3.96 g) in 80 mL of IPA. The resulting mixture was stirred at room temperature for 2 h until a white precipitate was formed. The mixture was then warmed up to reflux temperature, stirred for 45 minutes and then slowly allowed to cool to room temperature. The white solid was collected by filtration and dried in vacuo. This material was recrystallised 4 times from IPA (10 volumes) to give 2.3 g of a white solid.
This material was then suspended in sodium hydroxide (1 M aqueous solution, 400 mL) and Et2O (400 mL) and allowed to stir at room temperature until complete dissolution. After separation of the two phases, the aqueous layer was extracted again with Et2O (3 x 250 mL). Combined organic layers were washed with sodium hydroxide (1 M solution, 3 x 200 mL) and then dried over Na2SO4. Evaporation of solvent in vacuo gave the title compound (1.24 g) as white solid.
The absolute configuration of the optical isomers was assigned as described for Preparation 18. The assignment of the absolute configuration of the title compound was confirmed by a single crystal X-ray structure obtained from a crystal of (1 S,5f?)-1-(4-bromophenyl)-3- azabicyclo[3.1.0]hexane, (S)-(+)-O-acetyl mandelic acid salt. Both, analysis based on the known configuration of the (S)(+)-acetyl mandelic acid and on the basis of anomalous dispersion effects confirmed the assignment of the title compound as being (1 S,5R)-1-(4- bromophenyl)-3-azabicyclo[3.1.Ojhexane.
NMR (1H, CDCI3): δ 7.43 (d, 2H), 7.09 (d, 2H), 3.25 (d, 1 H), 3.15 (m, 2H), 3.06 (d, 1 H), 1.71 (m, 1 H), 0.95 (dd, 1 H), 0.89 (t, 1 H), NH not observed.
MS {ml z)\ 239 [MH]+.
Analytical chromatography
Column: chiralcel OD 5 μm, 250 x 4.6 mm
Mobile phase: A: n-Hexane; B: lsopropanol +0.1% lsopropyl amine Gradient: isocratic 2% B Flow rate: 1 rπUmin
UV wavelengh range: 200-400 nm
Analysis time 25 min
Ret. time 22.3 min, purity > 99 % a/a
Specific Optical Rotation: [D]0 = - 86 ° (CDCI3, T = 20 0C, c = 0.0053 g/0.8 mL).
Preparation 33: (1 /?,5S/1 S,5R)-1 -[2-(Trifluoromethyl)phenyl]-3- azabicyclo[3.1.Ojhexane
Figure imgf000045_0001
The title compound was prepared in 53 mg yield from commercially available methyl [2- (trifluoromethyl)phenyl]acetate (944 mg) following the methods described in preparations 1 , 2, 3, 4 and 5.
MS (m/z): 228 [MH]+.
Preparation 34: ϊ-[4-[(MR,5SΛ
Figure imgf000045_0002
(methyloxy)phenyl]ethanone
Figure imgf000045_0003
To a mixture of AICI3 (2 eq) in 1 ,2-dichloroethane (anhydrous, 9 ml_) at 0 0C was added acetyl chloride (1.05 eq). The reaction mixture was stirred at 0 0C for 15 min and a solution of 1-[3-(methyloxy)phenyl]-3-(trifluoroacetyl)-3-azabicyclo[3.1.0]hexane (1.1 g, obtained in analogy to the method described in preparation 7 from 1-[3- (methyioxy)phenyi]-3-azabicyclo[3.1.0]hexane) in 1 ,2-dichloroethane (anhydrous, 9 ml_) was added. The reaction mixture was stirred at RT for 1.5 h. HCI (1 M, 4 mL) was added followed by water (20 mL) and the mixture was extracted with dichloromethane. The organic layer was washed with saturated aqueous NaHCO3 and dried over Na2SO4. The solution was filtered and the filtrate was concentrated in vacuo. The crude product was purified by flash chromatography (cyclohexanes: EtOAc 6:4) to give 593 mg as a colourless liquid of the protected amine. 143 mg of the protected amine was dissolved in MeOH : H2O (3 ml_:3 mL) and K2CO3 (4 eq) was added stirring the mixture at 50 0C for 2.5 h. The reaction mixture was extracted with dichloromethane and the organic layer was washed with saturated aqueous NaHCO3 and dried over Na2SO4. The solution was filtered and the filtrate was concentrated in vacuo to give the title compound as a white solid (88 mg).
MS (m/z): 232 [MH]+.
HPLC: conditions 1
Analytical
Column: Supelcosil ABZ+Plus 33 x 4.6 mm, 3 Dm Mobile phase: A: H2O+0.1% HCOOH, B: CH3CN
Gradient: 0% (B) for 1 min, from 0% (B) to 95% (B) in 5 min, 95% (B) for 2 min
Flow rate: 1 mlJmin
UV wavelength: 285 nm, band width 130 nm
Mass range: 100-1000 amu
Ionization: ES+ Rt 2.971 min
Preparation 35: 1-[4-[(1R,5S/1S,5R)-3-Azabicyclo[3.1.0]hex-1-yl)-2- (methyloxy)phenyl]-1 -propanone
Figure imgf000046_0001
The title compound was prepared using propionyl chloride in place of acetyl chloride, in 106 mg yield from 147 mg of protected amine obtained in 705 mg from 1-[3- (methyloxy)phenyl]-3-(trifluoroacetyl)-3-azabicyclo[3.1.0]hexane (1.07 g) as described for preparation 34. MS (/77/z): 246 [MH]+.
HPLC: conditions 1 R, 3.249 min
Preparation 36: 1 (1 /?,5S/1 S,5R)-[2-Fluoro-5-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.OJhexane
Figure imgf000047_0001
The title compound was prepared in 112 mg yield from 2-fluoro-5-(trifluoromethyl)aniline (1.09 g) following the procedures reported for preparations 37 and 6. NMR (1H, CDCI3): δ 7.45 (m, 2H), 7.1 (m, 1 H), 3.2 (m, 2H), 3.05 (m, 2H), 1.7 (m, 1 H), 0.95 (m, 1 H), 0.9 (m, 1 H), NH not observed. MS {m/z): 246[MH]+.
Preparation 37: 1 (1 R.5S/1 S,5R)-[2-Fluoro-4-(trifluoromethyl)phenyl]-3 azabicyclo[3.1.0]hexane-2,4-dione
Figure imgf000047_0002
To a slurry of maleimide (1.7 eq), anhydrous CuCI2 (1.2 eq) and terf-butyl nitrite (1.5 eq) in CH3CN (35 mL) at 0 0C a solution of 2-fluoro-4-(trifluoromethyl)aniline (16.3 g) in CH3CN (6.5 mL) was added dropwise. The reaction mixture was stirred at room temperature for 1 h and HCI (10%, aqueous, 196 mL) was added. The mixture was extracted with EtOAc, the organic layer was washed with saturated aqueous NaCI and dried over Na2SO4. The solution was filtered and the filtrate was concentrated in vacuo. By NMR analysis the crude mixture resulted a 1 :4 mixture of the arylated maleimide hydrogen chloride adduct (component A) and unreacted maleimide (component B).
A DMSO (140 mL) solution of this crude product was added dropwise to a preformed solution of trimethylsulfoxonium iodide (2 eq with respect to component A plus 2 eq with respect to component B) in anhydrous DMSO (412 mL) to which NaH (3 eq with respect to component A plus 2 eq with respect to component B) had been added portionwise. The reaction mixture was stirred for 30 min and AcOH (2 eq) was added followed by water. The reaction mixture was extracted with Et2O and then with EtOAc, the combined organic layers were washed with saturated aqueous NaCI and dried over Na2SO4. The solution was filtered and the filtrate was concentrated in vacuo. The crude product obtained was triturated with water and then with cyclohexanes to give the title compound as light brown solid (5.98 g).
NMR (1H, CDCI3): δ 7.55-7.3 (m, 3H), 2.8-2.7 (m, 1 H), 2.1 (m, 1H), 2.0 (m, 1 H) , NH not observed. MS (m/z): 274[MH]+.
Preparation 38 (1 /?,5S/1 S,5R)-1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000048_0001
To a solution of (IR.SS/I S^RH-^-fluoro^trifluoromethyOphenyll-S-azabicyclo- [3.1.0]hexane-2,4-dione (2.6 g) in anhydrous tetrahydrofuran (56 ml_), BH3 in tetrahydrofuran (1 M, 4 eq) was added at 0 0C. The reaction mixture was stirred at 65 0C for 24 h, cooled to RT and MeOH was added until gas evolution ceased. Solvent was removed in vacuo, MeOH was added (200 mL) p-tolueneulfonic acid (3 eq) was added and the reaction mixture was stirred at 65 0C for 6 h, the reaction mixture was cooled to room temperature and a saturated solution of K2CO3 (1.7 eq) was added. The mixture was extracted with dichloromethane, the organic layer was washed with saturated aqueous NaCI and dried over Na2SO4. The solution was filtered and the filtrate was concentrated in vacuo to give the title compound as colourless oil (2.1 g).
NMR (1H, CDCI3): δ 7.2-7.4 (m, 3H), 3.2 (m, 2H), 3.1 (m, 2H), 1.8 (m, 1 H), 0.8 (m, 2H), NH not observed. MS (m/z): 246[MH]+.
Preparation 39: (1S,5/?)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.OJhexane
Figure imgf000048_0002
(1f?)-(-)-10-Camphorsulfonic acid (4.19 g) was added in portions to a stirred solution of (I R.SS/I S.δ^-i-^-fluoro^-OrifluoromethyOphenylj-S-azabicyclo^.i .Olhexane (4.4 g) in CH3CN (44 mL). The resulting mixture was stirred at room temperature for 20 min until a white precipitate formed. The mixture was then warmed up to reflux temperature, stirred for 45 minutes and then slowly allowed to cool to room temperature. The white solid was collected by filtration and dried in vacuo. This material was recrystallised 2 times from CH3CN (25 mL per g solid) to give 1.57 g of a white solid. This material was then suspended in sodium hydroxide (1 M solution, 1.1 eq) and dichloromethane (100 ml_) and allowed to stir at room temperature until complete dissolution. After separation of the two phases, the aqueous layer was extracted again with dichloromethane. The combined organic layers were washed with sodium hydroxide and then dried over Na2SO4. Evaporation of solvent in vacuo gave the title compound (874 mg) as colorless liquid.
Analytical chromatography
Column: chiralcel OD 10 Dm, 250 x 4.6 mm Mobile phase: A: n-Hexane; B: lsopropanol +0.1% lsopropyl amine
Gradient: isocratic 2% B
Flow rate: 0.8 mL/min
UV wavelengh range: 200-400 nm
Analysis ret. time (min) % a/a 17.18 >99.5 (1 S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
Preparation 40: (1 S,5f?)-3-(3-Chloropropyl)-1 -[4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.OJhexane
Figure imgf000049_0001
To a solution of (1 S,5R)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (1.00 g) in dry tetrahydrofuran (5 ml_), diisopropylethylamine (2.4 mL) and 1-bromo-3-chloropropane (3.7 mL) were added and the resulting mixture was heated at reflux for 3 hours. After cooling at room temperature it was diluted with ethyl acetate (30 mL) washed twice with a saturated solution of NH4CI in water (20 mL) and once with a saturated solution of NaHCO3 in water (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel chromatography eluting with cyclohexane/EtOAc 7:3 to give the title compound as a colourless oil (1.26 g).
NMR (1H, CDCI3): δ 7.50 (d, 2H) 7.19 (d, 2H), 3.59 (t, 2H), 3.33 (d, 1H), 3.09 (d, 1H), 2.58 (m, 2H), 2.66 (dd, 1 H), 2.46 (dd, 1 H), 1.92 (m, 2H), 1.74 (m, 1H), 1 ,67 (t, 1 H), 0.81 (dd, 1 H). MS (m/z): 304 [MH]+. Preparation 41 : (IS.SRJ-S-β-ChloropropylH-p-fluoro^trifluoromethyOphenyll-S- azabicyclo[3.1.0]hexane
Figure imgf000050_0001
To a solution of (1 S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (300 mg) in dry tetrahydrofuran (3 ml_), diisopropylethylamine (0.65 mL) and 1-bromo-3- chloropropane (1.01 mL) were added and the resulting mixture was refluxed for 3 hours. After cooling at room temperature it was diluted with ethyl acetate (15 mL) washed twice with a saturated solution of NH4CI in water (10 mL) and once with a saturated solution of NaHCO3 in water (10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by chromatography (silica gel) eluting with cyclohexane/EtOAc 6:4 to give the title compound as yellow oil (345 mg).
NMR (1H, CDCI3): δ 7.24 (d, 2H), 7.16 (t, 1 H), 3.51 (t, 2H), 3.18 (dd, 1 H), 3.03 (d, 1 H), 2.54 (t, 2H), 2.48 (dd, 1 H), 2.37 (d, 1 H), 1.83 (m, 2H), 1.69 (m, 1 H), 1.34 (t, 1 H), 0.70 (dd, 1 H). MS (m/z): 322 [MH]+.
Preparation 42: (1 R.5S/1 S,5R)-1 -[3-Fluoro-4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000050_0002
The title compound was prepared in 338 mg yield from 3-fluoro-4-(trifluoromethyl)aniline (2 g) following the procedures reported for Preparations 37 and 6.
NMR (1H, CDCI3): δ 7.5 (m, 1 H), 6.9 (m, 2H), 3.3-3.0 (m, 4H), 1.7 (m, 1H), 0.95 (m, 2H), NH not observed. MS (m/z): 246 [MH]+.
Preparation 43: (1R,5S/1S,5/?)-1-[4-(Methyloxy)phenyl]-3-(trifluoroacetyl)-3- azabicyclo[3.1.0]hexane
Figure imgf000050_0003
The title compound was prepared in 1.80 g yield (95%) as a colorless oil from (1/?,5S/1 S,5ft)-1-[4-(methoxy)phenyl]-3-azabicyclo[3.1.0]hexane (1.25 g) in analogy to the method described in Preparation 7.
MS (m/z): 286 [MH]+.
Preparation 44: 1 -{2-(Methyloxy)-5-[(1 R,5S/1S,5R)-Z-(tτ\f luoroacetyl)-3- azabicyclo[3.1.0]hex-1-yl]phenyl}ethanone and 1-{2-hydroxy-5-[(1/?,5S/7S,5/?)-3- (trifluoroacetyO-S-azabicycloβ.i .Olhex-i-yllphenytyethanone
Figure imgf000051_0001
To a suspension of AICI3 (12.6 mmol) in dry 1 ,2-dichloroethane (16 mL) at 0 0C acetyl chloride (6.6 mmol) was added and the mixture was stirred at this temperature for 15 min. A solution of (1R,5S/1 S,5R)-1-[4-(methyloxy)phenyl]-3-(trifluoroacetyl)-3- azabicyclo[3.1.0]hexane (1.81 g, 6.3 mmol) in 1 ,2-dichloroethane (16 mL) was then added. The reaction mixture was allowed to stir at 0 °C for 15 min and overnight at room temperature. 1 M aqueous HCI was then added and the mixture was extracted with dichloromethane. The organic phase was washed with 5% NaHCO3 and water, dried over Na2SO4 and concentrated in vacuo. The two products were separated by flash chromatography (cyclohexane/ethyl acetate from 95/5 to 80/20) to give 965 mg of 1-{2- (methyloxyJ-δ-KI R.SS/tS.SRJ-S-^rifluoroacetyO-S-azabicyclotS.I .Olhex-i- yl]phenyl}ethanone (48%) and 266 mg of 1-{2-hydroxy-5-[(1/?,5S/7S,5/?)-3- (trifluoroacetyl)-3-azabicyclo[3.1.0]hex-1-yl]phenyl}ethanone (18%) as yellow oils.
MS (mfz): 328 [MH]+, 1-{2-(methyloxy)-5-[(1f?,5S/fS,5/?)-3-(trifluoroacetyl)-3- azabicyclo[3.1.0]hex-1-yl]phenyl}ethanone; 312 [M-H]", 1-{2-hydroxy-5-[(1R,5S/7S,5f?)-3- (trifluoroacetyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenyl}ethanone.
Preparation 45: 1 -[5-[(1 R,5S/1 S,5R)-3-Azabicyclo[3.1.0]hex-1 -yl]-2- (methyloxy)phenyl]ethanone
Figure imgf000051_0002
The title compound was prepared in 624 mg yield (91%) as a colorless oil from 1-{2- (methyloxyJ-S-KI RSS/fS.SRJ-S-ttrifluoroacetyO-a-azabicyclop.i .Olhex-i- yl]phenyl}ethanone (965 mg) in analogy to the method described in Preparation 12. MS (m/z): 232 [MH]+.
Preparation 46: 1 -{5-[(1 /?,5S/f S,5R)-3-Azabicyclo[3.1.0]hex-1 -yl]-2- hydroxyphenyl}ethanone
Figure imgf000052_0001
The title compound was prepared in 151 mg yield (82%) as a colorless oil from 1-{2- hydroxy-S-^I R.SS/I S.δR^a^trifluoroacetyO-S-azabicyclop.i .Olhex-i-yllphenylJethanone (266 mg) in analogy to the method described in Preparation 12.
MS (m/z): 216 [M-H]".
Preparation 47: (1 S,5/?/1 /?,5S)-1 -(4-Bromophenyl)-3-(3-chloropropyl)-3- azabicyclo[3.1.OJhexane
Figure imgf000052_0002
To a solution of racemic (1 S, 5R/1/?,5S)-1-(4-bromophenyl)-3-azabicyclo[3.1. OJhexane (0.12 g) in dry tetrahydrofuran (2 ml_), diisopropylethylamine (0.22 mL) and 1-bromo-3- chloropropane (0.062 mL) were added and the resulting mixture was heated at reflux for 3 hours. After cooling to room temperature the solvent was removed in vacuo and the resulting crude oil was taken up in dichloromethane (10 mL). This solution was then washed twice with a saturated solution of NH4CI in water (5 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified passing the sample through a 2 g silica cartridge (Varian) with a gradient elution from cyclohexane to cyclohexane/EtOAc 7:3, to give the title compound as a colourless oil (0.10 g).
NMR (1H, DMSO): δ 7.45 (d, 2H), 7.10 (d, 2H), 3.65 (t, 2H), 3.30 (d, 1 H), 3.00 (d, 1 H), 2.55 (t, 2H), 2.45 (m, 1H), 2.40 (dd, 1H), 1.85 (m, 2H), 1.80 (m, 1H), 1.30 (t, 1H), 0.70 (m, 1 H). MS {mlz): 314, 316, 318 [MH]+.
Preparation 48: (1R,5S/1S,5R)- 1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1. OJhexane
Figure imgf000053_0001
The crude title compound was prepared in 0.36 g yield from commercially available methyl 3,4-dichlorophenylacetate (1 g, 4.57 mmol) following the methods described in preparations 1 , 2, 3, 4, 6.
The title compound was separated to give the separated enantiomers by preparative chromatography using a chiral column chiralcel AD 10 um, 250 x 21 mm, eluent A: n- hexane; B: isopropanol + 0.1 % isopropyl amine, gradient isocratic 2% B, flow rate 7 mL/min, detection UV at 200-400 nm. Retention times given were obtained using an analytical HPLC using a chiral column chiralcel AD 5 um, 250 x 4.6 mm, eluent A: n- hexane; B: isopropanol +0.1% Isopropyl amine, gradient isocratic 2% B, flow rate 1.2 mL/min, detection UV at 200-400 nm.
Enantiomer 1 , (1ft,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, was recovered in 20 mg yield as white solid from the racemate (60 mg). Rt. = 41 min.
Enantiomer 2, (1 S,5R)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, was recovered in 28 mg yield as white solid from the racemate (60 mg). Rt. = 43.4 min.
The absolute configuration of (I S.SRJ-i-β^-dichlorophenyO-S-azabicycloβ.i .OJhexane was assigned using ab initio VCD and ab initio OR analyses.
Specific Optical Rotation of (I S.SRJ-i-β^-dichlorophenyO-S-azabicycloβ.i .OJhexane: [0]D = - 67.9 ° (CDCI3, T = 20 0C, c ≡ 0.01g/mL).
NMR (1H, CDCI3): δ 7.35 (d, 1 H), 7.27 (s, 1H), 7.02 (dd, 1 H), 3.25 (d, 1 H), 3.13 (bm, 2H), 3.06 (d, 1 H), 1.71 (m, 1 H), 0.93 (m, 2H), NH not observed. MS {m/z): 228 [MH]+,
Preparation 49: 1-(Phenylmethyl)-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-2,5- dihydro-1 H-pyrrole
Figure imgf000053_0002
Diisopinocampheylborane was prepared following the procedure reported in J. Org. Chem. 1984, 49, 945-947. 2-[(1Z)-3-Chloro-1-(chloromethyl)-1-propen-1-yl]-4,4,5,5- tetramethyl-1 ,3,2-dioxaborolane (previously described in Tetrahedron Lett. 1993, 34, 4827-4828) was prepared following the general procedure reported in Tetrahedron Lett. 1989, 30, 2929, using 1 ,4-dichloro-2-butyne. The material thus obtained was further converted following the procedure reported in Synlett 2002, 5, 829-831. This latter procedure was modified in that isolation of the the title product was achieved (rather than by distillation) by extraction of a solution of the crude reaction products in acetonitrile with cyclohexane, to provide the title compound (containing ~ 10% in moles of benzylamine) after evaporation of the volatiles from the cyclohexane phase.
Preparation 50: 2-[1 -(Phenylmethyl)-2,5-dihydro-1 H-pyrrol-3-yl]-5- (trifluoromethyl)pyridine
Figure imgf000054_0001
To a solution of 2-bromo-5-(thfluoromethyl)pyridine (4.42 mmol) in dry tetrahydrofuran (45 ml.) 1 -(phenylmethyl)-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-2,5-dihydro-1 H- pyrrole (3.4 mmol), tetrakis(triphenylphosphine)palladium(0) (0.196 mmol) and cesium fluoride (13,2 mmol) were added at room temperature. The resulting mixture was stirred at 80 0C for 1.5 hours. After cooling solvent was evaporated under reduced pressure and the residue was partitioned between dichloromethane (25 mL) and sodium hydroxyde (15 ml_, 1 M). The organic phase was evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (AcOEt: cyclohexane=1 :10 to 4:6) to give 0.33 g of the title compound (y= 24%).
NMR (1H, CDCI3): δ 9.8 (s,1 H), 7.85 (dd, 1 H), 7.5 - 7.2 (m, 6H), 6.7 (s, 1 H), 3.95 (m, 2H), 3.9 (s, 2H), 3.75 (m, 2H). MS (mlz): 305 [MH]+.
Preparation 51 : 2-[1 -(Phenylmethyl)-2,5-dihydro-1 H-pyrrol-3-yl]-6- (trifluoromethyl)pyridine
Figure imgf000054_0002
2-[1-(Phenylmethyl)-2,5-dihydro-1 H-pyrrol-3-yl]-6-(trifluoromethyl)pyridine was prepared in analogy to the method described in Preparation 50 in 0.56 g (y= 42%) as an oil.
NMR (1H, CDCI3): δ 7.7 (t, 1 H), 7.85 (dd, 1 H), 7.4-7.1 (m, 6H), 6.5 (s, 1 H), 3.90 (sb, 2H), 3.8 (s, 2H), 3.6 (m, 2H). MS {mlz): 305 [MH]+.
Preparation 52: 3-(Phenylmethyl)-1 -[5-(trifluoromethyl)-2-pyridinyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000055_0001
To a slurry of sodium hydride (83 mg) and trimethylsulfoxonium iodide (0.46 g) DMSO (anhydrous, 3 mL) was added dropwise (gas evolution). The resulting mixture was allowed to stir at room temperature for 0.5 h. A solution of 2-[1-(phenylmethyl)-2,5- dihydro-1/7-pyrrol-3-yl]-5-(trifluoromethyl)pyridine (330 mg) in DMSO (anhydrous, 6 mL) was added at room temperature. After 1 h a saturated solution of ammonium chloride (4 mL) was added and the mixture extracted with dichloromethane (2 x 10 mL). Volatiles from the organic phase were evaporated under reduced pressure, the residue charged onto an SCX column and eluted with MeOH followed by MeOH/NH3 0.25 M. The methanole/ammonia fractions were concentrated under reduced pressure to give 0.31 g of the title compound (y= 89%).
NMR (1H, CDCI3): δ 8.78 (s,1 H), 8.03 (dd, 1 H), 7.32 (m, 5H), 7.25 (m, 1 H), 3.66 (dd, 2H), 3.25 (d, 1 H), 2.96 (d, 1 H), 2.80 (d, 1 H), 2.46 (sb, 1H), 2.05 (q, 1 H), 1.58 (m, 1 H), 1.22 (m, 1 H). MS (mlz): 317 [MH]+.
Preparation 53: 3-(Phenylmethyl)-1 -[6-(trifluoromethyl)-2-pyridinyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000055_0002
3-(Phenylmethyl)-1-[6-(trifluoromethyl)-2-pyridinyl]-3-azabicyclo[3.1.0]hexane was prepared in analogy to the method described in Preparation 52 (0.46 g, 79%) as an oil.
NMR (1H, CDCI3): δ 7.7 (t, 1 H), 7.4 (d, 1 H), 7.35 (m, 5H), 7.2 (d, 1 H), 3.7 (s, 2H), 3.4 (d, 1 H), 3.1 (d, 1 H), 2.85 (d, 1 H), 2.55 (m, 1 H), 2.1 (m, 1 H), 1.7 (m, 1 H), 1.3 (m, 1 H). MS {mlz): 317 [MH]+.
Preparation 54: 1-[5-(Trifluoromethyl)-2-pyridinyl]-3-azabicyclo[3.1.0]hexane
Figure imgf000055_0003
3-(Phenylmethyl)-1 -[5-(trifluoromethyl)-2-pyridinyl]-3-azabicyclo[3.1.OJhexane was dissolved in ethanol (15 mL), hydrochloridic acid (3M, 0.76 ml_) was added followed, in inert atmosphere, by Pd/C 10% w/w (120 mg). After 20 h under a hydrogen atmosphere (1 atm) the mixture was filtered. Solvent was removed under reduced pressure. A saturated solution of sodium bicarbonate was added (10 mL) and the mixture extracted with diethyl ether (2 x 10 mL) to provide the title compound (0.14 g, 81%) after evaporation of volatiles.
NMR (1H, DMSO-d6): δ 8.7 (s, 1 H), 7.8 (d, 1 H), 7.15 (d, 1 H), 3.4 - 3.2 (dd, 2H), 3.1 (m, 2H), 2.05 (m, 1H), 1.4 (m, 1H), 1.05 (t, 1H).
Preparation 55: 2-Fluoro-4-[1 -(phenylmethyl)-2,5-dihydro-1 H-pyrrol-3-yl]benzonitrile
Figure imgf000056_0001
The title compound was prepared in analogy to the method described in Preparation 50 in 0.44 g (y= 31%) as an oil.
NMR (1H, CDCI3): δ 7.55 (t,1H), 7.4 - 7.2 (m, 5H), 7.2 (d, 1 H), 7.1 (d, 1H), 6.4 (bs, 1 H), 3.9 (s, 2H), 3.8 (m, 2H), 3.75 (m, 2H). MS (m/z): 279 [MH]+.
Preparation 56: 2-Fluoro-4-[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-1- yl]benzonitrile
Figure imgf000056_0002
The title compound was prepared in analogy to the method described in Preparation 52 in 0.39 g (y= 84%) as an oil.
NMR (1H, CDCI3): δ 7.41 (t,1 H), 7.25 - 7.15 (m, 5H), 6.85 - 6.8 (dd, 2H), 3.64 - 3.56 (dd, 2H), 3.19 (dd, 1H), 3.01 (dd, 1H), 2.53 (dd, 1H), 2.47 (dd, 1H), 1.73 (q, 1H), 1.67 (m, 1H), 0.81 (m, 1 H). MS (mlz): 293 [MH]+.
Preparation 57: 1-[3-Fluoro-4-(1/-/-pyrrol-1-ylmethyl)phenyl]-3-azabicyclo[3.1.0]hexane
Figure imgf000057_0001
To a solution of {[4-(3-azabicyclo[3.1.0]hex-1-yl)-2-fluorophenyl]methyl}amine dihydrochloride in methanol/tetrahydrofuran (anhydrous, 1/1 , 5 ml_) , which was prepared in analogy to the method described in Preparation 54 starting from 1.1 mmol of 2-fluoro-4- [3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-1-yl]benzonitrile and used without further purification, a solution of 2,5-bis(methyloxy)tetrahydrofuran (2.53 mmol), H2SO4 (4.4 mmol) in methanol/tetrahydrofuran (anhydrous, 1/1 , 5 ml.) was added dropwise over 5 min at room temperature. After standing over night at room temperature a saturated solution of NaHCO3 was slowly added, extraction with 2x 15 ml. of dichloromethane followed by preparative HPLC purification provided 14 mg of titled compound as an oil (y = 5%) .
NMR (1H, CDCI3): δ 6.88 - 6.82 (m, 3H), 6.67 (t, 2H), 6.14 (t, 2H), 5.04 (s, 2H), 3.21 (d, 1 H), 3.1 (d, 1 H), 3.09 (d, 1 H), 3.01 (d, 1 H), 1.67 (m, 1 H), 0.88 (m, 2H). MS (mlz): 257 [MH]+.
Preparation 58: (1 R.5S/1 S,5f?)-3-(3-Chloropropyl)-1 -[6-(trifluoromethyl)-3-pyridinyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000057_0002
The title compound was prepared in 522 mg yield (84%) as a colorless oil from (I R.SS/I S.SRJ-i-ie^trifluoromethyO-S-pyridinyll-S-azabicyclotS.I .Olhexane (584 mg) in analogy to the method described in Preparation 40.
NMR (1H, CDCI3): δ 8.47 (s, 1 H), 7.55 (m, 2H), 3.59 (t, 2H), 3.33 (d, 1 H), 3.09 (d, 1 H), 2.6 (m, 3H), 2.52 (dd, 1 H), 1.92 (m, 2H), 1.78 (m, 1 H), 0.85 (m, 1 H), 0.81 (dd, 1 H). MS (mlz): 305 [MH]+.
Preparation 59: S-^IR.SS/IS.δ^-S^a-ChloropropyO-S-azabicycloia.i .Olhex-i-yl]^- methyl-1 ,3-benzothiazole
Figure imgf000058_0001
The title compound was prepared in 480 mg yield (84%) as a colorless oil from 5- [(I R.SS/I S.δRS^S-azabicyclotS.I .Olhex-i-yl^-methyl-I .S-benzothiazole (374 mg) in analogy to the method described in Preparation 40.
NMR (1H, CDCI3): δ 7.70 (m, 2H), 7.11 (d, 1 H), 3.59 (t, 2H), 3.38 (d, 1 H), 3.09 (d, 1 H), 2.8 (s, 3H), 2.66 (m, 3H), 2.53 (dd, 1 H), 1.95 (m, 2H), 1.74 (m, 1 H), 1 ,44 (t, 1 H), 0.83 (dd, 1 H). MS (m/z): 307 [MH]+.
Preparation 60: 1 (1 R.5S/1 S,5R)-[3-Fluoro-5-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane-2,4-dione
Figure imgf000058_0002
To a slurry of maleimide (1.8 eq), anhydrous CuCI2 (1.2 eq) and tert-butyl nitrite (1.5 eq) in CH3CN (5 mL) at 0 0C a solution of 3-fluoro-5-(trifluoromethyl)aniline (2.2 g) in CH3CN (4 ml.) was added dropwise. The reaction mixture was stirred at room temperature for 2 h and HCI (aqueous 6 M, 30 ml_) was added. The mixture was extracted with EtOAc, the organic layer dried over Na2SO4. The solution was filtered and the filtrate was concentrated in vacuo. The filtered was triturated with water and dried in vacuo.
A DMSO (10 mL) solution of this crude product was added dropwise to a preformed solution of trimethylsulfoxonium iodide (2 eq) in anhydrous DMSO (20 mL) to which NaH
(15 eq) had been added portionwise. The reaction mixture was stirred for 30 min and water was added followed by a satured solution of NH4CI (until pH 6.5). The reaction mixture was extracted with Et2O, the combined organic layers were washed with saturated aqueous NaCI and dried over Na2SO4. The solution was filtered and the filtrate was concentrated in vacuo. The crude product obtained was triturated with cyclohexane to give the title compound as light green solid (1.02 g).
NMR (1H, CDCI3): δ 7.4-7.20 (m, 3H), 2.85-2.75 (m, 1 H), 2.0 (m, 1 H), 1.85 (m, 1 H), NH not observed. MS (mlz): 274[MH]+. Preparation 61 : (1R,5S/1S,5/? )-1-[3-Fluoro-5-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.OJhexane
Figure imgf000059_0001
The title compound was prepared in 650 mg yield from (1R,5S/1 S,5R)-1-[3-fluoro-5- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane-2,4-dione following the procedure reported for Preparation 38 .
NMR (1H, CDCI3): δ 7.05-7.40 (m, 3H), 3.1-3.3 (m, 4H), 1.7 (m, 1 H), 0.9 (m, 2H)1 NH not observed. MS {m/z): 246[MH]+.
Preparation 62: (1R,5S/1S,5R )-1-[2-Fluoro-3-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000059_0002
The title compound was prepared in 947 mg yield from 2-fluoro-3-(trifluoromethyl) aniline (3 g) following the procedures reported for Preparations 60 and 38.
NMR (1H, CDCI3): δ 7.2 (m, 2H), 6.9 (m, 1H), 3.0-2.7 (m, 4H), 1.6 (m, 1H), 0.7 (m, 2H); MS (mlz): 246[MH]+.
Preparation 63: (1R,5S/1S,5R )-1-[4-(Methyloxy)-5-(trifluoromethyl)phenyl]-3- azabicyclo[3.1. OJhexane
Figure imgf000059_0003
The title compound was prepared in 430 mg yield from 4-(methyloxy)-5-(trifluoromethyl) aniline (2.2 g) following the procedures reported for Preparations 60 and 38.
NMR (1H, CDCI3): δ 7.4-7.3 (m, 2H), 6.9 (m, 1 H), 3.9 (s, 3H), 3.2-3.0 (m, 4H), 1.9 (s, 1 H), 1.65 (m, 1 H), 0.8 (m, 2H). MS (mlz): 258[MH]+.
Preparation 64: (1R,5S/1S,5/? )-1-(4-Chloro-2-fluorophenyl)-3- azabicyclo[3.1.OJhexane
Figure imgf000060_0001
The title compound was prepared in 360 mg yield from 4-chloro-2-fluoro aniline (1.87 g) following the procedures reported for Preparations 60 and 38.
NMR (1H1 CDCI3): δ 7.2-7.0 (m, 3H), 3.2-3.0 (m, 4H), 2.0 (s, 1 H), 1.75 (m, 1 H), 0.8 (m, 2H). MS (m/z): 212[MH]+.
Preparation 65: (1/?,5S/1S,5/? )- 1-{3-[(Trifluoromethyl)oxy]phenyl}-3- azabicyclo[3.1.0]hexane
Figure imgf000060_0002
The title compound was prepared in 600 mg yield from 3-trifuoromethyloxy aniline (2.65 g) following the procedures reported for Preparations 60 and 38.
NMR (1H, CDCI3): δ 7.3-7 (m, 4H), 3.3-3.0 (m, 4H), 1.8 (s, 1 H), 1.75 (m, 1 H), 0.95 (m, 2H); MS (m/z): 212[MH]+.
Preparation 66: (1R,5S/1 S,5F? )-1-(2-Fluoro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane
Figure imgf000060_0003
The title compound was prepared in 148 mg yield from 2-fluoro-4-methyl aniline (2.18 g) following the procedures reported for Preparations 60 and 38.
NMR (1H, CDCI3): δ 7.2 (m, 1 H), 6.85 (m, 2H), 3.2-2.9 (m, 4H), 2.25 (s, 3H), 1.75 (s, 1 H), 1.65 (m, 1 H), 0.9 (m, 2H); MS (m/z): 192 [MH]+.
Preparation 67: (1 R.5S/1 S,5R )- 1 -[3-Chloro-4-(methyloxy)phenyl]-3- azabicyclo[3.1.OJhexane
Figure imgf000060_0004
The title compound was prepared in 60 mg yield from 2-chloro-4-methyl aniline (2.36 g) following the procedures reported for Preparations 60 and 38.
NMR (1H, CDCI3): δ 7.15-7 (m, 2H), 6.85 (m, 1 H), 3.85 (s, 3H), 3.2-2.9 (m, 4H), 1.8-1.6 (m, 2H), 0.75 (m, 2H); MS (m/z): 224[MH]+.
Preparation 68: (1R,5S/1S,5R)-1,1-Dimethylethyl 1 -(4-bromophenyl)-3- azabicyclo[3.1.0]hexane-3-carboxylate
Figure imgf000061_0001
To a stirred solution of (1 R,5S/1 S,5ft)-1-(4-bromophenyl)-3-azabicyclo[3.1.0]hexane (Preparation 6, 1.3 g) in dichloromethane (20 ml.) at room temperature, triethylamine (0.99 mL) and bis(1 ,1-dimethylethyl) dicarbonate were added. Stirring was continued over 6 h, then the reaction mixture was concentrated under vacuum and the crude product treated with diethyl ether and water. The organic phase was washed with saturated ammonium chloride solution, dried over sodium sulphate and the solvent evaporated under vacuum to give a crude product that was purified by chromatography over silica gel (cyclohexane/ETOAC 9/1 ) affording the title compound (1.68 g, 91%).
MS (m/z): 282.1 [MH -C4H8]M Br.
Preparation 69: (1R,5S/1S,5/?)-1,1-Dimethylethyl 1-[4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate
Figure imgf000061_0002
To a stirred solution of (1 R,5S/1 S,5R)-1 ,1-dimethylethyl 1-(4-bromophenyl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (2 g) in DMF (30 mL), at RT, bis(pinacolate)di boron (2.25 g), potassium acetate (1.75 g) and PdCI2(dppf) (0.15 g) were subsequently added. The reaction mixture was heated at 85 °C for 1.5 h, poured into water and extracted twice with diethylether, and the organic phase was washed with brine and dried over sodium sulphate. The solvent was evaporated under vacuum and the crude product purified by chromatography over silica gel (cyclohexane/ETOAC 9/1) affording the title compound as a white solid (2.1 g, 92%).
MS (m/z): 330.3 [MH - C4H8]+, 1 Br. Preparation 70: (1/?,5S/1S,5R)-1,1 -Dimethylethyl 1-(3-bromophenyl)-3- azabicyclo[3.1.0]hexane-3-carboxylate
Figure imgf000062_0001
The title compound was prepared in 94% yield as a white solid in analogy to the method described for Preparation 68 starting from (1 R,5S/1 S,5R)-1-(3-bromophenyl)-3- azabicyclo[3.1.0]hexane (7.4 g).
MS (ml z): 282.1 [MH -C4H8]M Br.
Preparation 71 : (1 R.5S/1 S,5R)-1 ,1 -Dimethylethyl 1 -[3-(4 ,4,5,5-tetramethyM ,3,2- dioxaborolan^-yOphenyll-S-azabicycloβ.i.OJhexane-S-carboxylate
Figure imgf000062_0002
The title compound was prepared in 84% yield as a white solid in analogy to the method described for Preparation 69 starting from (IR1SSZI S1SR)-1 , 1 -dimethylethyl 1-(3- bromophenyO-S-azabicycloβ.i .Olhexane-S-carboxylate (2.5 g).
MS (ml z): 330.3 [MH - C4H8]M Br.
Preparation 72: (1 K.5S/1 S,5/?)-1 -[4-(2,4-Dimethyl-1 ,3-thiazol-5-yl)phenyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000062_0003
To a stirred solution of (1 R,5S/1 S,5R)-1 ,1 -dimethylethyl 1-[4-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan^-yOphenyll-S-azabicycloβ.i .OJhexane-S-carboxylate (0.3 g) in tetrahydrofuran (12 ml_), at RT and under a nitrogen atmosphere, 5-bromo-2,4-dimethyl- 1 ,3-thiazole (0.22 g), cesium fluoride (0.47 g) and tetrakis-(triphenylphosphin)- palladium(O) (0.06 g) were subsequently added. The reaction mixture was heated at 80 0C for 4 h and the solvent evaporated under vacuum. The crude product was treated with diethyl ether and saturated aqueous ammonium chloride solution, the organic phase was washed with brine, dried over sodium sulphate and concentrated under vacuum. The crude product was purified by chromatography over silica gel (cyclohexane/ETOAC 8/1 ). The purified product was then dissolved in CH2CI2 (10 ml_) and trifluoroacetic acid was added (4 ml_). After 2 h the reaction mixture was treated with solid sodium carbonate and the solvent evaporated. The residue was treated with water and extracted with CH2CI2, the organic phase washed with brine, dried over sodium sulphate and evaporated to give the title compound (0.1g, 34%).
MS (m/z): 271.2 [MH]+.
Preparation 73: (1R,5S/1S,5/?)-1-{4-[6-(Trifluoromethyl)-2-pyridinyl]phenyl}-3- azabicyclo[3.1.0]hexane
Figure imgf000063_0001
The title compound was prepared in analogy to the method described for Preparation 72 (using 2-bromo-6-(trifluoromethyl)pyridine) in 60% yield.
MS (m/z): 305.3 [MH]+.
Preparation 74: (1 A?,5S/1 S,5/?)-1 -[4-(3,5-Dimethyl-4-isoxazolyl)phenyl]-3- azabicyclo[3.1.OJhexane
Figure imgf000063_0002
To a stirred solution of (1/?,5S/1S,5/?)-1 ,1-dimethylethyl 1-(4-bromophenyl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (0.37 g) in toluene (5 ml.) and ethyl alcohol (2 ml_), at RT and under a nitrogen atmosphere, (3,5-dimethyl-4-isoxazolyl)boronic acid (0.25 g), tetrakis-(triphenylphosphin)-palladium(0) (0.03 g) and a saturated solution of potassium carbonate (2 ml_) were subsequently added. The reaction mixture was heated at 88 0C for 2 h, and the solvents evaporated under vacuum. The crude product was treated with diethyl ether and water, the organic phase washed with brine, dried over sodium sulphate, concentrated under vacuum and extracted twice with ether. The solvent was evaporated and the crude product purified by chromatography over silica gel (cyclohexane/ETOAC 8/1 ). The recovered product was then dissolved in CH2CI2 (10 mL) and trifluoroacetic acid was added (4 mL). After 3 h the reaction mixture was treated with solid sodium carbonate and the solvent evaporated. The residue was treated with water and extracted with CH2CI2, the organic phase washed with brine, dried over sodium sulphate and evaporated to give the title compound (0.12 g, 45%).
MS (ml z)\ 255.2[MH]+.
Preparation 75: (1 R.5S/1 S,5/?)-1 -[3-(2,4-Dimethyl-1 ,3-thiazol-5-yl)phenyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000064_0001
The title compound was prepared in analogy to the method described for Preparation 72, using (1f?,5S/1 S,5F?)-1 ,1-dimethylethyl 1-[3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yOphenyll-S-azabicycloβ.i .OJhexane-S-carboxylate intermediate 4), in 50% yield. MS (ml z): 271.3 [MH]+.
Preparation 76: (1 R.5S/1 S,5R)-1 -[3-(5-Methyl-2-thienyl)phenyl]-3- azabicyclo[3.1.OJhexane
Figure imgf000064_0002
The title compound was prepared in analogy to the method described for Preparation 72, using (1R,5S/1 S,5R)-1 ,1-dimethylethyl 1-[3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate intermediate 4), in 55% yield. MS (m/z): 256.2[MH]+.
Preparation 77: 5-(2,4-Dimethyl-1 ,3-oxazol-5-yl)-4-methyl-2,4-dihydro-3H-1 ,2,4- triazole-3-thione
Figure imgf000064_0003
2,4-Dimethyl-1 ,3-oxazole-5-carboxylic acid (0.8 g), Λ/-methylhydrazinecarboxamide (0.6 g), 1-(3-Dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (1.09 g), HOBt (0.038 g) and triethylamine (0.86 ml) were dissolved, under nitrogen, in dry DMF (15 ml) at room temperature. The mixture was stirred overnight, then DMF was removed under vacuum. NaOH (0.75M, 10 ml) was added and mixture was heated at 80 0C for 3 h. The reaction mixture was cooled to 0 0C and acidified to ca. pH 5 with HCI (aqueous, 37%). The suspended product was isolated by filtration, washing with water (2x3 ml). The cake was dried at room temperature overnight under vacuum to give the title compound in a 3:2 mixture with 2,4-dimethyl-1 ,3-oxazole-5-carboxylic acid as a solid foam (0.68 g, 57% yield).
NMR (1H, CDCI3): δ 3.80 (s, 3H), 2.60 (s, 3H), 2.40 (s, 3H), NH/SH not observed.
Preparation 78: 3-[(3-Chloropropyl)thio]-5-(2,4-dimethyl-1 ,3-oxazol-5-yl)-4-methyl- 4W-1,2,4-triazole
Figure imgf000065_0001
The product mixture from Preparation 77 was suspended in EtOH (10 ml). NaOEt (21% solution in EtOH, 1.14 ml) was added followed by 1-bromo-3-chloropropane (0.41 ml), the solution stirred at 90 0C for 45 min, then cooled to 25 0C. Acetic acid (0.1 eq.) was added than solvent was removed under vacuum. The solid was purified by silica gel column chromatography, eluting with cyclohexane/EtOAc to give the title compound as a solid foam (0.44 g, 54% yield).
NMR (1H, CDCI3): δ 3.70 (t+s, 5H), 3.35 (t, 2H), 2.50 (s, 3H), 2.4 (s, 3H), 2.30 (m, 2H). MS (m/z): 287 [MH]+.
Example 1: S-IS-US-KIR.SS/IS.SRJ-i^-MethoxyphenyO-S-azabicyclotS.I.Olhex-S- yl]propyl}thio)-4-methyl-4H-1,2,4-triazol-3-yl]-2-methylquinoline hydrochloride
Figure imgf000065_0002
A mixture of (1 R,5S/1S,5R)-1-[4-(methoxy)phenyl]-3-azabicyclo[3.1.0]hexane (Preparation 5, 42 mg), 5-{5-[(3-chloropropyl)thio]-4-methyl-4/-/-1 ,2,4-triazol-3-yl}-2-methylquinoline (0.26 mmol), Na2CO3 (0.44 mmol) and NaI (0.22 mmol) in DMF (anhydrous, 0.4 mL) was heated at 60 °C for 24 h. After elimination of the solvent under vacuo, the residue was dissolved in ethyl acetate and the organic layer was washed with saturated aqueous NaHCO3 and dried over Na2SO4. This solution was filtered and the filtrate was concentrated in vacuo. The crude was purified by flash chromatography (dichloromethane to 10% MeOH in dichloromethane) to give 65 mg of the free base of the title compound. To a solution of this material in dichloromethane (0.2 mL) was added 0.14 mmol of HCI (1M in Et2O), the solvent evaporated under vacuo and the material thus obtained triturated with Et2O to give 69 mg of the title compound as a white slightly hygroscopic solid (59% yield).
[The procedure may in analogy be adapted to other combinations of 1 -substituted 3- azabicyclo[3.1.0]hexanes and 3-substituted 5-[(3-chloropropyl)thio]-4-methyl-4/-/-1 ,2,4- triazols. An equivalent molar amount of K2CO3 may be used to replace Na2CO3.]
NMR (1H, DMSO): δ 10.57 (bs,1 H), 8.28 (bs, 1 H), 8.2 (d, 1 H), 7.94 (t, 1 H), 7.82 (d, 1 H), 7.56 (d, 1H), 7.25 (d, 2H), 6.91 (d, 2H), 4.01 (dd, 1H), 3.7 (m, 1 H), 3.74 (s, 3H), 3.6-3.2 (m, 6H), 3.42 (s, 3H), 2.75 (s, 3H), 2.24 (quint, 2H), 2.08 (quint, 1 H), 1.62/1.05 (t/t, 2H). MS (m/z): 486.3[MH]+.
Example 1 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 2.1 cm, eluent CO2 containing 20% (ethanol + 0.1% isopropanol), flow rate 25 mL/min, P 194 bar, T 35 0C, detection UV at 220 nm, loop 1 ml_. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 20% (ethanol + 0.1 % isopropanol), flow rate 2.5 mUmin, P 194 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 15 mg yield as white solid (y=27%) from the racemate (60 mg). Rt. = 39.2 min.
Enantiomer 2 was recovered in 17 mg yield as white solid (y=30%) from the racemate (60 mg). Rt. = 43.4 min.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 2: δ-lS-Ka-^IR.SS/IS.S^-i^-BromophenyO-S-azabicycloia.i.Olhex-S- yl]propyl}thio)-4-methyl-4H-1,2,4-triazol-3-yl]-2-methylquinoline hydrochloride
Figure imgf000066_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 39 mg yield as a white slightly hygroscopic solid (y=40%) from (1R,5S/1 S,5R)-1-(4- bromophenyl)-3-azabicyclo[3.1.0]hexane (40 mg).
NMR (1H, DMSO): δ 10.28 (bs,1 H), 8.16 (dd, 2H), 7.89 (dd, 1 H), 7.76 (d, 1 H), 7.55 (d, 2H), 7.49 (d, 1 H), 7.28 (d, 2H), 4.06 (bm, 1 H), 3.77 (bm, 1 H), 3.6 (bm, 2H), 3.44 (s, 3H), 3.5-3.2 (bm, 4H), 2.71 (s, 3H), 2.23 (m, 3H), 1.58/1.14 (t/m, 2H). MS (m/z): 534.1 [MH]+, 1 Br.
Example 2 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel OJ-H, 25 x 2.1 cm, eluent CO2 containing 12% (ethanol + 0.1 % isopropylamine), flow rate 2.5 mL/min, P 196 bar, T 36 0C, detection UV at 220 nm, loop 1 ml_. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel OJ-H, 25 x 0.46 cm, eluent CO2 containing 10% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 196 bar, T 35 0C, detection UV at 220 nm. Enantiomer 1 was recovered in 7 mg yield as white solid, hydrochloride salt from the racemate (39 mg). Rt. = 56.8 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 7 mg yield as white solid, hydrochloride salt from the racemate (39 mg). Rt. = 62.5 min. Purity >99% a/a by UV.
The absolute configuration of Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be 5-[5-({3-[(1R,5S)-1-(4- bromophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl-4H-1 ,2,4-triazol-3-yl]-2- methylquinoline. (1S.5R)- 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane (see Preparation 48) was used used as the reference.
The absolute configuration of Enantiomer 2 was assigned as described for Enantiomer 1 to be δ-fS-^S-KI S.SRJ-i^-bromophenyO-S-azabicyclolS.I .Olhex-S-yllpropylJthioH- methyl-4/-/-1 ,2,4-triazol-3-yl]-2-methylquinoline.
Enantiomer 1 : Specific Optical Rotation of the corresponding free base: [D]0 = +47 ° (CHCI3, T = 20 0C, c = 0.066 g/mL).
Enantiomer 2: Specific Optical Rotation of the corresponding free base: [D]D = -42 ° (CHCI3, T = 20 °C, c = 0.065 g/mL).
Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
Example 3: 2-Methyl-5-[4-methyl-5-({3-[(1 R5S/1 S,5f?)-1-phenyl-3-azabicyclo[3.1.0]hex-3- yl]propyl}thio)-4H-1 ,2,4-triazol-3-yl]quinoline hydrochloride
Figure imgf000067_0001
The title compound was prepared in analogy to the method described in Example 1 in 74 mg yield as a white slightly hygroscopic solid (y=59%) from (1/?,5S/1 S,5/?)-1-phenyl-3- azabicyclo[3.1.0]hexane (40 mg).
NMR (1H, DMSO): δ 10.4 (bs,1 H), 8.3 (bs, 1 H), 8.2 (d, 1 H), 7.9 (t, 1 H), 7.8 (d, 1 H), 7.6 (bd, 1 H), 7.4-7.3 (m, 5H), 4.0-3.5 (m/m, 2H), 3.7-3.45 (m/m, 2H), 3.5-3.3 (m, 7H), 2.73 (s, 3H)1 2.3 (m, 3H), 1.60,1.1 (t,t 2H). MS (m/z): 456.3[MH]+.
Example 3 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chiralcel OD 10 μm, 250 x 20 mm, eluent A: n-hexane; B: isopropanol, gradient isocratic 35% B, flow rate 7 mLVmin, detection UV at 200-400 nm, CD 230 nm. Retention times given were obtained using an analytical HPLC using a chiral column Chiralcel OD 5 μm, 250 x 4.6 mm, eluent A: n-hexane; B: isopropanol, gradient isocratic 25% B, flow rate 1 mL/min, detection UV at 200-400 nm.
Enantiomer 1 was recovered in 15 mg yield as white solid (y=27%) from the racemate (60 mg). Rt. = 39.2 min.
Enantiomer 2 was recovered in 17 mg yield as white solid (y=30%) from the racemate (60 mg). Rt. = 43.4 min.
Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
Example 4: 5-[5-({3-[(1 R.5S/1 S,5R)-1 -(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hex-3- yl]propyl}thio)-4-methyl-4H-1,2,4-triazol-3-yl]-2-methylquinoline hydrochloride
Figure imgf000068_0001
The title compound was prepared in analogy to the method described in Example 1 in 65 mg yield as a white slightly hygroscopic solid (y=52%) from (1R,5S/1S,5R)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane (50 mg).
NMR (1H, DMSO): δ 10.6 (s,1 H), 8.32 (bs, 1 H), 8.21 (d, 1 H), 7.96 (d, 1 H), 7.84 (d, 1 H), 7.66 (d, 1 H), 7.61 (d, 1 H), 7.6 (d, 1 H), 7.31 (dd, 1 H), 4.06 (m, 2H), 3.74 (m, 2H), 3.7-3.2 (m, 4H), 3.36 (s, 3H), 2.76 (s, 3H), 2.25 (m, 4H), 1.69 (m, 1 H), 1.2 (m, 1 H). MS (mlz): 524.3[MH]+, 2Cl.
Example 4 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) as described in Example 1. Enantiomer 1 was recovered in 19 mg yield as white solid (y=36%) from the racemate (56 mg). Rt. = 26.9 min.
The absolute configuration of Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be 5-[5-({3-[(1 S,5ft)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl-4/-/-1 ,2,4-triazol-3-yl]-2- methylquinoline. (1 S,5f?)- 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane (see Preparation 48) was used used as the reference.
The absolute configuration of Enantiomer 2 was assigned as described for Enantiomer 1 to be 5-[5-({3-[(1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4- methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline.
Enantiomer 1 : Specific Optical Rotation of the corresponding free base: [O]0 = -38.4 ° (CDCI3, T = 20 °C, c = 0.010 g/mL).
Enantiomer 2 was recovered in 14 mg yield as white solid (y=26%) from the racemate (56 mg). Rt. = 31.4 min.
Enantiomer 2: Specific Optical Rotation of the corresponding free base: [D]0 = +34.4 ° (CDCI3, T = 20 0C, c = 0.010 g/mL).
Enantiomer 1 showed fpKi (D3) > 0.6 log-unit higher than Enantiomer 2.
Example 5: 5-[5-({3-[(1 R.5S/1 S,5/?)-1 -(4-fert-Butylphenyl)-3-azabicyclo[3.1.0]hex-3- yl]propyl}thio)-4-methyl-4H-1,2,4-triazol-3-yl]-2-methyIquinoline hydrochloride
Figure imgf000069_0001
The title compound was prepared in analogy to the method described in Example 1 in 38 mg yield as a white slightly hygroscopic solid (y=51%) from (1 R,5S/1 S,5R)-1-(4-tert- butylphenyl)-3-azabicyclo[3.1.0]hexane (29 mg).
NMR (1H1 DMSO): δ 10.16 (bs,1 H), 8.15 (dd, 2H), 7.89 (t, 1 H), 7.76 (d, 1H), 7.49 (d, 1 H), 7.36 (d, 2H), 7.23 (d, 2H), 4.05 (dd, 1 H), 3.77 (dd, 1 H), 3.58 (m, 2H), 3.44 (s, 3H), 2.7 (bm, 4H), 2.34 (s, 3H), 2.23 (t, 2H), 2.15 (t, 1 H), 1.51 (t, 1 H), 1.27 (s, 9H), 1.14 (m, 1 H). MS (m/z): 512.4 [MH]+. Example 5 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) as described in Example 1 but applying a pressure of 200 bar instead of 194 bar.
Enantiomer 1 was recovered in 6.5 mg yield as white solid (y=30%) from the racemate (23 mg). Rt. = 7.0 min.
Enantiomer 2 was recovered in 5 mg yield as white solid (y=23%) from the racemate (23 mg). Rt. = 7.8 min.
Enantiomer 2 showed fpKi (D3) > 0.9 log-unit higher than Enantiomer 1.
Example 6: 4-[(1 R.5S/1 S,5R)-3-(3-{[4-Methyl-5-(2-methylquinolin-5-yl)-4tf-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]benzonitrile hydrochloride
Figure imgf000070_0001
The title compound was prepared in analogy to the method described in Example 1 in 19 mg yield as a white slightly hygroscopic solid (y=27%) from (1 R,5S/1 S,5R)-1-(4- cyanophenyl)-3-azabicyclo[3.1.0]hexane (25 mg).
NMR (1H, DMSO): δ 10.45 (bs,1 H), 8.26 (bd, 1 H), 8.17 (d, 1 H), 7.93 (t, 1 H), 7.8 (d/d, 3H), 7.5 (d, 1 H), 7.46 (d, 2H), 4.09 (d, 1 H)1 3.76 (d, 1H), 3.67 (t, 1 H), 3.6-3.2 (bm, 5H), 3.43 (s, 3H), 2.73 (s, 3H), 2.34 (m, 1H), 2.25 (quint., 2H),1.71/1.22 (dt, 2H).
Example 7: 4-[(1 R.5S/1 S,5R)-3-(3-{[4-Methyl-5-(2-methylquinolin-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenol hydrochloride
Figure imgf000070_0002
The title compound was prepared in analogy to the method described in Example 1 in 10 mg yield as a white slightly hygroscopic solid (y=11 %) from (1R,5S/1 S,5R)-1-(4- hydroxyphenyl)-3-azabicyclo[3.1.0]hexane (38 mg). NMR (1H, DMSO): δ 10.17 (bs,1 H), 9.4 (s,1 H), 8.15 (bd, 2H), 7.89 (d, 1 H), 7.75 (d, 1 H), 7.48 (d, 1 H), 7.12(d, 2H), 6.73 (d, 2H), 3.98 (dd, 1 H), 3.74 (m, 1 H), 3.5 (bm, 2H), 3.44 (s, 3H), 3.5-3.2 (bm, 4H), 2.7 (s, 3H), 2.22 (bquint. 2H), 2.03 (m, 1 H),1.46/1.03 (dm, 2H). MS (mlz): 486.2[MH]+.
Example 8: (1 R.5S/1 S,5/?)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000071_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 75 mg yield as a white slightly hygroscopic solid (y=70%) from (1R,5S/1 S,5R)-1-phenyl-3- azabicyclo[3.1.0]hexane (40 mg).
NMR (1H, DMSO): δ 10.46 (bs,1 H), 8.58 (s, 1 H), 7.4-7.2 (m, 5H), 4.04 (dd, 1 H), 3.73 (m, 1H), 3.7 (s, 3H), 3.7-3.4 (m, 2H), 3.4-3.2 (m+t, 4H), 2.39 (s, 3H)1 2.17 (m, 3H), 1.64,1.1 (2t, 2H).
Example 9: (1 /?,5S/1 S,5/?)-1 -(4-Bromophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol- 5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000071_0002
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 24 mg yield as a white slightly hygroscopic solid (y=28%) from (1f?,5S/1 S,5R)-1-(4- bromophenyl)-3-azabicyclo[3.1.0]hexane (40 mg).
NMR (1H1 DMSO): δ 10.29 (bs,1 H), 8.58 (s, 1 H), 7.55 (dd, 2H), 7.27 (dd, 2H), 4.03 (dd, 1 H), 3.73 (dd, 1 H), 3.7 (s, 3H), 3.55 (m, 2H), 3.5-3.2/3.28 (m+t, 4H), 2.39 (s, 3H), 2.19 (m, 3H), 1.59/1.12 (2t, 2H). MS {mlz): 474.1 [MH]+.
Example 9 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel AS-H, 25 x 2.1 cm, eluent CO2 containing 11% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0C, detection UV at 220 nm, loop 2 ml_. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO2 containing 10% (ethanol + 0.1 % isopropyilamine), flow rate 2.5 mL/min, P 199 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 59 mg yield as white solid, hydrochloride salt from the racemate (138 mg). Rt. = 22.2 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 50 mg yield as white solid, hydrochloride salt from the racemate (138 mg). Rt. = 30.8 min. Purity >99% a/a by UV.
The absolute configuration of Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be (IS, 5 R)-I -(4- bromophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hexane. (7R,5S)-1-(4-Bromophenyl)-3- azabicyclo[3.1.0]hexane (compare Preparation 32) was used used as the reference.
The absolute configuration of Enantiomer 2 was assigned as described for Enantiomer 1 to be (1R,5S)-1-(4-bromophenyl)-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane.
Enantiomer 1 : Specific Optical Rotation of the corresponding free base: [D]0 = -51 ° (CHCI3, T = 20 0C, c = 0.00913 g/mL).
Enantiomer 2: Specific Optical Rotation of the corresponding free base: [π]D = +27 ° (CHCI3, T = 20 0C, c = 0.01 13 g/mL).
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 10: (1 R.5S/1 S,5R)-1 -(4-fert-Butylphenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000072_0001
-Cl
The title compound was prepared in analogy to the method described in Example 1 in 52 mg yield as a white slightly hygroscopic solid (y=57%) from (1 R,5S/1 S,5f?)-1-(4-fert- butylphenyl)-3-azabicyclo[3.1.0]hexane (40 mg).
NMR (1H, CD3OD): δ 8.4 (s, 1 H), 7.42 (d, 2H), 7.28 (d, 2H), 4.11 (d, 1 H), 3.88 (d, 1 H), 3.8 (s, 3H), 3.65 (m, 2H), 3.43 (t, 2H), 3.39 (t, 2H), 2.47 (s, 3H), 2.29 (m, 2H), 2.21 (m, 1 H), 1.44 (m, 1H), 1.33 (s, 9H), 1.3 (m, 1H). MS (m/z): 452.3[MH]+. Example 11 : (1 /?,5S/1 S, 5/?)-1 -(3,4-Dichlorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000073_0001
The title compound was prepared in analogy to the method described in Example 1 in 35 mg yield as a white slightly hygroscopic solid (y=32%) from (1 R,5S/1 S,5R)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane (50 mg).
NMR (1H, DMSO): δ 10.11 (vbs, 1 H), 8.58 (s, 1 H), 7.6 (d+d, 2H), 6.29 (dd, 1 H), 4.04/3.74 (2dd, 2H), 3.7 (s, 3H), 3.6-3.2 (m, 4H), 3.28 (t, 2H), 2.39 (s, 3H), 2.26 (quint, 1 H)1 2.15 (quint., 2H), 1.53/1.2 (2t, 2H). MS (m/z): 464.1[MH]+, 2Cl.
Example 11 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO2 containing 8% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 194 bar, T 36 0C, detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO2 containing 8% (ethanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 190 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 12.5 mg yield as white solid, hydrochloride salt from the racemate (29 mg). Rt. = 38.0 min. Purity 98.6% a/a by UV.
Enantiomer 2 was recovered in 12.5 mg yield as white solid, hydrochloride salt from the racemate (29 mg). Rt. = 40.8 min. Purity 98.6% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 0.5 log-units higher than Enantiomer 2.
Example 12: (1R.5S/1 S,5R)-1-(4-methoxyphenyl)-3-(3-{[4-methyl-5-(4-methyl-1, 3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000073_0002
H-Cl The title compound was prepared in analogy to the method described in Example 1 in 38 mg yield as a white slightly hygroscopic solid (y=39%) from (1 R5S/1 S,5f?)-1-(4- methoxyphenyl)-3-azabicyclo[3.1.0]hexane (40 mg).
NMR (1H, DMSO): δ 10.18 (bs, 1 H), 8.58 (s, 1 H), 7.24 (d, 2H), 6.91 (d, 2H), 3.97 (dd, 1 H), 3.74 (s, 3H), 3.7 (s, 3H), 3.7 (m, 1 H), 3.6-3.2 (m, 4H), 3.27 (t, 2H), 2.39 (s, 3H), 2.15 (quint, 2H), 2.07 (quint., 1 H), 1.49/1.05 (2t, 2H). MS (m/z): 426.2[MH]+.
Example 12 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO2 containing 9% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0C, detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO2 containing 8% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 190 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 5 mg yield as white solid, hydrochloride salt from the racemate (30 mg). Rt. = 28.7 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 12.5 mg yield as white solid, hydrochloride salt from the racemate (30 mg). Rt. = 36.4 min. Purity >99% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 13: (1 /?,5S/1 S,5R)-1 -[4-(5-methyl-3-isoxazolyl)phenyl]-3-(3-{[4-methyl-5-(4- methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000074_0001
H"cι
The title compound was prepared in analogy to the method described in Example 1 in 30 mg yield as a white slightly hygroscopic solid (y=25%) from (1 f?,5S/1 S,5R)-1-[4-(5-methyl- 3-isoxazolyl)phenyl]-3-azabicyclo[3.1.0]hexane (55 mg).
NMR (1H, CD3OD): δ 8.37 (s, 1 H), 7.8 (d, 2H), 7.43 (d, 2H), 6.55 (s, 1 H), 4.16/3.88 (2d, 2H), 3.78 (s, 3H), 3.7 (m, 2H), 3.48-3.4 (2t, 4H), 2.48 (s, 3H), 2.45 (s, 3H), 2.29 (m, 3H), 1.51/1.37 (2t, 2H). MS (m/z): 477.2[MH]+. Example 14: (1S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3- yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane
Figure imgf000075_0001
A mixture of (1 S,5R)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (Preparation 18, 10.4 g), 3-[(3-chloropropyl)thio]-4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazole (Preparation 14, 15.0 g), K2CO3 (7.5 g) and NaI (8.23 g) in DMF (anhydrous, 100 mL) were heated at 60 0C for 15 h. The mixture was then allowed to cool to room temperature, diluted with Et2O (250 mL) and water (200 mL). After separation of the two phases, the aqueous layer was extracted again with Et2O (2 x 200 mL). The combined organic layers were washed with water (2 x 150 mL) and then dried over Na2SO4. After evaporation of the solvent in vacuo, the crude product was purified by flash chromatography (dichloromethane to 10% MeOH in dichloromethane) to give 16.5 g of a yellow solid. The material thus obtained was triturated with Et2O to provide the title compound (13 g) as white solid (y = 61%).
Assignment of the configuration of the title compound is based on two lines of evidence: The fact that it was prepared from (1S,5R)-1-[4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane (of known configuration, see Preparation 14) and by comparison with the spectroscopic data obtained for (1 S,5R)-1-[4-(trifluoromethyl)-phenyl]-3- azabicyclo[3.1.0]hexane: Bands in the VCD spectrum of the title compound are coincident with the corresponding bands in the spectrum of (1 S,5R)-1-[4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane, additionally the sign of the specific rotation is the same for both compounds.
NMR (1H, CDCI3): δ 7.89 (m, 1 H)1 7.49 (d, 2H), 7.18 (d, 2H), 3.67 (s, 3H), 3.31 (m, 2H), 3.30 (d, 1H), 3.09 (d, 1H), 2.61 (m, 2H), 2.56 (d, 1 H), 2.5 (s, 3H), 2.45 (d, 1 H), 1.97 (m, 2H), 1.73 (m, 1 H), 1.47 (t, 1 H), 0.8 (dd, 1 H). MS (m/z): 464 [MH]+.
Example 15: (1 S,5/?)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4/7-1 ,2,4-triazol-3- yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000075_0002
Hydrochloric acid (1 M solution in Et2O, 19.4 mL) was added dropwise under N2 to a solution of (1 S,5f?)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (Example 14, 9 g) in Et2O (anhydrous, 135 mL). The resulting suspension was allowed to stir at room temperature for 2 h. The solid was then filtered, washed with Et2O and dried in vacuo overnight to provide the title compound (8.9 g) as off white solid (y = 92%).
NMR (1H, DMSO): δ 10.16 (bs, 1 H), 8.58 (s, 1 H), 7.72 (d, 2H), 7.51 (d, 2H), 4.1 (dd, 1 H), 3.78 (dd, 1 H), 3.70 (s, 3H), 3.66 (m, 2H), 3.29 (t, 2H), 2.5 (bm, 2H), 2.39 (s, 3H), 2.33 (quint, 2H), 2.19 (m, 1 H), 1.62/1.23 (t/t, 2H). MS (m/z): 464 [MH]+.
Example 16: (1 R.5S/1 S,5R)-1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5- (4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]- hexane hydrochloride
Figure imgf000076_0001
A mixture of (IR.SS/I S.δ^-i-^-Fluoro^-^rifluoromethyOphenyll-S-azabicyclo- [3.1.0]hexane (Preparation 38, 700 rng, 2.8 mmol), 3-[(3-Chloropropyl)thio]-4-methyl-5-(4- methyl-1 ,3-oxazol-5-yl)-4/-/-1 ,2,4-triazole (Preparation 14, 3.4 mmol), Na2CO3 (3.4 mmol) and NaI (3.4 mmol) in DMF (anhydrous, 6 mL) was heated at 60 0C for 24 h. After elimination of the solvent under vacuo, the residue was dissolved in ethyl acetate and the organic layer was washed with saturated aqueous NaHCO3 and dried over Na2SO4. This solution was filtered and the filtrate was concentrated in vacuo. The crude was purified by flash chromatography (dichloromethane to 10% MeOH in dichloromethane) to give 503 mg of the free base of the title compound.
NMR (1H, CDCI3): δ 7.89 (s, 1 H), 7.32-7.2 (m, 3H), 3.70 (s, 3H), 3.30 (t, 2H), 3.26 (dd, 1 H), 3.10 (dd, 1 H), 2.60 (t, 2H), 2.52 (dd, 1H), 2.51 (s, 3H), 2.43 (dd, 1H), 1.94 (m, 2H), 1.74 (m, 1 H), 1.40 (t, 1 H), 0.76 (dd, 1 H). MS (m/z): 482.2[MH]+.
The title compound was obtained as a white solid following the method described for Example 15.
NMR (1H, DMSO): δ 10.28 (bs,1 H), 8.58 (s, 1 H), 7.73 (d, 1 H), 7.6 (m, 2H), Al 3.57 (d/m, 2H), 3.79 (d, 1 H), 3.69 (s, 3H), 3.5-3.2 (vbm, 1 H), 3.27 (t, 2H), 2.5 (m, 2H), 2.4 (m, 1 H), 2.38 (s, 3H), 2.14 (quint., 2H), 1.62/1.16 (2t, 2H).
Example 16 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chiralpak AD 10 μm, 250 x 21 mm, eluent A: n-hexane; B: isopropanol + 0.1% isopropyl amine, gradient isocratic 9% B, flow rate 7 mL/min, detection UV at 200-400 nm. Retention times given were obtained using an analytical HPLC using a chiral column Chiralpak AD-H 5 μm, 250 x 4.6 mm, eluent A: n-hexane; B: isopropanol, gradient isocratic 15% B, flow rate 0.8 mL/min, detection UV at 200-400 nm.
Enantiomer 1 was recovered as white solid, Rt. = 15.4 min.
Enantiomer 2 was recovered as white solid, Rt. = 16.3 min.
Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
Example 17: (1 R,5Sή S,5fl)-3-(3-{[4-Methyl-5-(4-methyM ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-[3-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000077_0001
H-Cl
(i/R.δS/I S.SRJ-i-tS-CTrifluoromethyOphenyll-S-azabicyclotS.I .OJhexane was prepared in analogy to the method described in Preparations 15, 16 and 17. From this material the title compound was obtained as a white slightly hygroscopic solid following the method described for Examples 14 and 15.
NMR (1H, DMSO): δ 10.5 (bs,1 H), 8.58 (s, 1 H), 7.7-7.5 (m, 4H), 4.09 (m, 1 H), 3.8-3.2 (m, 8H), 3.29 (t, 2H), 2.39 (s, 3H), 2.3 (m, 1 H), 2.18 (m, 2H), 1.68 (t, 1 H), 1.21 (t, 1 H). MS (m/z): 464 [MH]+.
Example 17 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 10% (ethanol + 0.1 % isopropanol), flow rate 2.5 mL/min, P 180 bar, T 35 0C, detection UV at 220 nm, loop 1 mL. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 10% (ethanol + 0.1% isopropanol), flow rate 22 mL/min, P 190 bar, T 36 0C, detection UV at 220 nm.
Enantiomer 1 was recovered as white solid, Rt. = 17.6 min.
Enantiomer 2 was recovered as white solid, Rt. = 18.4 min.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2. Example 18: (1 R.5S/1 S,5R)-1 -[4-Fluoro-3-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5- (4-methyl-1 ,3-oxazol-5-yl)-4W-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]- hexane hydrochloride
Figure imgf000078_0001
(I R.SS/I S^RJ-i-^-Fluoro-S-^rifluoromethyOphenyll-S-azabicyclo^.i .Olhexane was prepared in analogy to the method described in Preparations 15, 16 and 17. From this material the title compound was obtained as a white slightly hygroscopic solid following the method described for Examples 14 and 15.
NMR (1H, DMSO): δ 10.2 (bs, 1 H), 8.58 (s, 1 H), 7.75 (dm, 1 H), 7.72 (m, 1 H), 7.53 (t, 1 H), 4.06 (dd, 1 H), 3.74 (dd, 1 H), 3.7 (s, 3H), 3.6 (m, 2H), 3.4 (m, 2H), 3.28 (t, 2H), 2.39 (s, 3H), 2.26 (m, 1H), 2.18 (m, 2H), 1.54 (t, 1H), 1.22 (dd, 1 H). MS (m/z): 481 [MH]+.
Example 19: 1-[5-[(fS,5R/ffl,5S)-3-(3-{[4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H- 1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-2- (methyloxy)phenyl]ethanone hydrochloride
Figure imgf000078_0002
The title compound was prepared in analogy to the method described in Example 1 in 25 mg yield as a white slightly hygroscopic solid from (1R,5S/1 S,5R)-1-[5-(3- azabicyclo[3.1.0]hex-1 -yl)-2-(methyloxy)phenyl]ethanone (32 mg).
NMR (1H, DMSO): δ 10.31 (bs,1 H), 8.58 (s, 1 H), 7.52 (d, 1 H), 7.49 (dd, 1 H), 7.16 (d, 1 H), 3.98 (dd, 1 H), 3.89 (s, 3H), 3.7 (m, 4H), 3.6-3.2 (bm, 4H), 3.27 (t, 2H), 2.5 (m, 3H), 2.39 (s, 3H), 2.15 (quint, 2H), 2.09 (quint, 1 H), 1.54-1.08 (2t, 2H). MS {m/z): 468[MH]+.
Example 19 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 196 bar, T 36 0C, detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 190 bar, T 35 0C, detection UV at 220 nm. Enantiomer 1 was recovered in 14 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 12.5 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 16 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 16.8 min. Purity >99% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 20: (YS,5R/f/?,5S)-1-(4-Chlorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000079_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 99 mg yield as a white slightly hygroscopic solid from (1/?,5S/1 S,5/?)-1-(4-chlorophenyl)-3- azabicyclo[3.1.0]hexane (58 mg). NMR (1H, DMSO): δ 9.93(bs,1 H), 8.58 (s, 1 H), 7.42 (d, 2H), 7.33 (d, 2H), 4.04 (dd, 1 H), 3.75 (dd, 1H), 3.7 (s, 3H), 3.5 (m, 2H), 3.3 (bm, 4H), 2.39 (s, 3H), 2.2 (m, 1 H), 2.15 (m, 2H), 1.47-1.14 (2t, 2H). MS (mlz): 431[MH]+.
Example 20 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO2 containing 15% (ethanol + 0.1 % isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0C1 detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 2.5 mLΛπin, P 190 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 17 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 7.8 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 17 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 9.7 min. Purity >99% a/a by UV.
The absolute configuration of Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be (1S,5f?)-1-(4- chlorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hexane. 5-[5-({3-[(1 R,5S)-1-(4-Bromophenyl)-3- azabicyclotS.I .Olhex-S-ylJpropylJthioH-methyl^H-i ^^-triazol-S-yO^-methylquinoline (compare Example 2) was used used as the reference.
The absolute configuration of Enantiomer 2 was assigned as described for Enantiomer 1 to be (1 f?,5S)-1 -(4-chlorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4tf-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane.
Enantiomer 1 : Specific Optical Rotation of the corresponding free base: [D]D = -25 ° (CHCI3, T = 20 0C, c = 0.0066 g/mL).
Enantiomer 2: Specific Optical Rotation of the corresponding free base: [D]0 = +29 ° (CHCI3, T = 20 0C, c = 0.0068 g/mL).
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 21 : {1S.5R/1 /?,5S)-1-(4-Fluorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4W-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000080_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 78 mg yield as a white slightly hygroscopic solid from (1 R,5S/1 S,5R)-1-(4-florophenyl)-3- azabicyclo[3.1.0]hexane (49 mg).
NMR (1H, DMSO): δ 10.06 (bs,1 H), 8.58 (s, 1 H), 7.36 (dd, 2H), 7.19 (t, 2H), 4.02 (dd, 1 H), 3.74 (dd, 1 H), 3.7 (s, 3H), 3.55 (m, 2H)1 3.5-3.2 (bm, 4H), 2.39 (s, 3H), 2.15 (m, 3H), 1.49- 1.1 (2t, 2H). MS {ml z): 414[MH]+.
Example 21 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO2 containing 7% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 196 bar, T 36 0C, detection UV at 220 nm, loop 1 ml_. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO2 containing 6% (ethanol + 0.1% isopropylamine), flow rate 2.5 rπUmin, P 190 bar, T 350C, detection UV at 220 nm.
Enantiomer 1 was recovered in 14 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 26.2 min. Purity >99% a/a by UV. Enantiomer 2 was recovered in 16 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 32.4 min. Purity >99% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 22: (^S,5R/f/?,5S)-1-(3-Chlorophenyl)-5-methyl-3-(3-{[4-methyl-5-(4-methyl- 1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane hydrochloride
Figure imgf000081_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 184 mg yield as a white slightly hygroscopic solid from (1 f?,5S/1 S,5R)-1-(3-chlorophenyl)-3- azabicyclo[3.1.0]hexane (116 mg).
NMR (1H, DMSO): δ 9.88 (bs,1 H). 8.58 (s, 1 H)1 7.43 (d, 1 H), 7.4-7.2 (m, 3H), 4.06 (dd, 1 H), 3.75 (dd, 1H), 3.7 (s, 3H), 3.62-3.54 (t/m, 2H), 3.5-3.3 (bm, 4H), 2.39 (s, 3H), 2.25 (m, 1 H), 2.15 (m, 2H), 1.46-1.19 (2m, 2H). MS {m/z): 431[MH]+.
Example 22 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 15% (ethanol + 0.1 % isopropylamine), flow rate 22 ml_/min, P 192 bar, T 36 0C, detection UV at 220 nm, loop 1 ml_. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 180 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 18 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 29.6 min. Purity 100% a/a by UV.
Enantiomer 2 was recovered in 16 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 32.0 min. Purity 100% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 23: (fS,5R/7/?,5S)-1-(3-Fluorophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4W-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000082_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 150 mg yield as a white slightly hygroscopic solid from (1R,5S/1 S,5R)-1-(3-fluorophenyl)-3- azabicyclo[3.1.0]hexane (116 mg).
NMR (1H, DMSO): δ 10.21 (bs,1 H), 8.58 (d, 1 H), 7.4 (m, 1 H), 7.2-7.0 (m, 3H), 4.03 (dd, 1 H), 3.75 (dd, 1 H), 3.7 (s, 3H), 3.61 (t/m, 1 H), 3.52 (m, 1 H), 3.3 (m, 2H), 3.28 (t, 2H), 2.38 (s, 3H), 2.25 (m, 1 H), 2.16 (m, 2H), 1.57-1.17 (t/m, 2H). MS (m/z): 414 [MH]+.
Example 23 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO2 containing 7% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0C, detection UV at 220 nm, loop 1 ml_. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO2 containing 6% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 190 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 12 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 24.6 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 14.5 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 26.0 min. Purity >99% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 24: (1 S,5fl/f K,5S)-3-(3-{[4-methyl-5-(4-methyM ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-S-yllthiolpropylJ-i-ia-tmethyloxyJphenyll-S-azabicyclo^.i .Olhexane hydrochloride
Figure imgf000082_0002
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 140 mg yield as a white slightly hygroscopic solid from (1 f?,5S/1 S,5fi)-1-(3-methoxyphenyl)-3- azabicyclo[3.1.0]hexane (116 mg). NMR (1H, DMSO): δ 10.16 (bs,1 H), 8.58 (d, 1 H), 7.26 (dd, 1 H), 6.85 (m, 3H), 4.03 (dd, 1 H), 3.77 (s, 3H), 3.72 (dd, 1 H), 3.7 (s, 3H), 3.6-3.3 (bm, 4H), 3.28 (t/m, 2H), 2.39 (s, 3H), 2.18 (m, 3H), 1.53-1.1 (t/m, 2H). MS {mlz): 426 [MH]+.
Example 24 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel OJ-H, 25 x 2.1 cm, eluent CO2 containing 13% (2-propanol + 0.1% isopropylamine), flow rate 22 mL/min, P 200 bar, T 36 0C, detection UV at 220 nm. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralcel OJ-H, 25 x 0.46 cm, eluent CO2 containing 13% (2-propanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 180 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 13.5 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 24.2 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 13.5 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 26.8 min. Purity >99% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 25: (fS,5R)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(tetrahydro-2H-pyran-4- yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000083_0001
The title compound was prepared in analogy to the method described in Example 1 in 33 mg yield as a white slightly hygroscopic solid from (1 S,5R)-1-(4-bromophenyl)-3- azabicyclo[3.1.0]hexane (Preparation 32, 30 mg).
NMR (1H, CD3OD): δ 7.54 (d, 2H), 7.28 (d, 2H), 4.08 (m, 3H), 3.8-3.6 (m, 2H), 3.72 (s, 3H), 3.65 (m, 3H), 3.47 (t, 2H), 3.3 (m, 3H), 2.25 (m, 3H), 1.93 (m, 4H), 1.48-1.34 (2m, 2H). MS (mlz): 478[MH]+.
Example 26: (fS,5R)-1-(4-Bromophenyl)-3-[3-({4-methyl-5-[4-
(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}thio)propyl]-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000083_0002
The title compound was prepared in analogy to the method described in Example 1 in 36 mg yield as a white slightly hygroscopic solid from (1 S,5R)-1-(4-bromophenyl)-3- azabicyclo[3.1.0]hexane (Preparation 32, 30 mg).
NMR (1H, CD3OD): δ 7.96 (m, 4H), 7.54 (d, 2H), 7.29 (t, 2H), 4.14 (d, 1 H), 3.90 (m, 1 H), 3.75 (S, 3H), 3.66 (m, 2H), 3.50 (m, 2H), 3.43 (t, 2H), 2.30 (m, 3H), 1.50 (m, 1 H), 1.34 (t, 1 H). MS (m/z): 578[MH]+.
Example 27: (7S,5/?)-1-(4-Bromophenyl)-3-(3-{[4-methyl-5-(3-pyridinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000084_0001
The title compound was prepared in analogy to the method described in Example 1 in 49 mg yield as a white slightly hygroscopic solid from (1 S,5fi)-1-(4-bromophenyl)-3- azabicyclo[3.1.0]hexane (Preparation 32, 30 mg).
NMR (1H, CD3OD): δ 8.97 (m, 1 H), 8.82 (m, 1 H), 8.31 (m, 1 H), 7.75 (m, 1 H), 7.53 (d, 2H), 7.29 (t, 2H), 4.15 (d, 1 H), 3.90 (d, 1 H), 3.75 (s, 3H), 3.67 (m, 2H), 3.50 (m, 2H), 3.42 (t, 2H), 2.29 (m, 3H), 1.51 (m, 1 H), 1.34 (t, 1 H). MS (mlz): 471 [MH]+.
Example 28: (fS,5A?)-1-(4-Bromophenyl)-3-(3-{[5-(3,4-difluorophenyl)-4-methyl-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.OJhexane hydrochloride
Figure imgf000084_0002
The title compound was prepared in analogy to the method described in Example 1 in 26 mg yield as a white slightly hygroscopic solid from (1S,5R)-1-(4-bromophenyl)-3- azabicyclo[3.1.0]hexane (Preparation 32, 30 mg).
NMR (1H, CD3OD): δ 7.72 (m, 1H), 7.55 (m, 4H), 7.28 (d, 2H), 4.13 (d, 1H), 3.89 (d, 1 H), 3.7 (s, 3H), 3.64 (m, 2H), 3.43 (t, 2H), 3.38 (m, 2H), 2.29 (m, 3H), 1.48 (m, 1 H), 1.34 (t, 1 H). MS (m/z): 506[MH]+.
Example 29: θ-IS-KS-^IS.SR/tR.SSJ-i^-ChlorophenyO-S-azabicycloIS.I .Olhex-S- yl]propyl}thio)-4-methyl-4H-1,2,4-triazol-3-yl]-2-methylquinoline hydrochloride
Figure imgf000085_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 110 mg yield as a white slightly hygroscopic solid from (1R5S/1 S,5R)-1-(4-chlorophenyl)-3- azabicyclo[3.1.0]hexane (87 mg).
NMR (1H, CD3OD): δ 8.95 (d,1 H), 8.39 (d, 1 H), 8.28 (t, 1 H), 8.13 (d, 1 H), 7.96 (d, 1 H), 7.37 (m, 4H), 4.17 (d, 1 H), 3.93 (d, 1 H), 3.71 (m, 2H), 3.62 (s, 3H), 3.5 (2m, 4H), 3.04 (s, 3H), 2.37 (m, 2H), 2.27 (m, 1 H), 1.55 (m, 1 H), 1.31 (m, 1 H). MS (m/z): 490 [MH]+.
Example 29 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 25% (ethanol + 0.1 % isopropylamine), flow rate 22 mL/min, P 199 bar, T 36 0C, detection UV at 220 nm. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 25% (ethanol + 0.1% isopropylamine), flow rate 2.5 ml_/min, P 180 bar, T 35 0C, detection UV at 220 nm. Enantiomer 1 was recovered in 13.5 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 24.3 min. Purity 87.6% a/a by UV.
Enantiomer 2 was recovered in 5 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 26.5 min. Purity 100% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 30: (1S,5R/1 K,5S)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 , 2,4- triazol-3-yl]thio}propyl)-1-{4-[(trifluoromethyl)oxy]phenyl}-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000085_0002
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 246 mg yield as a white slightly hygroscopic solid from (1R,5S/1 S,5f?)-1-{4- [(trifluoromethyl)oxy]phenyl}-3-azabicyclo[3.1.0]hexane (205 mg). NMR (1H, DMSO): δ 10.33 (bs,1 H), 8.58 (s, 1 H), 7.43 (d, 2H), 7.36 (d, 2H), 4.04 (dd, 1 H), 3.73 (dd, 1 H), 3.7 (s, 3H), 3.6-3.2 (bm, 6H), 2.39 (s, 3H), 2.2 (m, 3H), 1.61-1.16 (2t, 2H). MS (m/z): 480[MH]+.
Example 30 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chirapak AS-H, 25 x 2 cm, eluent A: n-hexane; B: isopropanol, gradient isocratic 15% B v/v, flow rate 7 mL/min, detection UV at 220 nm. Retention times given were obtained using chiral column Chiracel OD, 25 x 0.46 cm, eluent A: n-hexane; B: isopropanol, gradient isocratic 10% B v/v, flow rate 1 mL/min, detection UV at 220 nm.
Enantiomer 1 was recovered in 15 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 28.3 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 16 mg yield as white solid, hydrochloride salt from the racemate (40 mg). Rt. = 50.6 min. Purity >99% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 31 : (7S,5R/7R,5S)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-[2-methyl-4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.OJhexane hydrochloride
Figure imgf000086_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 46 mg yield as a white slightly hygroscopic solid from (1 R,5S/1 S,5fi)-1-[2-methyl-4- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (71.5 mg).
NMR (1H, DMSO): δ 10.25 (bs,1 H), 8.58 (s, 1 H), 7.6 (m, 3H), 3.97-3.7 (dd/m, 2H), 3.79/3.4 (dd/m, 2H), 3.69 (s, 3H), 3.27 (t, 2H), 2.5 (m, 2H), 2.48 (s, 3H), 2.38 (s, 3H), 2.2 (m, 1 H), 2.13 (quint., 2H), 1.61-1.01 (2t, 2H). MS (mlz): 478[MH]+.
Example 32: not used
Example 33: (1 S.5R/1 R,5S)-3-(3-{[4-Methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-{4-[(trifluoromethyl)oxy]phenyl}-3-azabicyclo[3.1. OJhexane hydrochloride
Figure imgf000087_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 72 mg yield as a white slightly hygroscopic solid from (1 R,5S/1 S,5R)-1-{4- [(trifluoromethyl)oxy]phenyl}-3-azabicyclo[3.1.0]hexane (100 mg).
NMR (1H, DMSO): δ 10.45 (bs, 1 H), 7.44 (d, 2H), 7.36 (d, 2H), 4.04 (bm, 1 H), 3.94 (dm, 2H), 3.73 (bm, 1 H), 3.55 (s, 3H), 3.6-3.3 (bm, 6H), 3.22 (t, 2H), 3.13 (m, 1 H), 2.23 (m, 1 H), 2.21 (m, 2H), 1.9-1.7 (m, 4H), 1.63-1.16 (2t, 2H). MS (m/z): 483 [MH]+.
Example 33 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO2 containing 8% (2-propanol + 0.1% isopropylamine), flow rate 22 mL/min, P 200 bar, T 36 0C, detection UV at 220 nm. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO2 containing 8% (2-propanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 180 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 15 mg yield as white solid, hydrochloride salt from the racemate (65 mg). Rt. = 23.2 min. Purity 100% a/a by UV.
Enantiomer 2 was recovered in 12 mg yield as white solid, hydrochloride salt from the racemate (65 mg). Rt. = 24.6 min. Purity 100% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 34: (1 f?,5S/1 S,5f?)-1-(3-Bromophenyl)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5- yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000087_0002
H-Cl
The title compound was prepared in 23 mg yield as a white slightly hygroscopic solid from (1R,5S/1 S,5R)-1-(3-bromophenyl)-3-azabicyclo[3.1.0]hexane (140 mg) in analogy to the method described in Example 1 and purifying the free base of the title compound by preparative HPLC using a column X Terra MS C18 5μm, 100 x19 mm, eluent A: H2O+0.1% TFA; B: CH3CN+0.1 % TFA, gradient 10% (B) for 1 min, from 10% (B) to 35% (B) in 12 min, flow rate 17 mL/min, detection UV at 200-400 nm. Retention times given were obtained using column X Terra MS C18 5μm, 50 x 4.6 mm, eluent A: H2O+0.1% TFA; B: CH3CN+0.1% TFA, gradient isocratic 25% B v/v, flow rate 1 mL/min, detection UV at 200-400 nm. Rt. = 6.26 min. Purity 96.4% a/a by UV.
NMR (1 H1 DMSO): δ 9.9 (bs,1 H), 8.58 (s, 1 H), 7.57 (s, 1 H), 7.47 (m, 1 H), 7.3 (m, 2H), 4.04 (m, 1 H), 3.75 (dd, 1 H), 3.7-3.2 (m, 6H), 3.7 (s, 3H), 2.39 (s, 3H), 2.23 (m, 1 H), 2.15 (m, 2H), 1.47 (t, 1 H), 1.2 (t, 1 H). MS (m/z): 512[MH]+.
Example 35: (tS,5R)-3-(1-Methyl-3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4- triazol-3-yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000088_0001
A mixture of (I S.SRJ-S-β-chloro-i-methylpropyO-i-μ-^rifluoromethyOphenyll-S- azabicyclo[3.1.0]hexane hexane (Preparation 20, 105 mg), 4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-2,4-dihydro-3/-/-1 ,2,4-triazole-3-thione (0.43 mmol), TEA (0.46 mmol) and NaI (0.43 mmol) in DMF (anhydrous, 1.6 ml.) was heated at 60 0C for 12 h. After elimination of the solvent under vacuo, the residue was dissolved in ethyl acetate and the organic layer was washed with H2O and dried over Na2SO4. This solution was concentrated in vacuo, treated with cyclohexane and filtered to give 125 mg of the free base of the title compound. To a solution of this material in dichloromethane (0.2 mL) was added 0.34 mmol of HCI (1 M in Et2O), the solvent evaporated under vacuo and the material thus obtained triturated with Et2O to give 105 mg of the title compound as a white slightly hygroscopic solid.
MS(m/z): 478[MH]+.
Example 35 was separated to give the separated diastereoisomers by semi-preparative HPLC using a chiral column Chirapak AD, 25 x 2 cm, eluent A: n-hexane; B: ethanol÷ 0.1% isopropylamine, gradient isocratic 15% B v/v, flow rate 7 ml_/min, UV wavelength range 220-400 nm. Retention times given were obtained using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent A: n-hexane; B: ethanol÷ 0.1% isopropylamine, gradient isocratic 17% B v/v, flow rate 1 mL/min, UV wavelength range 200-400 nm.
Diastereoisomer 1 was recovered in 30 mg yield as a white solid, hydrochloride salt from the diastereomeric mixture (105mg). Rt. = 17.9 min. Purity 99.4% a/a by UV NMR (1H, DMSO): δ 10.33 (bs,1 H), 8.58 (s, 1 H), 7.71 (d, 2H), 7.53 (d, 2H), 4.07 (dd, 1 H), 3.78 (dd, 1 H), 3.7 (s, 3H), 3.7 (m, 1 H), 3.56 (bs, 2H), 3.4 (m, 1 H), 3.18 (m, 1 H), 2.4 (s, 3H), 2.4-2.3 (m, 1 H), 2.26-2.09 (m, 2H), 1.72 (m, 1 H), 1.42 (d, 3H), 1.2 (m, 1 H). MS (m/z): 478[MH]+. Diastereoisomer 2 was recovered in 46 mg yield as white solid, hydrochloride salt from the diastereomeric mixture (105mg). Rt. = 21.2 min. Purity >99% a/a by UV NMR (1H, DMSO): δ 10.26 (bs,1H), 8.58 (s, 1H), 7.7 (d, 2H), 7.51 (d, 2H), 4.14 (dd, 1H), 3.8-3.6 (m, 3H), 3.7 (s, 3H), 3.53 (bs, 1 H), 3.4 (m, 1 H), 3.18 (m, 1 H), 2.38 (s, 3H), 2.4- 2.25 (m, 2H), 2.1 (m, 1 H)1 1.69 (m, 1 H), 1.39 (d, 3H), 1.2 (m, 1 H). MS (m/z): 478[MH]+.
Example 36: (1 R.5S/1 S,5R)-1 -[2-Fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-
(4-methyl-1,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3- azabicyclo[3.1.OJhexane hydrochloride
Figure imgf000089_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 144 mg yield as a white slightly hygroscopic solid from 1 (1R,5S/1 S,5f?) -[2-fluoro-5- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (109 mg).
NMR (1H, CD3OD): δ 8.41 (s,1 H), 7.8 (m, 1 H), 7.74 (m, 1 H), 7.39 (t, 1 H), 4.13 (d, 1 H), 3.95 (d, 1 H), 3.81 (s, 3H), 3.73 (bd, 1 H), 3.54 (d, 1 H), 3.48 (m, 2H), 3.41 (m, 2H), 2.48 (s, 3H), 2.39 (m, 1 H), 2.28 (q, 2H), 1.58 (m, 1 H), 1.35 (m, 1 H). MS (m/z): 482[MH]+.
Example 36 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chirapak AS-H, 25 x 2 cm, eluent A: n-hexane; B: isopropanol + 0.1 % isopropylamine, gradient isocratic 10% B v/v, flow rate 7 mL/min, detection UV at 220 nm. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 7% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 180 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 48 mg yield as a white solid, hydrochloride salt from the racemate (138 mg). Rt. = 21.2 min. Purity 100% a/a by UV.
Enantiomer 2 was recovered in 46 mg yield as white solid, hydrochloride salt from the racemate (138 mg). Rt. = 22.7 min. Purity 99% a/a by UV.
Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1. Example 37: 1 -[4-[(1 K.5S/1 S,5/?)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-2- (methyloxy)phenyl]ethanone hydrochloride
Figure imgf000090_0001
The title compound was prepared in analogy to the method described in Example 1 in 70 mg yield as a white slightly hygroscopic solid from 1-[4-[(1 S,5R /1R,5S)-3- azabicyclo[3.1.0]hex-1-yl]-2-(methyloxy)phenyl]ethanone (87 mg).
NMR (1H, CDCI3) of the corresponding free base: δ 8.0 (s,1H), 7.7 (d, 1H), 6.7-6.8 (m, 2H), 3.9 (s, 3H), 3.7 (s, 3H), 3.35 (m, 4H), 3.1 (d, 1 H), 2.6 (m, 3H), 2.55 (s, 3H), 2.5 (s, 3H), 2.45 (m, 1H), 2.0 (m, 2H), 1.75 (m, 1 H), 0.8 (m, 1 H). MS (m/z): 468[MH]+.
Example 38: 1-[4-[(1R,5S/1S,5R)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-(methyloxy)phenyl]-1 - propanone hydrochloride
Figure imgf000090_0002
The title compound was prepared in analogy to the method described in Example 1 in 75 mg yield as a white slightly hygroscopic solid from 1-[(1S,5R /1R,5S)-3- azabicyclo[3.1.0]hex-1 -yl)-2-(methyloxy)phenyl]-1 -propanone (106 mg).
Free base NMR (1H, CDCI3): δ 7.9 (s,1 H), 6.65 (d, 1 H), 6.7 (m, 2H), 3.9 (s, 3H), 3.7 (s, 3H), 3.35 (m. 3H), 3.1 (d, 1H), 2.9 (m, 2H), 2.6 (m, 3H), 2.5 (s, 3H), 2.45 (m, 1H), 2.0 (m, 2H), 1.8 (m, 1 H), 1.1 (m, 3H), 0.8 (m, 1 H). MS (m/z): 482[MH]+.
Example 39: (1 R.5S/1 S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-[2-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000090_0003
The title compound was prepared in analogy to the method described in Example 1 in 7 mg yield as a white slightly hygroscopic solid from (1 f?,5S/1 S,5f?)-1-[2- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (53 mg).
NMR (1H, DMSO): δ 10.48 (bs,1 H), 8.55 (s, 1 H), 7.9-7.6 (m, 4H), 3.9-3.1 (bm, 8H), 3.68 (s, 3H), 2.36 (s, 3H), 2.13 (m, 2H), 1.66 (m, 1 H), 1.2 (m, 1 H), 1.1 (m, 1 H). MS (m/z): 464[MH]+.
Example 40: (1 S,5R)-1 -[2-Fluoro-4-(trif luoromethyl)phenyl]-3-(3-{[4-methyl-5-(4- methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-a2abicyclo[3.1.0]hexane hydrochloride
Figure imgf000091_0001
The free base of the title compound was prepared in analogy to the method described in Example 1 from (1 S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane. A mixture of (1 S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (Preparation 39, 727mg, 2.97mmol), 3-[(3-Chloropropyl)thio]-4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4/-M ,2,4-triazole (Preparation 14, 3.6mmol.), K2CO3 (3.6mmol.) and NaI (2.97mmol) in DMF anhydrous was heated at 60 0C for 24 h. After elimination of the solvent under vacuo, the residue was dissolved in ethyl acetate and the organic layer was washed with saturated aqueous NaHCO3 and dried over Na2SO4. This solution was filtered and the filtrate was concentrated in vacuo. The crude was purified by flash chromatography (dichloromethane to 10% MeOH in dichloromethane) to give 940 mg of the free base of the title compound.
This free base (886 mg) was converted to the hydrochloride salt (847 mg) according to the method described in Example 1. The title compound was obtained as a white solid.
Analytical Chiral HPLC confirmed the product to be identical to Enantiomer 2 of Example 16.
NMR and MS data corresponded to those reported for Example 16.
The absolute configuration of the title compound was confirmed using comparative VCD and comparative OR analyses of the corresponding free base to be (1 S,5R)-1-[2-fluoro-4- (trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hexane. (1 S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol- 5-yl)-4/-/-1 ,2,4-triazol-3-yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane (see Example 14) was used used as the reference. Specific Optical Rotation of the corresponding free base: [α]D = - 42 ° (CDCI3, T = 25 0C, c ≡ 0.005 g/0.8 ml_).
Examples 41-52:
To a solution of the respective 3-thio-5-aryl-1 ,2,4-triazole (prepared in analogy to the method described in Preparation 13, 0.131 mmol) in dry acetonitrile (2 mL) 2-tert- butylimino-2-diethylamino-1 ,3-dimethyl-perhydro-1 ,3,2-diaza-phosphorine on polystyrene (90 mg, 2.2 mmol/g) was added and the resulting mixture was shaken for 30 minutes at room temperature. (1 S,5R)-3-(3-Chloropropyl)-1 -[4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane (40 mg) was added and the resulting mixture was shaken at 70 0C for three hours. After cooling the resin was removed by filtration, washed with methanol (2 mL), and then the solvent was removed under reduced pressure. Purifications were carried out using mass directed HPLC using a Waters XTerra Prep MS C18 10μm, 30x150 mm column using the following conditions:
Figure imgf000092_0001
A= H2O + 0.1% formic acid B = ACN + 0.1% formic acid
Then solvent was removed under reduced pressure to give the respective compounds as formate salts. The residues were taken up with methanol (1 mL) and loaded on SCX SPE cartridges (1g), washed with methanol (3 mL) and eluted with a 2 M ammonia solution in methanol (3 mL), then the solvent was removed under reduced pressure. The residues were taken up with dichloromethane (1 mL) and a 1.0 M HCI solution in diethylether was added (0.131 mmol), then the solvent was removed under reduced pressure to give product compounds summarised in TABLE 1 as hydrochloride salts.
Analytical Chromatographic conditions: Column: X Terra MS C18 5 mm, 50 x 4.6 mm
Mobile phase: A: NH4HCO3 sol. 10 mM, pH10; B: CH3CN
Gradient: 10% (B) for 1 min, from 10% (B) to 95% (B) in 12 min, 95% (B) for 3 min
Flow rate: 1 ml_/min
UV wavelenght range: 210-350 nm
Mass range: 100-900 amu Ionization: ES+
TABLE 1
R
EX Name and Structure Analytical data
(min)
NMR (1H, DMSO): δ
(1 S,5R)-3-(3-{[4-Methyl-5-(2- 10.84 (bs, HCI), 8.77 methyl-3-pyridinyl)-4H-1 ,2,4- (dd, 1 H), 8.19 (bd, 1 H), triazol-3-yl]thio}propyl)-1 -[4- 7.71 (d, 2H), 7.66 (m, (trifluoromethyl)phenyl]-3- 1H), 7.51 (d, 2H), 4.08 azabicyclo[3.1.0]hexane (dd, 1 H), ca 3.8 (s, 3H),
41
-
Figure imgf000093_0001
MS (m/z): 474 [MH]+.
42
Figure imgf000093_0002
(1 S,5R)-3-(3-{[5-(1 ,5-Dimethyl- 1 H-pyrazol-4-yl)-4-methyl-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-1 - [4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
43 9.27 MS (m/z): 477 [MH]+
Figure imgf000093_0003
(1 S,5R)-3-(3-{[4-Methyl-5-(5-
44 pyrimidinyl)-4H-1 ,2,4-triazol-3- 8.92 MS (m/z): 461 [MH]+ yl]thio}propyl)-1-[4- (trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
Figure imgf000094_0001
(1 S,5R)-3-(3-{[4-Methyl-5-(6- methyl-3-pyridinyl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1 -[4- (trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
9.47 MS (m/z): 474 [MH]+
Figure imgf000094_0002
(1 S,5R)-3-(3-{[5-(2,4-Dimethyl- 1 ,3-thiazol-5-yl)-4-methyl-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-1 - [4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane
9.79 MS (m/z): 494 [MH]+
Figure imgf000094_0003
(1 S,5R)-3-(3-{[4-Methyl-5-(5- NMR (1H, DMSO): δ
10.15 methyl-2-pyrazinyl)-4H-1 ,2,4- 10.41 (bs, HCI), 9.11 triazol-3-yl]thio}propyl)-1 -[4- (bs, 1 H), 8.63 (bs, 1 H), (trifluoromethyl)phenyl]-3- 7.66 (d, 2H), 7.44 (d, azabicyclo[3.1.0]hexane 2H), 4.02 (dd, 1 H),
Figure imgf000095_0001
(1 S,5R)-3-(3-{[4-Methyl-5- (tetrahydro-2H-pyran-4-yl)-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-1 ■ [4-(trifluoromethyl)phenyl]-3- azabicyclo[3.1.0]hexane hydrochloride 9.15 MS (m/z): 467 [MH]+
Figure imgf000095_0002
NMR (1H, DMSO): δ
2-Methyl-6-{4-methyl-5-[(3- 10.41 (bs, HCI), 8.67 {(1S,5R)-1-[4-(trifluoromethyl)- (bs, 1H), 8.47 (s, 1 H), phenyl]-3-azabicyclo[3.1.0]hex- 8.2 (s, 2H), 7.72 (m, 3-yl}propyl)thio]-4H-1 ,2,4- 1 H), 7.68 (m, 2H), 7.49 triazol-3-yl}quinoline (m, 2H), 4.07 (m, 1 H),
Figure imgf000095_0003
MS (m/z): 524 [MH]+.
8-Fluoro-2-methyl-5-{4-methyl- 5-[(3-{(1 S,5R)-1 -[4-(trifluoro- methyl)phenyl]-3-azabicyclo- [3.1.0]hex-3-yl}propyl)thio]-4H- 1 ,2,4-triazol-3-yl}quinoline
10.14 MS (m/z): 542 [MH]+
Figure imgf000095_0004
2-Methyl-5-{4-methyl-5-[(3- 10.12 MS (m/z): 524 [MH]+ {(1 S,5R)-1-[4-(trifluoro- methyl)phenyl]-3-azabicyclo- [3.1.0]hex-3-yl}propyl)thio]-4H- 1 ,2,4-triazol-3-yl}quinoline hydrochloride
Figure imgf000096_0001
Examples 53-58:
To a solution of the respective 3-thio-5-aryl-1 ,2,4-triazole (0.124 mmol) in dry acetonitrile (2 ml.) 2-te/f-butylimino-2-diethylamino-1 ,3-dimethyl-perhydro-1 ,3,2-diaza-phosphorine on polystyrene (85 mg, 2.2 mmol/g) was added and the resulting mixture was shaken for 30 minutes at room temperature, then (1 S,5f?)-3-(3-chloropropyl)-1-[2-fluoro-4- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (40 mg) was added and the resulting mixture was shaken at 50 °C overnight. After cooling the resin was removed by filtration, washed with methanol (2ml_) and then the solvent was removed under reduced pressure. Purifications were carried out using mass directed HPLC:
Preparative chromatographic conditions (prep. HPLC of 6 out of 6 compounds)
Column: X Terra MS C18 5 mm, 100 x 19 mm
Mobile phase: A: NH4HCO3 sol. 10 mM, pH10; B: CH3CN
Gradient: 30% (B) for 1 min, from 30% (B) to 95% (B) in 9 min, 95% (B) for 3 min
Flow rate: 17 ml_/min
L)V wavelenght range: 210-350 nm Mass range: 100-900 amu
Ionization: ES+
Then solvent was removed under reduced pressure to give compounds as free bases. The residues were taken up with dichloromethane (2 mL) and a 1.0 M HCI solution in diethylether was added (0.124 mmol) then solvent was removed under reduced pressure to give to give product compounds summarised in TABLE 2 as hydrochloride salts.
Analytical chromatographic conditions Column: X Terra MS C18 5 mm, 50 x 4.6 mm
Mobile phase: A: NH4HCO3 sol. 10 mM, pH10; B: CH3CN
Gradient: 30% (B) for 1 min, from 30% (B) to 95% (B) in 9 min, 95% (B) for 3 min Flow rate: 1 mL/min
UV wavelenght range: 210-350 nm
Mass range: 100-900 amu Ionization: ES+ TABLE 2
R
EX Name and Structure Analytical data
(min)
Figure imgf000097_0001
(1 S,5R)-3-(3-{[5-(2,4-Dimethyl-1 ,3- NMR (1H, DMSO): δ
56 7.17 thiazol-5-yl)-4-methyl-4H-1 ,2,4- 10.45 (bs, HCI), 7.73 triazol-3-yl]thio}propyl)-1-[2-fluoro- (d, 1 H), 7.67 (t, 1 H), 4-(trifluoromethyl)phenyl]-3- 7.62 (d, 1 H), 4.01 (d, azabicyclo[3.1.0]hexane 1 H), 3.79 (d, 1 H), 3.6- hydrochloride 3.3 (m, 5H), 3.5-3.3 (t,
57
Figure imgf000098_0001
(1S,5R)-1-[2-Fluoro-4- NMR (1H, DMSO): δ
(trifluoromethyl)phenyl]-3-[3-({4- 10.64 (bs, HCI), 7.98 methyl-5-[4-(trifluoromethyl)- (d, 2H), 7.95 (d, 2H), phenyl]-4H-1 ,2,4-triazol-3- 7.73 (d, 1 H), 7.70 (t, yl}thio)propyl]-3- 1H), 7.61 (d, 1 H), 4.00 azabicyclo[3.1.0]hexane (d, 1 H), 3.79 (d, 1 H),
58 hydrochloride 8.92 3.67 (s, 3H), 3.55 (d,
Figure imgf000098_0002
Example 59: 1-{4-[(1/?,5S/1 S,5/?)-3-(3-{[4-Methyl-5-(2-methyl-5-quinolinyl)-4H-1 ,2,4- triazol-S-yllthiolpropylJ-S-azabicyclotS.I .Olhex-i-yllphenyl^-pyrrolidinone hydrochloride
Figure imgf000099_0001
H-Cl
A Schlenk tube was charged with 5-[5-({3-[(1 R5S/1 S,5f?)-1-(4-bromophenyl)-3- azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline (cf. Example 2; 0.15 g), 2-pyrrolidinone (32 mg), tris(dibenzylideneacetone)-dipalladium(0) (6 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (10 mg), cesium carbonate (130 mg) and 1 ,4-dioxane (2 ml_). The Schlenk tube was sealed with a teflon screwcap and the reaction mixture was stirred at 100 0C for 12 h. The reaction mixture was allowed to cool to room temperature, diluted with dichloromethane (10 ml_), filtered and concentrated in vacuo. The crude product was purified by flash chromatography (dichloromethane to 10% MeOH in dichloromethane) to give 60 mg of the free base of the title compound. To a solution of this material in dichloromethane (0.4 mL) was added HCI (0.11 mL, 1 M in Et2O), the solvent evaporated in vacuo and the material thus obtained triturated with Et2O to give 64 mg of the title compound as a white solid.
NMR (1H, DMSO): δ 10.48 (bs,1 H), 8.24 (bd, 1 H), 8.18 (d, 1 H), 7.93 (t, 1 H), 7.81 (d, 1 H), 7.62 (d, 2H), 7.54 (d, 1H), 7.31 (d, 2H), 4.04 (dd, 1H), 3.82 (t, 2H), 3.76 (dd, 1H), 3.70/3.10 (bm, 8H), 3.45 (s, 3H), 2.74 (s, 3H), 2.25 (m, 2H), 2.16 (m, 1 H), 2.07 (m, 2H), 1.63/1.10 (t/t, 2H). MS (m/z): 539 [MH]+.
Example 60: 5-{5-[(3-{(1 /?,5S/1 S,5R)-1 -[4-(1 ,1 -Dioxido-2-isothiazolidinyl)phenyl]-3- azabicyclo[3.1.0]hex-3-yl}propyl)thio]-4-methyl-4H-1,2,4-triazol-3-yl}-2- methylquinoline hydrochloride
Figure imgf000099_0002
A Schlenk tube was charged with 5-[5-({3-[(1 R,5S/1 S,5R)-1-(4-bromophenyl)-3- azabicyclo[3.1.0]hex-3-yl]propyl}thio)-4-methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline (cf. Example 2; 0.15 g), isothiazolidine 1 ,1 -dioxide (46 mg), tris(dibenzylideneacetone)- dipalladium(O) (6 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (10 mg), cesium carbonate (130 mg) and 1 ,4-dioxane (2 mL). The Schlenk tube was sealed with a teflon screwcap and the reaction mixture was stirred at 100 0C for 12 h. The reaction mixture was allowed to cool to room temperature, diluted with dichloromethane (10 mL), filtered and concentrated in vacuo. The crude product was purified by flash chromatography (dichloromethane to 10% MeOH in dichloromethane) to give 50 mg of the free base of the title compound. To a solution of this material in dichloromethane (0.3 mL) was added HCI (0.087 mL, 1 M in Et2O), the solvent evaporated in vacuo and the material thus obtained triturated with Et2O to give 52 mg of the title compound as a white solid.
NMR (1H, DMSO): δ 10.57 (bs,1 H), 8.27 (bd, 1 H), 8.19 (d, 1 H), 7.94 (t, 1 H), 7.82 (d, 1 H), 7.55 (d, 1 H)1 7.32 (d, 2H), 7.18 (d, 2H), 4.03 (dd, 1H), 3.72 (m, 3H), 3.60/3.20 (bm, 8H), 3.45 (s, 3H), 2.75 (s, 3H), 2.41 (m, 2H), 2.25 (m, 2H), 2.14 (m, 1 H), 1.66/1.10 (t/m, 2H). MS (ml z)\ 575 [MH]+.
Example 61 : (1 /?,5S/1 S,5R)-1 -[3-Fluoro-4-(trifluoromethyl)phenyl]-5-methyl-3-(3-{[4- methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3- azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000100_0001
The title compound was prepared in analogy to the method described in Example 1 in 247 mg yield as a white slightly hygroscopic solid from (1 f?,5S/1 S,5R)-1-[3-fluoro-4- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (338 mg).
NMR (1H, CD3OD): δ 8.4 (s, 1H), 7.55 (t, 1H), 7.37 (d, 1H), 7.32 (d, 1 H), 4.2 (d, 1H), 3.91 (d, 1 H), 3.81 (s, 3H), 3.76 (d, 1 H), 3.67 (d, 1 H), 3.51 (t, 2H), 3.43 (t, 2H), 2.47 (s, 3H), 2.41 (m, 1 H), 2.31 (m, 2H), 1.61 (t, 1 H), 1.45 (t, 1 H). MS (mlz): 496 [MH]+.
Example 61 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 2.1 cm, eluent CO2 containing 12% (Ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 194 bar, T 36 0C, detection UV at 220 nm. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 10% (ethanol + 0.1 % isopropylamine), flow rate 2.5 mL/min, P 180 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 42 mg yield as white solid, hydrochloride salt from the racemate (100 mg). Rt. = 27.1 min. Purity 100% a/a by UV.
Enantiomer 2 was recovered in 34 mg yield as white solid, hydrochloride salt from the racemate (100 mg). Rt. = 31.0 min. Purity 100% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 2 log-unit higher than Enantiomer 2. Example 62: 1 -(2-(Methyloxy)-5-{(1 R,5S/1 S,5R)-3-[3-({4-methyl-5-[4- (trifluoromethyl)phenyl]-4H-1 ,2,4-triazol-3-yl}thio)propyl]-3-azabicyclo[3.1.0]hex-1 ■ yl}phenyl)ethanone hydrochloride
Figure imgf000101_0001
The title compound was prepared in analogy to the method described in Example 1 in 51 mg yield as a white solid (y=60%) from 1-[5-[(1R,5S/7S,5R)-3-azabicyclo[3.1.0]hex-1-yl]- 2-(methyloxy)phenyl]ethanone (35 mg) and 3-[(3-chloropropyl)thio]-4-methyl-5-[4- (trifluoromethyl)phenyl]-4H-1 ,2,4-triazole (60 mg, prepared in analogy to the method described in Preparation 13).
NMR (1H, CDCI3, free base): δ 7.80-7.70 (m, 4H), 7.50 (s, 1H), 7.27-7.20 (m, 1H), 6.85 (d, 1 H), 3.86 (s, 3H), 3.62 (s, 3H), 3.40-3.24 (m, 3H), 3.15 (d, 1 H), 2.58 (s, 3H), 2.65-2.55 (m, 2H), 2.54-2.45 (m, 2H), 2.10-1.90 (quint, 2H), 1.65-1.57(m, 1 H), 1.35 (m, 1 H), 0.75 (m, 1 H). MS (m/z): 531 [MH]+.
Example 63: 1 -[5-[(1 R.5S/1 S,5R)-3-(3-{[5-(3,4-Difluorophenyl)-4-methyl-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-2-(methyloxy)phenyl]ethanone hydrochloride
Figure imgf000101_0002
The title compound was prepared in analogy to the method described in Example 1 in 40 mg yield as a white solid (y=50%) from 1-[5-[(1R,5S/7S,5R)-3-azabicyclo[3.1.0]hex-1-yl]- 2-(methyloxy)phenyl]ethanone (35 mg) and 3-[(3-chloropropyl)thio]-5-(3,4-difluorophenyl)- 4-methyl-4/-/-1 ,2,4-triazole (54 mg, prepared in analogy to the method described in Preparation 13).
NMR (1H, CDCI3, free base): δ 7.56-7.19 (m, 5H), 6.84 (d, 1 H), 3.86 (s, 3H), 3.62 (s, 3H), 3.38-3.24 (m, 3H), 3.10 (d, 1 H), 2.58 (s, 3H), 2.65-2.42 (m, 4H), 2.10-1.90 (quint, 2H), 1.65-1.57(m, 1H), 1.35 (m, 1H), 0.75 (m, 1H). MS (m/z): 499 [MH]+.
Example 64: 1 -{2-(Methyloxy)-5-[(1 /?,5S/ϊS,5/?)-3-(3-{[4-methyl-5-(3-pyridinyl)-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenyl}ethanone hydrochloride
Figure imgf000102_0001
The title compound was prepared in analogy to the method described in Example 1 in 32 mg yield as a yellow solid (y=42%) from 1-[5-[(1R,5S/7S,5R)-3-azabicyclo[3.1.0]hex-1-yl]- 2-(methyloxy)phenyl]ethanone (35 mg) and 3-{5-[(3-chloropropyl)thio]-4-methyl-4H-1 ,2,4- triazol-3-yl}pyridine (48 mg, prepared in analogy to the method described in Preparation 13).
NMR (1H, CDCI3, free base): δ 8.87 (s, 1 H), 8.70 (d, 1 H), 8.0 (d, 1 H), 7.48 (s, 1 H), 7.43 (m, 1H), 7.23 (m, 1 H), 6.84 (d, 1H), 3.86 (s, 3H), 3.62 (s, 3H), 3.40-3.25 (m, 3H), 3.10 (d, 1 H), 2.58 (s, 3H), 2.67-2.42 (m, 4H), 2.10-1.90 (quint, 2H), 1.65-1.57(m, 1 H), 1.35 (m, 1 H), 0.75 (m, 1 H). MS (m/z): 464 [MH]+.
Example 65: 1-[5-[(1R,5S/7S,5f?)-3-(3-{[4-Methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-2-(methyloxy)phenyl]ethanone hydrochloride
Figure imgf000102_0002
The title compound was prepared in analogy to the method described in Example 1 in 50 mg yield as a yellow solid (y=60%) from 1-[5-[(1f?,5S/7S,5R)-3-azabicyclo[3.1.0]hex-1-yl]- 2-(methyloxy)phenyl]ethanone (35 mg) and 5-{5-[(3-chloropropyl)thio]-4-methyl-4/-/-1 ,2,4- triazol-3-yl}-2-methylquinoline (60 mg).
NMR (1H, DMSO): δ 10.38 (bs,1 H), 8.2 (m, 2H), 7.91 (t, 1 H), 7.78 (d, 1 H), 7.5 (m, 3H), 7.17 (d, 1 H), 4.02 (d, 1 H), 3.89 (s, 3H), 3.74 (dd, 1 H), 3.6-3.2 (m, 6H), 3.45 (s, 3H), 2.72 (s, 3H), 2.5 (s, 3H), 2.23 (quint, 2H), 2.11 (quint, 1 H), 1.57 (t, 1 H), 1.1 (t, 1 H). MS (m/z): 528 [MH]+.
Example 66: 1-{2-(Methyloxy)-5-[(1/?,5S/fS,5R)-3-(3-{[4-methyl-5-(tetrahydro-2H- pyran-4-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 - yl]phenyl}ethanone hydrochloride
Figure imgf000102_0003
The title compound was prepared in analogy to the method described in Example 1 in 24 mg yield as a white solid (y=32%) from 1-[5-[(1R,5S/tS,5f?)-3-azabicyclo[3.1.0]hex-1-yl]- 2-(methyloxy)phenyl]ethanone (35 mg) and 3-[(3-chloropropyl)thio]-4-methyl-5- (tetrahydro-2/-/-pyran-4-yl)-4H-1,2,4-triazole (50 mg, prepared in analogy to the method described in Preparation 13).
NMR (1H, CDCI3, free base): δ 7.49 (s, 1 H), 7.24 (m, 1 H), 6.85 (d, 1 H), 4.14-4.05 (m, 2H), 3.86 (s, 3H), 3.62 (s, 3H), 3.57-3.40 (m, 2H), 3.29-3.15 (m, 3H), 3.05 (d, 1 H), 2.82-2.95 (m, 1 H), 2.63-2.40 (m, 4H), 2.58 (s, 3H), 2.15-1.77 (m, 6H), 1.62 (m, 1 H), 1.32 (m, 1 H), 0.70 (m, 1H). MS (m/z): 471 [MHf.
Example 67: 1 -(2-Hydroxy-5-{(1 /?,5S/7S,5/?)-3-[3-({4-methyl-5-[4-
(trifluoromethyl)phenyl]-4H-1 ,2,4-triazol-3-yl}thio)propyl]-3-azabicyclo[3.1.0]hex-1 - yl}phenyl)ethanone hydrochloride
Figure imgf000103_0001
The title compound was prepared in analogy to the method described in Example 1 in 35 mg yield as a white solid (y=33%) from 1-{5-[(1ft,5S/7S,5f?)-3-azabicyclo[3.1.0]hex-1-yl]- 2-hydroxyphenyl}ethanone (43 mg) and 3-[(3-chloropropyl)thio]-4-methyl-5-[4- (trifluoromethyl)phenyl]-4/-/-1 ,2,4-triazole (80 mg, prepared in analogy to the method described in Preparation 13).
NMR (1H, CDCI3, free base): δ 12.2 (s, 1 H), 7.80-7.70 (m, 4H), 7.50 (s, 1 H), 7.30 (m, 1 H), 6.88 (d, 1 H), 3.86 (s, 3H), 3.40-3.25 (m, 3H), 3.10 (d, 1 H), 2.58 (s, 3H), 2.65-2.35 (m, 4H), 2.0 (quint, 2H), 1.58 (m, 1 H), 1.35 (m, 1 H), 0.70 (m, 1 H). MS (m/z): 517 [MH]+.
Example 68: 1 -{5-[(1 R,5S/1 S,5R)-3-(3-{[5-(3,4-Difluorophenyl)-4-methyl-4H-1 ,2,4- triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-2-hydroχyphenyl}ethanone hydrochloride
Figure imgf000103_0002
The title compound was prepared in analogy to the method described in Example 1 in 27 mg yield as a white solid (y=29%) from 1-{5-[(1R,5S/7S,5R)-3-azabicyclo[3.1.0]hex-1-yl]- 2-hydroxyphenyl}ethanone (40 mg) and 3-[(3-chloropropyl)thio]-5-(3,4-difluorophenyl)-4- methyl-4/-/-1 ,2,4-triazole (67 mg, prepared in analogy to the method described in Preparation 13).
NMR (1H, DMSO): δ 11.82 (s,1 H), 10.26 (bs, 1H), 7.85 (m, 1 H), 7.76 (d, 1 H), 7.67 (m, 1 H), 7.61 (m, 1 H), 7.51 (dd, 1 H), 6.97 (d, 1 H), 4.02 (dd, 1 H), 3.74 (dd, 1 H), 3.64 (s, 3H), 3.55 (m, 2H), 3.3 (m, 4H), 2.67 (s, 3H), 2.15 (m, 3H), 1.52 (t, 1 H), 1.13 (t, 1 H). MS (m/z): 485 [MH]+.
Example 69: 1-{2-Hydroxy-5-[(1/?,5S/f S,5R)-3-(3-{[4-methyl-5-(4-methyM ,3-oxazol-5- yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenyl}ethanone hydrochloride
Figure imgf000104_0001
The title compound was prepared in analogy to the method described in Example 1 in 36 mg yield as a white solid (y=43%) from 1-{5-[(1R,5S/7S,5R)-3-azabicyclo[3.1.0]hex-1-yl]- 2-hydroxyphenyl}ethanone (38 mg) and 3-[(3-chloropropyl)thio]-4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazole (57 mg).
NMR (1H, CDCI3, free base): δ 12.2 (s, 1H), 7.88 (s, 1 H), 7.50 (s, 1 H), 7.24 (m, 1 H), 6.58 (d, 1H), 3.68 (s, 3H), 3.32 (m, 3H), 3.10 (d, 1 H), 2.58-2.47 (m, 4H), 2.58 (s, 3H), 2.47 (s, 3H), 2.0 (m, 2H), 1.62 (m, 1 H), 1.35 (m, 1 H), 0.68 (m, 1 H). MS (m/z): 454 [MH]+.
Example 70: 1-{2-Hydroxy-5-[(1f?,5S/7S,5R)-3-(3-{[4-methyl-5-(2-methyl-5-quinolinyl)-4H- 1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]phenyl}ethanone hydrochloride
Figure imgf000104_0002
The title compound was prepared in analogy to the method described in Example 1 in 24 mg yield as a yellow solid (y=32%) from 1-{5-[(1R,5S/7S,5R)-3-azabicyclo[3.1.0]hex-1-yl]- 2-hydroxyphenyl}ethanone (30 mg) and 5-{5-[(3-Chloropropyl)thio]-4-methyl-4H-1 ,2,4- triazol-3-yl}-2-methylquinoline (55 mg).
NMR (1H, CDCI3, free base): δ 12.1 (s, 1 H), 8.10 (dd, 2H), 7.67 (t, 1 H), 7.50 (m, 2H), 7.23 (m, 2H), 6.85 (d, 1 H), 3.45-3.23 (m, 3H), 3.40 (s, 3H), 3.08 (d, 1 H), 2.67 (s, 3H), 2.65-2.41 (m, 4H), 2.55 (s, 3H), 2.02 (m, 2H), 1.58 (m, 1 H), 1.32 (m, 1 H), 0.64 (m, 1 H). MS {m/z): 514 [MH]+. Example 71 : 1 -[5-[(1 R,5S/7S,5/?)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-(methyloxy)phenyl]-1 - propanone hydrochloride
Figure imgf000105_0001
The title compound was prepared in analog y to the method described in Example 1 in 51 mg yield as a white solid (y=47%) from 1-[5-[(1 R,5S)-3-azabicyclo[3.1.0]hex-1-yl]-2- (methyloxy)phenyl]-1 -propanone (52 mg, prepared in analogy to the method described in Preparations 43-45) and 3-[(3-chloropropyl)thio]-4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1 ,2,4-triazole (69 mg).
NMR (1H, DMSO): δ 10.24 (bs,1 H), 8.52 (m, 1 H), 7.42 (d, 1 H), 7.40 (dd, 1 H), 7.08 (d, 1 H), 3.93 (dd, 1 H), 3.81 (s, 3H), 3.67 (dd, 1 H), 3.64 (s, 3H), 3.48 (m, 2H), 3.28 (m, 2H), 3.22 (t, 2H), 2.86 (q, 2H), 2.33 (s, 3H), 2.1 (m, 2H), 2.03 (m, 1 H), 1.48 (t, 1 H), 1.0 (t, 1 H), 1.04 (t, 3H). MS (m/z): 482 [MH]+.
The title compound was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column chiralpak AS-H 5 μm, 250 x 21 mm, eluent A: n-hexane; B: ethanol + 0.1% isopropylamine, gradient isocratic 40% B, flow rate 7 mL/min, detection UV at 200-400 nm. Retention times given were obtained using an analytical HPLC using a chiral column chiralpak AS-H 5 μm, 250 x 4.6 mm, eluent A: n-hexane; B: ethanol + 0.1% isopropylamine, gradient isocratic 40% B, flow rate 0.8 mL/min, detection UV at 200-400 nm.
Enantiomer 1 was recovered in 10 mg yield as white solid (y=30%) from the racemate (66 mg). Rt. = 17.2 min.
Enantiomer 2 was recovered in 10 mg yield as white solid (y=30%) from the racemate (66 mg). Rt. = 19.1 min.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 72: 2-Methyl-5-[(1 K,5S/7S,5/?)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)- 4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-1,3-benzothiazole hydrochloride
Figure imgf000105_0002
5-[(1 R,5S)-3-Azabicyclo[3.1.0]hex-1-yl]-2-methyl-1 ,3-benzothiazole was prepared from 2- methyl-1 ,3-benzothiazol-5-amine dihydrochloride in analogy to the method described in Preparations 15, 16 and 17. From this material the title compound was obtained as a yellow solid following the method described for Examples 14 and 15.
NMR (1H, DMSO): δ 10.54 (bs,1 H), 8.58 (m, 1 H), 8.0 (d, 1 H), 7.9 (d, 1 H), 7.34 (dd, 1 H), 4.0 (dd, 1 H), 3.75 (dd, 1H), 3.70 (s, 3H), 3.65 (m, 1 H), 3.57 (m, 1 H), 3.35 (m, 2H), 3.30 (t, 2H), 2.8 (S, 3H), 2.39 (s, 3H), 2.27 (m, 1 H), 2.19 (m, 2H), 1.7 (t, 1 H), 1.19 (t, 1 H). MS (m/z): 467 [MH]+.
The title compound was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column chiralpak AS-H 5 μm, 250 x 21 mm, eluent A: n-hexane; B: ethanol + 0.1% isopropylamine, gradient isocratic 13% B, flow rate 7 mL/min, detection UV at 200-400 nm. Retention times given were obtained using an analytical HPLC using a chiral column chiralpak AS-H 5 μm, 250 x 4.6 mm, eluent A: n-hexane; B: ethanol + 0.1% isopropylamine, gradient isocratic 13% B, flow rate 1 mL/min, detection UV at 200-400 nm.
Enantiomer 1 was recovered in 17 mg yield as white solid (y=62%) from the racemate (55 mg). Rt. = 17.1 min.
Enantiomer 2 was recovered in 18 mg yield as white solid (y=65%) from the racemate (55 mg). Rt. = 19.3 min.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 73: 2-MethyU6-[(1 R.5S/1 S,5R)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)- 4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-1 ,3-benzothiazole hydrochloride
Figure imgf000106_0001
6-[(1f?,5S/7S,5fi)-3-Azabicyclo[3.1.0]hex-1-yl]-2-methyl-1 ,3-benzothiazole was prepared from 2-methyl-1 ,3-benzothiazol-6-amine in analogy to the method described in Preparations 15, 16 and 5. From this material the title compound was obtained as a yellow solid following the method described for Examples 14 and 15.
NMR (1H, CD3OD): δ 8.39 (s,1 H), 7.98 (d, 1 H), 7.89 (d, 1 H), 7.5 (dd, 1 H), 4.19 (d, 1 H), 3.92 (d, 1H), 3.8 (s, 3H), 3.72 (d, 2H), 3.52 (t, 2H), 3.42 (t, 2H), 2.85 (s, 3H), 2.47 (s, 3H), 2.31 (m, 3H), 1.54 (t, 1 H), 1.41 (t, 1 H). MS {m/z)\ 467 [MH]+. Example 74: 1 -Methyl-5-[(1 R,5S/1 S15/?)-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-
4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hex-1-yl]-1H-indazole hydrochloride
Figure imgf000107_0001
5-[(1 R,5S/fS,5R)-3-Azabicyclo[3.1.0]hex-1-yl]-1-methyl-1 H-indazole was prepared from 1- methyl-1 /-/-indazol-5-amine in analogy to the method described in Preparations 15, 16 and 5. From this material the title compound was obtained as a yellow solid following the method described for Examples 14 and 15.
NMR (1H, DMSO): δ 10.4 (bs,1 H), 8.58 (m, 1 H), 8.01 (s, 1 H), 7.70 (d, 1 H), 7.63 (d, 1 H), 7.39 (dd, 1 H), 4.05 (m, 1H), 4.04 (s, 3H), 3.75 (d, 1 H), 3.70 (s, 3H), 3.59 (m, 2H), 3.39 (t, 2H), 3.26 (t, 2H), 2.39 (s, 3H), 2.18 (m, 3H), 1.61 (t, 1 H), 1.14 (t, 1 H). MS (mlz): 450 [MH]+.
The title compound was separated to give the separated enantiomers by semi-preparative SFC (Gilson) using a chiral column chiralpak AS-H, 250 x 21 mm, modifier: ethanol + 0.1% isopropylamine 12%, flow rate 22 mL/min, P 200 bar, T 36 0C, detection UV at 220 nm. Retention times given were obtained using an analytical SFC (Berger) using a chiral column chiralpak AS-H 5 μm, 250 x 46 mm, modifier: ethanol + 0.1% isopropylamine 12%, flow rate 2.5 mLJmin, P 180 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 25 mg yield as white solid (y=62%) from the racemate (80 mg). Rt. = 19.5 min.
Enantiomer 2 was recovered in 28 mg yield as white solid (y=70%) from the racemate (80 mg). Rt. = 22.8 min.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 75: (1 R.5S/Ϊ S,5K)-3-(3-{[4-Methyl-5-(4-methyM ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-[6-(trifluoromethyl)-3-pyridinyl]-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000107_0002
(1 R,5S/ϊS,5R)-1-[6-(Trifluoromethyl)-3-pyriclinyl]-3-azabicyclo[3.1.0]hexane was prepared from 6-(trifluoromethyl)-3-pyridinamine in analogy to the method described in Preparations 37 and 5. From this material the title compound was obtained as a yellow solid following the method described for Examples 14 and 15.
NMR (1H, DMSO): δ 10.46 (bs,1 H), 8.73 (bs, 1 H), 8.58 (m, 1 H), 8.0 (dd, 1 H), 7.90 (d, 1 H), 4.12 (m, 1 H), 3.78 (d, 1 H), 3.70 (s, 3H), 3.7 (m, 1 H), 3.54 (m, 1 H), 3.39 (t, 2H), 3.29 (s, 2H), 2.39 (m, 3H), 2.47 (m, 1 H), 2.18 (m, 2H), 1.71 (m, 1 H), 1.33 (m, 1H). NMR (19F, DMSO): δ -66.2 (s). MS (m/z): 465 [MH]+.
Examples 76-94:
To a solution of the respective 3-thio-5-aryl-1 ,2,4-triazole (prepared in analogy to the method described in Preparation 13, 0.063 mmol) in dry acetonitrile (2 mL) 2-tert- butylimino-2-diethylamino-1 ,3-dimethyl-perhydro-1 ,3,2-diaza-phosphorine on polystyrene (43 mg, 2.2 mmol/g) was added and the resulting mixture was shaken for 1 h at room temperature, then (1 f?,5S/1 S,5R)-1 -^-bromophenyO-S-β-chloropropyO-S-azabicycle- [3.1.0]hexane (20 mg) was added and the resulting mixture was shaken at 70 0C for 3.5 hours. After cooling the resin was removed by filtration, washed with dichloromethane (2 mL) and methanol (2 mL) and the collected liquid phase was evaporated under reduced pressure. Two isomers were formed by S- and N- alkylation, the major isomer being the desired S-alkylated. Those isomers were separated using mass directed HPLC using a Waters XTerra Prep MS C18 10 μm, 30x150 mm column using the following conditions:
Figure imgf000108_0001
A= H2O + 0.1% formic acid
B = acetonitrile + 0.1% formic acid
Then solvent was removed under reduced pressure to give title compounds as formate salts.
In the case of Examples 93 and 94 the isomers were separated by silica gel flash chromatography. The S-alkylated isomers were dissolved in dry diethyl ether and cooled at 0 0C. 1.2 eq of HCI (as 1.0 M solution in diethyl ether) were slowly added. The resulting precipitate was decanted, washed with pentane and filtered, yielding the products as the hydrochloride salts.
Analytical conditions:
Examples 76-90:
Column X-Terra MS C18 5 um, 50 x 4.6 mm Mobile Phase A: H20 + 0.1 % TFA; B: CH3CN + 0.1 % TFA Gradient 10% (B) for 1 min; from 10% (B) to 90% (B) in 12 min; 90%
(B) for 3 min
Flow rate 1 mL/min
UV wavelength 200-400 nm range
Mass range 100-900 amu lonisation ES+
Example 91 :
Column X-Terra MS C18 5 um, 50 x 4.6 mm Mobile Phase A: H20 + 0.2 % HCOOH; B: CH3CN + 0.2 % HCOOH Gradient 10% (B) for 1 min; from 10% (B) to 95% (B) in 12 min; 95% (B) for 3 min
Flow rate 1 mL/min
UV wavelength 210-400 nm range
Mass range 100-900 amu lonisation ES+
Example 93:
Analytical Column ZORBAX SB C18, 50 mm, 4.6 mm i.d.; 1.8 um
Mobile phase Amm.Acet., 5mM/ Acetonitrile+0.1%Formic Acid
Gradient 97/3 > 36/64 v/v in 3,5 min >0/100 v/v in 3.5 min
Flow rate 2 mL/min
Detection DAD, 210-350 nm
MS ES+
Retention time 2.42 min
[M+H]+ 484/486 (1 Br pattern)
Assay 98.17 % a/a (by DAD)
Example 94: Analytical Column ZORBAX SB C18, 50 mm, 4.6 mm i.d.; 1.8 urn
Mobile phase Amm.Acet., 5mM/ Acetonitrile+0.1 %Formic Acid
Gradient 97/3 > 36/64 v/v in 3.5 min >0/100 v/v in 3.5 min
Flow rate 2 mL/min
Detection DAD, 210-350 nm
MS ES+
Retention time 3.02 min
[M+H]+ 552/554 (1 Br pattern)
Assay 99.51 % a/a (by DAD)
EX Name and Structure R (min) Analytical data
NMR (1H, DMSO): 5 8.6
Figure imgf000110_0001
[MH]+.
NMR (1H, DMSO): δ 9.6
77
Figure imgf000110_0002
[MH]+.
(1 f?,5S/7S,5R)-1-(4-Bromophenyl)- NMR (1H, DMSO): 5 8.2 3-(3-{[5-(5-chloro-1 -methyl-1 H- (s, HCOOH), 8.0 (s,
78 pyrazol-4-yl)-4-methyl-4H-1 ,2,4- 6.94 1 H), 7.45 (d, 2H), 7.1 (d, triazol-3-yl]thio}propyl)-3- 2H), 3.9 (s, 3H), 3.55 (s, azabicyclo[3.1.0]hexane formate 3H), 3.3 (m, 1 H +
Figure imgf000111_0001
MS (m/z): 507, 509 [MH]+.
Figure imgf000111_0002
NMR (1H, DMSO): 5 8.2
(1R,5S/7S,5R)-1-(4-Bromophenyl)- (s, HCOOH), 7.8 (s, 3-(3-{[5-(1 ,5-dimethyl-1 H-pyrazol-4- 1 H), 7.45 (d, 2H), 7.1 (d, yl)-4-methyl-4H-1 ,2,4-triazol-3- 2H), 3.85 (s, 3H), 3.6 (s, yl]thio}propyl)-3- 3H), 3.3 (m, 1 H + azabicyclo[3.1.0]hexane formate DMSO), 3.2 (t, 2H), 3.0
Figure imgf000111_0003
[MH]+.
(1 F?,5S/fS,5R)-1-(4-Bromophenyl)- NMR (1H, DMSO): 5 9.4 3-(3-{[4-methyl-5-(5-pyrimidinyl)-4H- (d, 1 H), 9.2 (d, 2H), 8.2 1,2,4-triazol-3-yl]thio}propyl)-3- (s, HCOOH), 7.45 (d, azabicyclo[3.1.0]hexane formate 2H), 7.1 (d, 2H), 3.7 (s,
Figure imgf000111_0004
MS (m/z): 471 , 473 [MH]+.
Figure imgf000112_0001
[MH]+.
(1f?,5S/7S,5R)-1-(4-Bromophenyl)- NMR (1H, DMSO): 5 8.8 3-(3-{[4-methyl-5-(6-methyl-3- (d, 1 H)1 8.2 (S1
85 pyridinyl)-4H-1 ,2,4-triazol-3- 5.94 HCOOH), 8.0 (dd, 1 H), yl]thio}propyl)-3- 7.45 (d, 2H), 7.45 (d, azabicyclo[3.1.0]hexane formate 1H), 7.1 (d, 2H), 3.6 (s,
Figure imgf000113_0001
(m, 1 H), 0.75 (m, 1 H). MS (m/z): 484, 484 [MH]+.
Figure imgf000113_0002
NMR (1H, DMSO): δ
Figure imgf000113_0003
MS (m/z): 484, 486 [MH]+.
NMR (1H, DMSO): 5 8.2 (s, HCOOH), 7.45 (d,
(1F?,5S/7S,5R)-1-(4-Bromophenyl)- 2H), 7.1 (d, 2H), 3.7 (s, 3-[3-({4-methyl-5-[2-methyl-5- 3H), 3.3 (m, 1 H), 3.2 (t, (trifluoromethyl)-i ,3-oxazol-4-yl]-4H- 8.12 2H), 3.05 (m, 1 H), 2.65 1 ,2,4-triazol-3-yl}thio)propyl]-3- (t, 3H), 2.6 (t, 2H), 2.5 azabicyclo[3.1.OJhexane formate (m, 1 H), 2.4 (m, 1 H), 1.9 (m, 2H), 1.8 (m, 1 H),
Figure imgf000114_0001
NMR (1H, DMSO): 5 8.2
(1 R,5S/7S,5R)-1-(4-Bromophenyl)- (s, HCOOH), 7.45 (d,
3-(3-{[5-(2,4-dimethyl-1 ,3-thiazol-5- 2H), 7.1 (d, 2H), 3.5 (s, yl)-4-methyl-4H-1 ,2,4-triazol-3- 3H), 3.3 (m, 1 H + yl]thio}propyl)-3- water), 3.2 (t, 2H), 3.0 azabicyclo[3.1.0]hexane formate (m, 1H), 2.75 (s, 3H),
90
Figure imgf000114_0002
[MH]+.
91
Figure imgf000114_0003
[MH]+.
(1 R,5S/?S,5R)-1-(4-Bromophenyl)-
92
Figure imgf000115_0001
NMR (1H, DMSO): δ
93
Figure imgf000115_0002
MS (m/z): 484, 486 [MH]+.
(d,
94
Figure imgf000115_0003
5-[5-({3-[(1 R,5S/?S,5R)-1 -(4- NMR (1H, DMSO): Bromophenyl)-3- 10.6 (broad s, 1 H, HCI), azabicyclo[3.1.0]hex-3- 7.65 (s, 1 H), 7.5 (d, 2H),
95 n.d. yl]propyl}thio)-4-methyl-4H-1 ,2,4- 7.25 (d, 2H), 4.1 (s, 3H), triazol-3-yl]-1 -methyl-3- 4.0 (m, 1 H), 3.8 (s, 3H + (trifluoromethyl)-1 H-thieno[2,3- water), 3.7 (m, 1 H), 3.5 c]pyrazole hydrochloride (m, 2H), 3.25 (m, 4H),
Figure imgf000116_0001
Example 96: 3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-(1R,5R/fS,5S)-1-[5-(trifluoromethyl)-2-pyridinyl]-3- azabicyclo[3.1.OJhexane hydrochloride
Figure imgf000116_0002
The title compound was prepared in analogy to the method described in Example 1 as a white slightly hygroscopic solid (70 mg, 45%), from 1-[5-(trifluoromethyl)-2-pyridinyl]-3- azabicyclo[3.1.0]hexane.
NMR (corresponding free base, 1H, CD3OD): δ 8.71 (s, 1 H), 7.93 (s, 1 H), 7.78 (dd, 1 H), 7.15 (d, 1 H), 3.72 (s, 3H), 3.41 (d, 1 H), 3.36 (t, 2H), 3.13 (d, 1 H), 2.8 (d, 1 H), 2.68 (m, 2H), 2.54 (s, 3H), 2.48 (dd, 1H), 2.04 (m, 3H), 1.6 (m, 1 H), 1.26 (dd, 1 H). MS (m/z): 465 [MH]+.
Example 96 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chirapak AD-H 5 μm, 250 x 4.6 mm, eluent A: n-hexane; B: Ethanol + 0.1% isopropylamine, gradient isocratic 30% B v/v, flow rate 6 mL/min, detection UV at 270 nm. Retention times given were obtained using a chiral column Chirapak AD-H 5 μm, 250 x 4.6 mm, eluent A: n-hexane; B: Ethanol, gradient isocratic 30% B v/v, flow rate 0.8 mL/min, detection UV at 200 - 400 nm.
Enantiomer 1 was recovered in 18 mg yield as a white solid, hydrochloride salt from the racemate (70 mg). Rt. = 19.09 min. Purity 100% a/a by UV.
Enantiomer 2 was recovered in 18 mg yield as white solid, hydrochloride salt from the racemate (70 mg). Rt. = 21.6 min. Purity 99% a/a by UV.
Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
Example 97: 3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio}propyl)-(1R,5/?/YS,5S)-1-[6-(trifluoromethyl)-2-pyridinyl]-3- azabicyclo[3.1.0]hexane dihydrochloride
Figure imgf000117_0001
3-(Phenylmethyl)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-azabicyclo[3.1.0]hexane (0.19 mmol) was dissolved in 1 ,2-dichloroethane (1 imL) and 1 -chloroethyl chloridocarbonate was added (0.21 mmol). After two microwave cycles (5 min at 120 0C and 10 min at 140 0C) the solvent was removed at reduced pressure. Methanol (2 mL) was added and the solution was submitted to an additional microwave cycle (10 min, 120 0C). The solvent was removed at reduced pressure to give 47 mg of intermediate which was used without further purification and treated in analogy to the method described in Example 1 to give the title compound (5 mg, 5%) as a white slightly hygroscopic solid.
NMR (1H, CD3OD): δ 8.38 (s, 1 H), 7.99 (dd, 1 H), 7.67 (dd, 1H), 7.48 (dd, 1 H), 4.18 (d, 1 H), 4.06 (d, 1 H), 3.88 (d, 1 H), 3.79 (s, 3H), 3.63 (dd, 1 H), 3.50 (m, 2H), 3.41 (t, 2H), 2.49 (m, 1 H), 2.44 (s, 3H), 2.31 (m, 2H), 1.69 (m, 1 H), 1.65 (dd, 1 H). MS (mlz): 465 [MH]+.
Example 98: (1 R,5S/1S,5R)^ -[3-Fluoro-4-(1 H-pyrrol-1 -ylmethyl)phenyl]-3-(3-{[4. methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3- azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000117_0002
The title compound was prepared in analogy to the method described in Example 1 as a white slightly hygroscopic solid (5.4 mg, yield = 19%), from 1-[3-fluoro-4-(1 H-pyrrol-1 - ylmethyl)phenyl]-3-azabicyclo[3.1.0]hexane (Preparation 57).
NMR (as formate salt) (1H, CDCI3): δ 7,9 (s, 1H), 6.8 (m, 4H), 6.65 (s, 2H), 6.15 (s, 2H), 5.05 (s, 2H), 3.66 (s, 3H), 3.4 (d, 1 H), 3.25 (t, 2H), 3.2 (d, 1 H), 2,75 (t, 2H), 2.6 (d, 1 H), 2.55 (m, 1 H), 2.5 (s, 3H), 2.0 (m, 2H), 1.7 (m, 1 H), 1.45 (t, 1 H), 0.8 (m, 1 H); acidic proton not observed. MS (hydrochloride salt) {mlz): 475 [MH]+.
Examples 99-104:
Examples 99-104 were prepared as white slightly hygroscopic solids from (1 R,5S/1 S,5R)- 3-(3-chloropropyl)-1-[6-(trifluoromethyl)-3-pyridinyl]-3-azabicyclo[3.1.0]hexane (40 mg) in analogy to the method described for Examples 53-58. R
EX Name and Structure Analytical data
(min)
(1S,5R/1 R,5S)-3-(3-{[4- Methyl-5-(5-methyl-2- pyrazinyi)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1 - [6-(trifluoromethyl)-3- pyridinyl]-3- azabicyclo[3.1.OJhexane
99 hydrochloride 5.82 MS (m/z): 477 [MH]+
Figure imgf000118_0001
(1S,5R/1 R,5S)-3-(3-{[4-
100
Figure imgf000118_0002
(1 S,5R/1 R,5S)-3-(3-{[4- Methyl-5-(2-methyl-3- pyridinyl)-4H-1 ,2,4-triazol- 3-yl]thio}propyl)-1-[6-
101 4.82 MS (m/z): 476 [MH]+ (trifluoromethyl)-3- pyridinyl]-3- azabicyclo[3.1.OJhexane hydrochloride
Figure imgf000119_0001
(1 S,5R/1 R,5S)-3-{3-[(4- Methyl-5-phenyl-4H- 1 ,2,4-triazol-3- yl)thio]propyl}-1-[6- (trifluoromethyl)-3- pyridinyl]-3- azabicyclo[3.1.0]hexane 6.27 MS (m/z): 461 [MH]+ hydrochloride
Figure imgf000119_0002
(1S,5R/1 R,5S)-3-(3-{[5- (2,4-Dimethyl-1 ,3-thiazol- 5-yl)-4-methyl-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1 - [6-(trifluoromethyl)-3- pyridinyl]-3- 1 hZyTdroCc1hC!loΦri,de 1 °]heXane 5.40 MS (m/z): 496 [MH]+
Figure imgf000119_0003
(1S,5R/1R,5S)-3-[3-({4- Methyl-5-[4- (trifluoromethyl)phenyl]- 4H-1 ,2,4-triazol-3- yl}thio)propyl]-1-[6- 7.36 MS (m/z): 528[MH]+.
(trifluoromethyl)-3- pyridinyl]-3- azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000120_0001
Examples 105-109:
Examples 105-109 were prepared as white slightly hygroscopic solids from 5- [(1 R.5S/1 S,5R)-3-(3-chloropropyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-methyl-1 ,3-benzothiazole (40 mg) in analogy to the method described in Example 53-58.
R
EX Name Analytical data
(min)
(1S,5R/1 R,5S)-2-Methyl- 5-[3-(3-{[4-methyl-5-(5- methyl-2-pyrazinyl)-4H- 1 ,2,4-triazol-3- yl]thio}propyl)-3- azabicyclo[3.1.0]hex-1- yl]-1 ,3-benzothiazole hydrochloride
105 5.83 MS (m/z): 478 [MH]+
Figure imgf000120_0002
(1 S,5R/1 R,5S)-2-Methyl- 5-[3-(3-{[4-methyl-5-(6- methyl-3-pyrid i nyl )-4H- 1 ,2,4-triazol-3-
106 5.04 MS (m/z): 477 [MH]+ yl]thio}propyl)-3- azabicyclo[3.1.0]hex-1 - yl]-1 ,3-benzothiazole hydrochloride
Figure imgf000121_0001
,5R/1 5-(3-{3-[(4-methyl-5- phenyl-4H-1 ,2,4-triazol-3- yl)thio]propyl}-3- azabicyclo[3.1.0]hex-1 - yl)-1 ,3-benzothiazole hydrochloride 6.28 MS (m/z): 462 [MH]4
Figure imgf000121_0002
(1 S,5R/1 R,5S)-5-[3-(3- {[5-(2,4-Dimethyl-1 ,3- thiazol-5-yl)-4-methyl-4H- 1 ,2,4-triazol-3- yl]thio}propyl)-3- azabicyclo[3.1.0]hex-1 - yl]-2-methyl-1 ,3- benzothiazole 5.35 MS (m/z): 497 [MH]+ hydrochloride
Figure imgf000121_0003
(1S,5R/1 R,5S)-2-Methyl- NMR (1H1 DMSO): 5 7.98-8.03
5-{3-[3-({4-methyl-5-[4- (m, 4H), 7.97 (d, 1H), 7.89 (s,
(trifluoromethyl)phenyl]- 1 H), 7.45 (d, 1 H), 4.2 (d, 1 H),
4H-1 ,2,4-triazol-3- 3.91 (d, 1 H), 3.78 (s, 3H), 3.73 yl}thio)propyl]-3- ' (d, 2H), 3.49 (m, 4H), 2.88 (s, azabicyclo[3.1.0]hex-1- 3H), 2.36 (m, 3H), 1.6 (t, 1 H), yl}-1 ,3-benzothiazole 1.37 (t, 1 H). MS (m/z): 530 hydrochloride [MH]+.
Figure imgf000122_0001
Example 110: (1 R.5S/1 S,5R)-1 -[3-Fluoro-5-(trif luoromethyl)phenyl]-3-(3-{[4-methyl-5- (4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000122_0002
The title compound was prepared in analogy to the method described in Example 1 in 383 mg yield as a white slightly hygroscopic solid (y=46%) from (1 R,5S/1 S,5f?)-1-[3-fluoro-5- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (400 mg).
NMR (1H,CD3OD): δ 8.46 (S1I H)1 7.54 (bs, 1 H), 7.47 (bd, 1 H), 7.41 (bd, 1H), 4.19 (d, 1H), 3.09 (d, 1 H), 3.87 (s, 3H), 3.71 (m, 2H), 3.51 (t, 2H), 3.46 (t, 2H)1 2.49 (s, 3H), 2.33 (m, 3H), 1.67 (m, 1H), 1.39 (m, 1 H). MS (m/z): 482 [MH]+.
(1 R.5S/1 S,5R)-1 -[3-Fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-thazol-3-yl]thio}propyl)-azabicyclo[3.1.OJhexane hydrochloride was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel AD-H, 25 x 2.1 cm, eluent CO2 containing 9% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0C, detection UV at 220 nm, loop 2 ml_. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 10% (ethanol + 0.1% isopropyilamine), flow rate 2.5 mUmin, P 180 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 19.4 mg yield as white solid, hydrochloride salt from the racemate (100 mg). Rt. = 12.6 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 18.3 mg yield as white solid, hydrochloride salt from the racemate (100 mg). Rt. = 14.7 min. Purity >99% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2. Example 110: (1 R.5S/1 S,5R)-1 -[3-Fluoro-5-(trif luoromethyl)phenyl]-3-(3-{[4-methyl-5- (4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.OJhexane hydrochloride
Figure imgf000123_0001
The title compound was prepared in analogy to the method described in Example 1 in 383 mg yield as a white slightly hygroscopic solid (y=46%) from (1 f?,5S/1 S,5R)-1-[3-fluoro-5- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (400 mg).
NMR (1H,CD3OD): δ 8.46 (s,1 H), 7.54 (bs, 1 H), 7.47 (bd, 1 H), 7.41 (bd, 1H), 4.19 (d, 1 H), 3.09 (d, 1 H), 3.87 (s, 3H), 3.71 (m, 2H), 3.51 (t, 2H), 3.46 (t, 2H), 2.49 (s, 3H), 2.33 (m, 3H), 1.67 (m, 1H), 1.39 (m, 1 H). MS (m/z): 481 [MH]+.
(1 R,5SA S,5R)-1 -[3-Fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4/-/-1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.0]hexane hydrochloride was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel AD-H, 25 x 2.1 cm, eluent CO2 containing 9% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0C, detection UV at 220 nm, loop 2 mL. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO2 containing 10% (ethanol + 0.1% isopropyilamine), flow rate 2.5 mL/min, P 180 bar, T 35 0C, detection UV at 220 nm.
Enantiomer 1 was recovered in 19.4 mg yield as white solid, hydrochloride salt from the racemate (100 mg). Rt. = 12.6 min. Purity >99% a/a by UV.
Enantiomer 2 was recovered in 18.3 mg yield as white solid, hydrochloride salt from the racemate (100 mg). Rt. = 14.7 min. Purity >99% a/a by UV.
Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
Example 111 : (1 R.5S/1 S,5/?)-1 -[2-Fluoro-3-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5- (4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000124_0001
The title compound was prepared in analogy to the method described in Example 1 in 349 mg yield as a white slightly hygroscopic solid (y=45%) from (1 R,5S/1 S,5f?)-1-[2-fluoro-3- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (400 mg).
NMR (1H1CDSOD): δ 8.46 (s,1 H), 7.75-7.65 (m, 2H), 7.38 (t, 1 H), 4.1 (d, 1 H), 3.93 (d, 1H), 3.78 (s, 3H), 3.71 (d, 1 H), 3.54 (d, 1 H), 3.48 (t, 2H), 3.38 (t, 2H), 2.45 (s, 3H), 2.36 (m, 1 H), 2.25 (m, 2H), 1.54 (m, 1 H), 1.34 (m, 1 H). MS (m/z): 481 [MH]+.
(1 R.5S/1 S,5R)-1 -[2-Fluoro-3-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.0]hexane hydrochloride was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 250 x 4.6 mm, eluent n- Hexane/ Ethanol 88/12 (isocratic), flow rate 1 ml_/min, P 200-400 bar, T 36 0C, detection UV at 200-400 nm, loop 2 ml_. Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 250 x 4.6 mm, eluent n-Hexane/ Ethanol 88/12 (isocratic), flow rate 1 mL/min, P 200-400 bar, T 36 0C, detection UV at 200-400 nm.
Enantiomer 1 was recovered in 37 mg yield as white solid, hydrochloride salt from the racemate (98 mg). Rt. = 20.4 min. Purity 98.5% a/a by UV.
Enantiomer 2 was recovered in 35 mg yield as white solid, hydrochloride salt from the racemate (98 mg). Rt. = 23.0 min. Purity 99.5% a/a by UV.
Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
Example 112: (1K.5S/1 S,5R)-1-[4-(Methyloxy)-5-(trifluoromethyl)phenyl]-3-(3-{[4- methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)- azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000124_0002
H-Cl The title compound was prepared in analogy to the method described in Example 1 in 658 mg yield as a white slightly hygroscopic solid (y=76%) from (1 f?,5S/1 S,5f?)-1-[4- (methyloxy)-5-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (430 mg).
NMR (1H,CD3OD): δ 8.37 (s,1 H), 7.57 (m, 2H), 7.17 (d, 1 H) 3.9 (m, 4H), 3.77 (s, 3H), 3.74 (m, 1 H), 3.65-3.30 (m, 6H), 2.44 (s, 3H), 2.21 (m, 2H), 2.13 (m, 1 H), 1.43 (t, 1 H), 1.24 (m, 1 H). MS (m/z): 494 [MH]+.
(1 R.5S/1 S,5R)-1-[4-(Methyloxy)-5-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo[3.1.0]hexane hydrochloride was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 250 x 4.6 mm, eluent n- Hexane/ Ethanol + 0.1% isopropylamine 70/30 (isocratic), flow rate 6 mL/min, detection UV at 270 nm, loop 2 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 250 x 4.6 mm, eluent n-Hexane/ Ethanol 70/30 (isocratic), flow rate 0.8 mL/min, detection UV at 200-400 nm.
Enantiomer 1 was recovered in 18.3 mg yield as white solid, hydrochloride salt from the racemate (100 mg). Rt. = 15.5 min. Purity > 99% a/a by UV.
Enantiomer 2 was recovered in 22.2 mg yield as white solid, hydrochloride salt from the racemate (100 mg). Rt. = 17.5 min. Purity > 99% a/a by UV.
Enantiomer 2 showed fpKi (D3) > 2 log-units higher than Enantiomer 1.
Example 113: (1 /?,5S/1 S,5f?)-1 -[4-(4-Chloro-2-fluorophenyl]-3-(3-{[4-methyl-5-(4- methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-azabicyclo [3.1.0]hexane hydrochloride
Figure imgf000125_0001
The title compound was prepared in analogy to the method described in Example 1 in 112 mg yield as a white slightly hygroscopic solid from (1f?,5S/1S,5f?)-1-[4-chloro-2- fluorophenyl]-3-azabicyclo[3.1.0]hexane (130 mg).
NMR (1H,CD3OD): δ 8.27 (s, 1 H), 7.3 (t, 1 H), 7.1 (m, 2H), 3.95 (d, 1 H), 3.8 (d, 1 H), 3.67 (s, 3H), 3.56 (dd, 1 H), 3.4-3.2 (m, 5H), 2.34 (s, 3H), 2.15 (m, 3H), 1.4 (t, 1 H), 1.18 (t, 1 H). MS (m/z): 448 [MH]+. Example 114: (1 /?,5S/1 S,5K)-1 -[3-(2-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-{3-[(trifluoromethyl)oxy]phenyl}-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000126_0001
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 160 mg yield as a white slightly hygroscopic solid from 1-{3-[(trifluoromethyl)oxy]phenyl}-3- azabicyclo[3.1.0]hexane (150 mg).
NMR (1H,CD3OD): δ 8.41 (s, 1 H), 7.49 (t, 1 H), 7.3 (s, 1 H), 7.37 (d, 1 H), 7.24 (m,1 H), 4.17 (d,1 H), 3.9 (d, 1 H), 3.8 (s, 3H), 3.69 (d, 2H), 3.51 (t, 2H), 3.42 (t, 2H), 2.47 (s, 3H), 2.3 (m, 3H), 1.57 (dd, 1 H), 1.36 (t, 1 H). MS (mlz): 480 [MH]+.
Example 115: (1 R.5S/1 S,5R)-1 -(2-fluoro-4-methylphenyl)-3-(3-{[4-methyl-5-(4-methyl- 1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000126_0002
H-Cl
The title compound was prepared in analogy to the method described in Example 1 in 60 mg yield as a white slightly hygroscopic solid from 1 -(2-fluoro-4-methylphenyl)-3- azabicyclo[3.1.0]hexane (148mg).
NMR (1H,CD3OD): δ 8.39 (s, 1 H), 7.26 (t, 1 H), 7.01 (m, 2H), 3.93 (m,1 H), 3.77 (m, 4H), 3.61 (m, 1 H), 3.41-3.38 (m, 5H), 2.47 (s, 3H), 2.36 (s, 3H), 2.23 (m, 2H), 2.19 (m, 1 H), 1.45 (t, 1 H), 1.21 (t, 1 H). MS {mlz): 428 [MH]+.
Example 116: (1/?,5S/1S,5R)- 1-[3-Chloro-4-(methyloxy)phenyl]-3-(2-{[4-methyl-5-(4- methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000126_0003
H-Cl The title compound was prepared in analogy to the method described in Example 1 in 56 mg yield as a white slightly hygroscopic solid from 1-[3-chloro-4-(methyloxy)phenyl]-3- azabicyclo[3.1.0]hexane (60mg).
NMR (1H,CD3OD): δ 8.4 (s,1 H), 7.35 (m, 1 H), 7.1 (m, 2H), 4.01 (m,1 H), 3.89 (m,4H), 3.8 (s, 3H), 3.6-3.3 (m, 6H), 2.47 (s, 3H), 2.23 (m, 2H), 2.19 (m, 1 H), 1.4 (m, 1 H), 1.2 (m, 1 H). MS {m/z): 460 [MH]+.
Example 117: (1 R.5S/1 S,5R)-1 -[4-(2,4-Dimethyl-1 ,3-thiazol-5-yl)phenyl]-3-(3-{[4- methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3- azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000127_0001
A mixture of (1 R,5S/1 S,5R)-1-[4-(2,4-dimethyl-1 ,3-thiazol-5-yl)phenyl]-3-aza- bicyclo[3.1.0]hexane (70 mg), 3-[(3-chloropropyl)thio]-4-methyl-5-(4-methyl-1 ,3-oxazol-5- yl)-4/-/-1 ,2,4-triazole (85 mg), potassium carbonate (43 mg), Na2CO3 and sodium iodide (45 mg) in anhydrous DMF (0.6 ml.) was heated at 60 0C for 24 h. After elimination of the solvent in vacuo the residue was dissolved in ethyl acetate and the organic phase was washed with saturated aqueous sodium bicarbonate, dried over sodium sulphate and concentrated in vacuo. The crude was purified by flash chromatography (dichloromethane to 10% MeOH in dichloromethane) to give 65 mg of the free base of the title compound. To a solution of this material in dichloromethane (1 mL) was added HCI (1 M in Et2O, 0.13 mL), the solvent evaporated under vacuo and the material thus obtained triturated with Et2O to give 69 mg of the title compound as a white solid (50% yield).
NMR (1H, DMSO): δ 10.39 (bs, 1 H), 8.56 (s, 1 H), 7.39 (d, 2H), 7.35 (d, 2H), 4.02 (m, 1 H), 3.72 (m, 1 H), 3.68 (s, 3H), 3.60 (t, 1 H), 3.51 (bm, 1 H), 3.27 (m, 4H), 2.60 (s, 3H), 2.37 (s, 3H), 2.35 (s, 3H), 2.19 (m, 1 H), 2.16 (m, 2H), 1.62 (m, 1 H), 1.15 (m, 1 H); MS (m/z): 507.2 [MH]+.
Example 118: (1 R.5S/1 S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-{4-[6-(trifluoromethyl)-2-pyridinyl]phenyl}-3- azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000127_0002
The title compound was prepared in analogy to the method described in Example 117 (using (I RSS/I S.S^-i^-tθ-CtrifluoromethyO^-pyridinyllphenylJ-S-azabicyclo^.i .O]- hexane) in 55% yield as a white solid.
NMR (1H, CDCI3): δ 10.44 (bs, 1 H), 8.56 (s, 1 H), 8.29 (d, 1 H), 8.17 (t, 1 H), 8.09 (d, 2H), 7.84 (d, 1 H), 7.43 (d, 2H), 4.08 (m, 1 H), 3.75 (m, 1 H), 3.68 (s, 3H), 3.64 (t, 1 H)1 3.53 (bm, 1 H), 3.28 (m, 4H), 2.37 (s, 3H), 2.27 (m, 1 H), 2.17 (m, 2H), 1.68 (m, 1 H), 1.17 (m, 1 H); MS (mlz): 541.2 [MH]+.
Example 119. (1 /?,5S/1S,5/?)-1 -[3-(2,4-Dimethyl-1, 3-thiazol-5-yl)phenyl]-3-(3-{[4- methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3- azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000128_0001
The title compound was prepared in analogy to the method described in Example 117 (using (1R,5S/1 S,5R)-1-[3-(2,4-dimethyl-1 ,3-thiazol-5-yl)phenyl]-3-azabicyclo[3.1.0]- hexane) in 53% yield as a white solid.
NMR (1H, CDCI3): δ 10.53 (b, 1 H), 8.58 (s, 1 H), 7.43 (d, 1 H), 7.28-7.38 (m, 3H), 4.07 (dd, 1 H), 3.73 (dd, 1 H), 3.70 (s, 3H), 3.61 (t, 1 H), 3.53 (m, 1 H), 3.34 (m, 2H), 3.29 (t, 2H), 2.64 (s, 3H), 2.39 (s, 3H), 2.73 (s, 3H)1 2.23 (m, 1H), 2.20 (m, 2H), 1.68 (t, 1H), 1.16 (t, 1 H); MS (mlz): 507.1 [MH]+.
Example 120: (1 R.5S/1 S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-[3-(5-methyl-2-thienyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
Figure imgf000128_0002
The title compound was prepared in analogy to the method described in Example 117 (using (1 f?,5S/1 S,5R)-1-[3-(5-methyl-2-thienyl)phenyl]-3-azabicyclo[3.1.0]hexane) in 51% yield as a white solid.
NMR (1H, CDCI3): δ 10.44 (b, 1 H), 8.58 (s, 1 H), 7.49 (d, 1 H), 7.45 (dt, 1 H), 7.37 (t, 2H), 7.18 (dt, 1H), 6.84 (t, 1H), 4.08 (dd, 1H), 3.76 (dd, 1H), 3.70 (s, 3H), 3.62 (t, 1H), 3.54 (tm, 1 H)1 3.28 (t, 4H), 2.48 (s, 3H), 2.39 (S1 3H), 2.24 (m, 1H), 2.19 (t, 2H), 1.65 (t, 1H), 1.16 (t, 1 H); MS (m/z): 472.0 [MH]+.
Example 121 : (1A?,5S/1S,5R)-1-[4-(3,5-Dirnethyl-4-isoxazolyl)phenyl]-3-(3-{[4-methyl- 5-(4-methyM ,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3- azabicyclo[3.1.0]hexane
Figure imgf000129_0001
The title compound was prepared in analogy to the method described in Example 117 (using (1 R.5S/1 S,5F?)-1 -[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-3-azabicyclo[3.1.0]hexane), in 55% yield as a white solid.
MS (m/z): 491.2 [MH]+.
Example 122: (1S,5R)-3-(3-{[5-(2,4-Dimethyl-1,3-oxazol-5-yl)-4-methyl-4H-1, 2,4- triazol-3-yl]thio}propyl)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]- hexane hydrochloride
Figure imgf000129_0002
A mixture of (1 S,5R)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane (Preparation 18, 60 mg), 3-[(3-chloropropyl)thio]-5-(2,4-dimethyl-1 ,3-oxazol-5-yl)-4-methyl-4H-1 ,2,4- triazole (Preparation 78, 78 mg), 2-terf-butylimino-2-diethylamino-1 ,3-dimethyl-perhydro- 1 ,3,2-diaza-phosphorine on polystyrene (2.2 mmol/g, 140 mg) and a catalytic amount of NaI in acetonitrile dry (3 ml) was heated at 70 0C for 4 h, then overnight at 55 0C. The resin was removed by filtration and washed with acetonitrile (2 x 3 ml). The solvent was removed under vacuum, the remaining solid dissolved in DMF dry (0.5 ml), 3-[(3- chloropropyl)thio]-5-(2,4-dimethyl-1 ,3-oxazol-5-yl)-4-methyl-4H-1 ,2,4-triazole (Preparation 78, 60 mg) was added followed by potassium carbonate (118 mg). The resulting suspension was heated at 60 0C overnight. At room temperature a saturated solution of sodium bicarbonate was added (4 ml) and the suspension was extracted with DCM (2 x 6 ml). The resulting solution was charged onto a SCX column and eluted with MeOH followed by MeOH/NH3 0.25 M. The resulting material was purified by preparative HPLC and then converted to the hydrochloride salt following the method described for Example 15 to give the title compound as a white slightly hygroscopic solid (37 mg, 27% yield). NMR (1H, DMSO): δ 10.38 (b,1 H), 7.71 (d, 1 H), 7.64 (t, 1 H), 7.59 (d, 1 H), 3.98 (bd, 1 H), 3.76 (bd, 1 H), 3.65 (s, 3H), 3.54 (b, 1 H), 3.44 (bt, 1 H), 3.31 (b, 2H), 3.24 (t, 2H), 2.47 (s, 3H), 2.35 (m, 1 H), 2.29 (s, 3H), 2.1 1 (m, 2H), 1.63 (t, 1 H), 1.13 (t, 1 H). MS {m/z): 496 [MH]+.
Example 123: (1S,5R)-3-(3-{[5-(2,4-Dimethyl-1,3-oxazol-5-yl)-4-methyl-4H-1 ,2,4- triazol-3-yl]thio}propyl)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]- hexane hydrochloride
Figure imgf000130_0001
HPLC Methods
HPLC Assav (short run):
Column type Phenomenex LUNA
Column length [cm] 5
Internal diameter [cm] 0.2
Particle size [urn] 3.0
Mobile phase A: 0.05%v/v TFA in water / B: 0.05%v/v TFA in acetonitrile
Step 1 : Time-Reserv.A-Reserv.B Time Omin 100%A
Step 2: Time-Reserv.A-Reserv.B Time 8min 5%A
Step 3: Time-Reserv.A-Reserv.B Time 8.01min 100%A
Flow rate [imL/min] 1
Column temperature [ΛC] 40
Autosampler temperature [ΛC] AMB
Detector type UV
Wavelength [nm] 220
Injection volume [uL] 1
Run Time 8 min.
HPLC chiral 1
Column type Chiracel OD-H Column length [cm] 25 Internal diameter [cm] 4.6 Particle size [urn] 5 Mobile phase Heptane/IPA 85/15% v/v Flow rate [imL/min] 1 Column temperature [ΛC] 30
Autosampler temperature [ΛC] AMB
Detector type UV
Wavelength [nm] 220
Injection volume [uL] 10 Dilution Factor 5
HPLC Assay (long run):
Column type LUNA 3u phenyl - hexyl Column length [cm] 15 Internal diameter [cm] 0.46 Particle size [urn] 3.0 Mobile phase A: 0.05%v/v TFA in water / B: 0.05%v/v TFA in acetonitrile
Step 1 : Time-Reserv.A-Reserv.B Time 0 min 95%A - 5%B
Step 2: Time-Reserv.A-Reserv.B Time 30 min 5%A - 95%B Step 3: Time-Reserv.A-Reserv.B Time 30.01 min 95%A - 5%B
Flow rate [mL/min] 1
Column temperature [ΛC] 40
Autosampler temperature [ΛC] AMB
Detector type UV
Wavelength [nm] 220
Injection volume [uL] 10
Run Time 30 min.
HPLC chiral 2
Column type CHIRALPAK AD
Column length [cm] 25
Internal diameter [cm] 4.6 Particle size [urn] 10
Mobile phase Heptane/I PA 85/15% v/v
Flow rate [mL/min] 0.8
Column temperature [ΛC] 25
Autosampler temperature [ΛC] AMB
Detector type UV Wavelength [nm] 270
Injection volume [uL] 10
Dilution Factor 10 Preparation 123(1): 3-[(3-Chloropropyl)thio]-4-methyl-5-(4-methyl-1,3-oxazol-5-yl)- 4H-1,2,4-triazole
Scheme A
Figure imgf000132_0001
1
Preparation 123(1A): 4-methyl-1 ,3-oxazole-5-carboxylic acid
Figure imgf000132_0002
Ethyl^-chloroacetoacetate (28.6 g, 24.0 ml.) was dissolved in DMF (28.6 ml_) and formamide (19.5 mL) was added. The resulting solution was heated up to 120 0C (internal temperature) under nitrogen for 21 h. The mixture was allowed to cool down to 200C, diluted with ter-butyl methyl ether (172 mL) and washed with water (115 mL). The aqueous phase was extracted again with 115 mL of fert-butyl methyl ether and the combined organic layers were washed twice with water (86 mL) and treated with NaOH 3 N (86 mL). The resulting mixture was stirred at 200C for 3 hours. The organic layer was discarded while the aqueous was acidified with 20 mL of concentrated HCI (37% sol.) till pH 2 over 10 minutes. A precipitate started to crush out of solution. The suspension was stirred at 200C for 2 h, filtered and the cake washed with 14.3 mL of cold water (1O0C ca.). The collected solid was dried under high vacuum at 400C for 16 hours. The title compound was obtained in a theoretical yield of 35.3 % (7.81 g). NMR (1 H, DMSO-d6, δ ppm): 13.5 (bs, 1 H), 8.47 (s, 1 H), 2.38 (s, 3H) MS (m/z): 128[MH]+
Preparation 123(1 B): 4-methyl-5-(4-methyl-1.3-oxazol-5-vn-2.4-dihvdro-3/-/-1 ,2,4-triazole- 3-thione
Figure imgf000132_0003
4-Methyl-1.S-oxazole-δ-carboxylic acid (prepared according to the method of Preparation 1A, 12.9 g) was dissolved in DMF (60 mL) and treated with 4-methyl-3-thiosemicarbazide (11.61 g). Then disopropylethylamine (DIPEA) (31.OmL) was added at 2O0C. Under ice bath cooling, T3P 50% w/w in ethyl acetate (90 mL) was added drop wise, maintaining the temperature below 150C over 20 minutes. The resulting mixture was then stirred at 2O0C for 6 hours. The mixture was diluted with NaOH 4 M (120.0 ml_). The resulting bi-phasic mixture was allowed separating and the upper organic layer discarded. The aqueous layer (pH = 8) was adjusted to pH = 11 with additional NaOH 4 M (60 ml.) and then heated to 7O0C (internal temperature) for 30 minutes. After cooling down over night, HCI 37% was slowly added until pH=5 was reached. The suspension was stirred for 8 hours, then the solid was filtered and washed with water (60 ml_), and it was dried in a vacuum oven at 4O0C overnight. The title compound was obtained in a 53% theoretical yield (10.48 g).
NMR (I H, DMSO-d6, δ ppm): 14.1 1 (bs, 1 H), 8.60 (s, 1H), 3.61 (s, 3H), 2.33 (s, 3H) MS (m/z): 197[MH]+
3-r(3-chloropropynthiol-4-methyl-5-(4-methyl-1.3-oxazol-5-yl)-4H-1.2,4-triazole
Figure imgf000133_0001
4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-2,4-dihydro-3/-/-1 ,2,4-triazole-3-thione (prepared according to the method of Preparation 2A, 380 g) was added to a mixture of methanol (1140 mL) and acetone (2660 ml_), followed by K2CO3 (380 g) and 1-bromo-3- chloropropane (251 mL). The suspension was stirred at 20±2°C for 4h. The volume of solvent was reduced then ethyl acetate (4800 mL) was added and the organic layer was washed with water twice (2400 mL each). The organic layer was distilled to about 330OmL, diluted with ethyl acetate (3800 mL) and distilled again to the same level as before. Some precipitate was already observed when cooling the mixture that was stirred for 30 minutes. Heptane (3800 mL) was added slowly over a period of 30 minutes upon which more product crashed out as a fine, heavy solid. The suspension was stirred for four additional hours at 20±2°C. The solid was collected by filtration and washed with 114OmL of a ethyl acetate/ heptane (1 :2) mixture. The solid was dried in the oven at 400C under reduced pressure overnight to give 3-[(3-Chloropropyl)thio]-4-methyl-5-(4-methyl- 1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazole in a 59.3 theoretical yield (314 g).
NMR (1 H, DMSO-d6, δ ppm): 8.55 (s, 1H), 3.76 (t, 2H), 3.68 (s, 3H), 3.26 (t, 2H)1 2.37 (s, 3H), 2.14 (m, 2H) MS {mlz): 273[MH]+
Preparation 123(2): 3-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-pyrrole-2,5-dione
Figure imgf000133_0002
Maleimide (48.6 g) was suspended in acetonitrile (300 mL,) under N2 and tert-butyl nitrite (38 mL) followed by copper (II) chloride (45 g) were added. The resulting suspension was cooled down to 00C and neat 4-amino-2-fluorotrifluorobenzene (5Og, 35.2 mL) was added drop wise in 45min ca. The internal temperature was kept below 10°C during the aniline addition and gas developing was observed. The reaction mixture was allowed to stir at 00C for 1 h and then overnight at 200C. Then 10% HCI (300 mL,) was added. The biphasic mixture obtained was extracted with AcOEt (300 mL). The organic layer was washed with water (30OmL, 6vol) and then with 10% NaCI (300 mL). After solvent evaporation to dryness the residue was dissolved in IPA (200 mL) and re-distilled down to dryness. Then IPA (100 mL, 2 vol) and 2,6-Lutidine (17.5 mL) were added and the suspension refluxed for 20 min to obtain a clear dark solution. After cooling down to 200C the suspension was stirred overnight and then the solid filtered by washing upon the filter with water (200 mL). After drying at 500C under vacuum the product was obtained as beige solid in a 30.6% theoretical yield (22.13 g).
1 H NMR (DMSO-d6) ppm: 11.29 (br.s., 1 H); 8.21 (t, 1 H); 7.90 (d, 1 H); 7.75 (d, 1 H); 7.15 (s, 1 H)
Preparation 123(3): 1 (1 /?,5S/1 S,5R)-[2-Fluoro-4-(trifluoromethyl)phenyl]-3aza- bicyclo[3.1.0]hexane-2,4-dione
Figure imgf000134_0001
3A
Preparation 123(3A): 1 (1 R.5S/1 S,5/?)-[2-Fluoro-4-(trifluoromethyl)phenyl]-3 azabicyclo[3.1.0]hexane-2,4-dione
Potassium hydroxide (258.1 g) was added to a stirred suspension of trimethylsulfoxonium iodide (1013 g) in dimethylsulfoxide (4470 mL) under N2. The resulting mixture was allowed to stir at room temperature for 1 hr (or until a clear solution is observed). 3-[2-fluoro-4-(trifluoromethyl)phenyl]-1 H-pyrrole-2,5-dione (prepared according to the method of Preparation 2, 596.0 g) dissolved in dimethylsulfoxide (1490 mL) was then added drop wise in 30 minutes keeping the internal temperature below 250C and the resulting mixture was allowed to stir at room temperature for 2 h. The mixture was then diluted with tert-butyl methyl ether (6000 ml_) and HCI 2N (4800 ml.) was slowly added at room temperature. After separation of the two phases, the aqueous layer was extracted again with tert-butyl methyl ether (3000 ml_) and the collected organic layers washed twice with water (3000 mL) and then with NaC1 10% (3000 ml_). The organic layer was concentrated to 1800 mL then 4800 mL of tetrahydrofuran were added and the solution concentrated again to 1800 mL. The resulting tetrahydrofuran solution of 1 (1 R.5S/1 S.SRVP-Fluoro^-ttrifluoromethyOphenyll-S-azabicycloβ.1.0]hexane- 2,4-dione was used as such in the following step.
(IS.SRJ-i-^-Fluoro-^trifluoromethylJphenyπ-S-azabicycloIS.I .Olhexane salt of hydrochloric acid
NaBH4 (351 g) was charged under N2 followed by tetrahydrofuran (3600 mL) then the solution of 1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane in tetrahydrofuran prepared in the previous step was added dropwise in 1 h and the resulting suspension allowed to stir at room temperature for 1 hr. BF3-THF complex (1440 mL) was then added dropwise in 1 h and 30 min keeping the internal temperature around 250C and the resulting suspension was stirred at 250C for 24 hrs.
The mixture was cooled down to 00C and methanol (2400 mL) was cautiously added in 2.5 h monitoring gas evolution. The suspension was then heated to reflux for 30 min and distilled down to 2400 mL at atmospheric pressure. The resulting suspension was diluted with tert-butyl methyl ether (6000 mL) and HCI 2 N (3600 mL) and the mixture was then stirred at room temperature for 1 hr. The aqueous phase was discharged and the organic phase was washed twice with NaOH 2 N (2400 mL) and then with NaCI 10 % solution (3000 mL).
The organic phase was distilled down to 1800 mL then diluted with 3000 mL of tert-butyl methyl ether and again distilled down to 1800 mL. 3000 mL of tert-butyl methyl ether were added followed by 780 mL of HCI 5-6 N in isopropanol and the precipitation was immediately observed.
The suspension Was aged overnight and then the solid filtered off washing with tert-butyl methyl ether (1200 mL). After drying at 4O0C for 16 h, 1-[2-fluoro-4- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride salt (369.1 g) was obtained as a white solid in 57 mol % theoretical yield.
NMR (1 H, DMSO-d6, δ ppm): 9.64 (bs, 2H); 7.70 (dd, 1 H); 7.64 (t, 1 H); 7.58 (dd, 1 H); 3.62 (dd, 1 H); 3.50 (dd, 1H); 3.42 (d, 1 H); 3.35 (d, 1H); 2.24 (m, 1 H); 1.41 (t, 1 H); 1.15 (m, 1 H)
Preparation 123(4): (IS.SRH-p-fluoro^-ftrifluoromethyOphenyll-a-azabicyclo- [3.1.0]hexane salt of [(1 R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]- methanesulfonic acid
Figure imgf000136_0001
1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride salt obtained from Preparation 3 (369.0 g) was suspended in tert-butyl methyl ether (2950 ml) and treated with NaOH 1 N (1850 ml). The mixture was stirred for 15 minutes to achieve complete dissolution and then allowed to separate. The organic layer was washed twice with water (1850 ml) and then with 1850 ml of NaCI 10 % w/w solution. The organic layer was concentrated down to 1110 ml, diluted with more tert-butyl methyl ether (1850 ml) and distilled down to 1110 ml. The solution was diluted with acetonitrile (1850 ml) and distilled down again to 1110 ml. The resulting solution was diluted to 2960 ml and (-)-(R)-Camphorsulfonic acid was added (171.63 g). The exact amount of (-)-(R)-Camphorsulfonic acid was determined introducing a correction based on the assay w/w of the starting material.
Complete dissolution was observed followed after 30 minutes by precipitation. The slurry was aged for 22 hours at 200C under N2; then filtered and the cake washed with additional acetonitrile (740 ml). The collected solid was placed in the oven at 400C under reduced pressure for 18 h. 223.5 g of the title compound were obtained in a 35.8 % mol theoretical yield
1H NMR (DMSO-d6) ppm: 9.12 (br.s.; 2H); 7.72 (dd, 1H); 7.63 (t, 1H); 7.60 (m, 1 H); 3.67 (dd, 1 H); 3.56 (dd, 1 H); 3.47 (d, 1 H); 3.42 (d, 1 H); 2.90 (d, 1 H); 2.67 (m, 1 H); 2.41 (d, 1 H); 2.26 (m, 2H); 1.95 (t, 1 H); 1.87 (m, 1 H); 1.79 (d, 1 H); 1.30 (m, 3H); 1.19 (m, 1 H); 1.05 (s, 3H); 0.76 (s, 3H)
HPLC assay (short run): > 99% a/a
HPLC chiral 1 : enantiomeric excess (e.e.) > 80 %
(1 S,5R)-1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.Ojhexane tartrate
(1S,5f?)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane salt of[(1R,4S)- 7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid (310 g), prepared in an analogous way as described before in Preparation 123(4), was suspended in tert- butylmethyl ether (3.1 L) and treated with NaOH 1 N (1.55 L). After phase separation the organic layer was washed twice with water (1.55 L each) and then evaporated down to about 620 mL. Fresh tert-butylmethylether (620 mL) was added and the solution evaporated down again to 620 mL. After addition of DMF (0.93 L), the solution was evaporated down to about 0.93L. K2CO3 325 mesh (143 g), Kl (171 g) and 3-[(3- chloropropyl)thio]-4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazole (283 g) prepared in analogy with Preparation 123(1) were added at room temperature. The obtained suspension was then warmed at 62-63 0C for 5h and then cooled down to 200C. After dilution with ethyl acetate (1.55 L), water (1.55 L) was added and phases allowed separating. The organic layer was washed twice with water (775 mL each), diluted with further ethyl acetate (0.31 L), concentrated to 620 mL, diluted with additional ethyl acetate (620 mL) and evaporated down again to dryness. A portion of the so obtained yellow waxy solid (315g over a total of 330 g) was dissolved in acetone (2.30 L) and L-Tartaric Acid (93.3 g) was added at 20 0C. After 20 min water (74 mL) was added to dissolve completely the acid. Precipitation of a white solid immediately occurred. The mixture was stirred for 3h at 200C, then filtered and the cake washed with acetone/water 2/1 mixture (0.9 L). After drying under vacuum at 40°C for 2Oh, the title compound was obtained as an off-white solid (347 g) and 97.8% a/a typical purity by HPLC (short run).
NMR (1 H, DMSO-d6): 8.55 (s, 1 H), 7.61 (d, 1 H), 7.53 (m, 2H), 4.27 (s, 2H), 3.67 (s, 3H), 3.33 (d, 1 H), 3.19 (t, 2H), 3.13 (d, 1 H), 2.64 (t, 2H), 2.58 (dd, 1 H), 2.50 (m, 1 H), 2.37 (s, 3H), 1.94 (m, 1 H), 1.86 (m, 2H), 1.35 (t, 1 H), 0.82 (dd, 1 H). MS (m/z): 482[MH]+.
Example 124: Effect of acute administration of (1S,5R)-1-[2-Fluoro-4-(trifluoro- methyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3- yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride on sexual desire and consummatory behaviour in male rats
Background: In order to evaluate the effect on natural rewards and to potentially differentiate this approach compared with clinically active gold standards, the effect of the title compound (0.03, 0.3 and 3 mg/kg i.p.; -1 hour, prepared in an analogous way with Example 40) on sexual desire and consummatory performance was evaluated in the rat after acute administration. The effect of the title compound was assessed according to a Latin squared experimental design in male (about 30Og upon arrival) and female (25Og upon arrival) Wistar rats.
Method - Male rats, sexually experienced were treated with the title compound and submitted 1-hr later to a sexual incentive motivation test (10 minutes) in which male rats were singly exposed to receptive female and active male incentives (Agmo A., Journal of Comparative Psychology. 117(1 ), Mar 2003, 3-14). The following parameters were scored: (1 ) time spent in the incentive zones (close to the incentive cage); (2) number of visits to the zones, and (3) preference score (time spent in the sexual incentive zone / (time in the sexual incentive zone + time in the social incentive zone)). Immediately after the incentive motivation test each subject was transferred to an observation cage in the presence of a receptive female and its copulatory behaviour was then recorded until the end of the 1st post-ejaculatory interval. In the observation cage, the following behavioural parameters were recorded: (1) mount latency (time from the introduction of the female until the first mount with pelvic thrusting); (2) intromission latency (time from the introduction of the female until the first mount with vaginal penetration); (3) ejaculation latency (time from the 1st intromission until ejaculation); (4) post-ejaculatory interval (time from ejaculation until the following intromission); (5) number of mounts, and (6) number of intromission.
Results - Data are expressed as mean ± s.e.m.
Table 1- Effect of the title compound (0, 0.03, 0.3 and 3 mg/kg i.p. - 1 hour) on sexual incentive motivation of male rats
Figure imgf000138_0001
++p<0.01 ; receptive female vs. active male
Table 2- Effect of the title compound (0, 0.03, 0.3 and 3 mg/kg; i.p.. -1 hour) on male consummatory behaviour
Figure imgf000138_0002
p<0.05; "p<0.01 ; treatment vs. vehicle Conclusions - The title compound did not affect sexual desire of male rats when exposed to sexual and social stimuli. Interestingly a specific effect of the title compound was observed on ejaculation patterns as reflected by a significant increase in the number of mounts, ejaculation latency and post-ejaculatory interval.
Example 125: Effect of (1S,5R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4- methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo- [3.1.0]hexane tartrate on stress-induced food intake
Animal model for binge eating Dieting is the strongest predictor of overeating in response of stress. In this specific case, binge eating or binge/purge behaviours are recognized as key features of the human diseases (bulimia nervosa or anorexia, respectively). Two critical factors seem to modulate the production of binge eating: a history of food restriction and access of high palatable (HP) food (dense in fat and sugar) and the interaction with environmental stress. Based on these premises, preclinical models can be developed to explore the potential therapeutic effect of test compounds on binge eating. One model which may be used is described by Hagan et al (Hagan, M. M. et al., Physiol and Beh 77 (2002): 45-54).
Slight modifications such as those below may be applied to their model, for example:
• Instrument to deliver FS: Passive Avoidance (Gemini Avoidance System, Couboum Instrument , San Diego) may be used instead of the 4 closed runways with metal bar floors (Coulbourn Instruments Habitest System, Allentown, PA).
• Refeeding: 4 days instead of 6 days
• HP food: Baiocchi® (Barilla) instead of Oreo® biscuits
• For the submission of the animals to the pharmacological treatment, see: Placidi et al., lnt J Eat Disord 2004 36 (3) 328-41
Based on the model by Hagan et al, and incorporating the above changes, a model for binge eating may be set up as follows. Female Sprague Dawley rats (7 weeks old) can be single housed at 21 + 1 C and under a 12 h/12h light/dark cycle (dark phase: 18:00 - 06:00) for all the period of the experiment. Before beginning, rats can be habituated to these conditions for 7 days. The rats can then be divided into 2 groups (16 animals/group). One group may take food ad lib (non restricted group: NR) for the 24 days of the experiment, while the other (Restricted Group: R) may receive a restricted diet (66 % of the quantity food intake that the other control group was eating) during 4 days, and eat ad lib for the following 4 days. This cycle can be repeated 3 times. Following the last day of refeeding, each group can be subdivided in two. Eight animals of group NR and 8 animals of group R can receive a stress stimulus (4 Foot Shocks (FS) of 0.6 mA separated by 15 sec intervals) while the other 2 subgroups can remain in the same cage where FS is delivered for the same period of time, but without receiving the FS (no shocked: NS). The 4 groups are S/NR, NS/NR, S/R and NS/R. Immediately following time in the shock apparatus, rats can be submitted to a pharmacological treatment (administration of the test compound or of the vehicle) and then be returned to the animal colony. A pre-measured amount of pellets or HP food (Baiocchi®) can be put in each cage, and food intake measured after 4 h. Food intake can be expressed in kcal.
Other relevant pre-clinical models have been described by, for example, Hudson A. L., Man J., Willems R., Nutt D. J. and Ashton D., at the 28th Annual Meeting Canadian College of Neuropsychopharmacology, July 2-5, 2005, St John's, Newfoundland, Canada.
Rationale - The effects of the title compound, prepared in an analogous way with Example 123, were tested in the animal model discussed above. The aim of the present study was to assess the effect of this compound in animals that received 3 cycles of diet (restricted: R) and stress (shocked) conditions similar to binge eating in humans.
Methods - Female Sprague Dawley rats (7-week old) were single housed at 21 + 1 °C and under a 12 h/12h light/dark cycle (dark phase: 18:00 - 06:00) for all the entire experimental period. Rats received a restricted diet (66 % of the food intake vs. control group) during 4 days, and ate ad libitum for the following 4 days. This cycle was repeated 3 times. Additionally, two other groups were eating ad libitum (not restricted: NR) and received the shock (NR/S). Following the last day of refeeding, the animals received a stress stimulus (4 Foot Shocks (FS) of 0.6 mA separated by 15 sec intervals) and received vehicle or the title compound (0.03, 0.3 or 3 mg/kg i.p.) immediately after the shock. These were the S/R (shocked/Restricted) rats. The S/NR rats received the shock and vehicle or the title compound (prepared in an analogous way with Example 123; 3 mg/kg i.p.) in the same way as the S/R groups. Immediately following time spent in the shock apparatus, rats were returned to the animal colony. A pre-measured amount of Chow (pellets) or HP food (Baiocchi®) was put in each cage, and food intake was measured after 4 hrs.
Results -
Figure imgf000140_0001
Data analysis has been performed using a statistical program (Statistica, STASOFT) Analysis of the first 4 groups (S/R): there was a significant effect of the title compound on total Food Intake (1-way ANOVA (F(1 , 36)= 7.75; p = 0.008); the highest dose of 3 mg/kg significantly decreased total food intake.
There was a significant effect of the title compound on HP (ANOVA (F(1 , 36)= 11.6,p = 0.002); the highest dose of 3 mg/kg significantly decreased HP intake (Dunnett's: p < 0.01). There was a significant effect of the title compound on Chow (F(1 , 36)= 4.29, p = 0.04); the highest dose of 3 mg/kg significantly decreased chow Intake (Dunnett's, p < 0.05).
The compound did not show any inhibitory effect in non-stressed animals, in respect to controls.
Conclusion - The title compound produced a significant inhibitory effect on stress-induced overeating. No significant effects were observed in non-stressed animals.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims:

Claims

Claims
1. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof:
Figure imgf000142_0001
wherein:
G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, Dydroxyl, cyano, C1-4alkyl, haloC^alkyl, C1-4alkoxy, haloC1-4alkoxy, C^alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl;
R3 1 s C^alkyl;
R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 1 1-membered bicyclic group, any of which groups is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy,
C1-4alkanoyl;
R5 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N- pyrrolyl, 1 ,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2- pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, CiJtalkyl, halod^alkyl, C1.
4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1 , such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1 ; in the preparation of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the preparation of a medicament for the treatment of premature ejaculation.
2. Use of a compound of formula (I) according to claim 1 in the preparation of a medicament for the treatment of binge eating.
3. Use of a compound of formula (I) according to claim 1 in the preparation of a medicament for the treatment of premature ejaculation.
4. Use, according to claim 1, in which the compound of formula (I) is (1 S,5R)-1-[2- fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-
1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt or solvate thereof.
5. Use, according to claim 2, in which the compound of formula (I) is (1 S,5R)-1-[2- fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt or solvate thereof.
6. Use, according to claim 3, in which the compound of formula (I) is (1 S,5R)-1-[2- fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt or solvate thereof.
7. A method of treating a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal (e.g. human), comprising administering to a mammal in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof .
8. A method of treating binge eating in a mammal (e.g. human), comprising administering to a mammal in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof .
9. A method of treating premature ejaculation in a mammal (e.g. human), comprising administering to a mammal in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof .
10. A method of treating a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation, according to claim 7, in which the compound of formula (I) is ) is (1 S,5R)-1-[2- fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4/-/- 1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt or solvate thereof.
11. A method of treating binge eating, according to claim 8, in which the compound of formula (I) is ) is (1 S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4- methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt or solvate thereof.
12. A method of treating premature ejaculation, according to claim 9, in which the compound of formula (I) is ) is (1 S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-(3- {[4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4/-/-1 ,2,4-triazol-3-yl]thio}propyl)-3-aza- bicyclo[3.1.OJhexane or a pharmaceutically acceptable salt or solvate thereof.
13. A compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation.
14. A compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of binge eating.
15. A compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of premature ejaculation.
16. (1 S,5R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation.
17. (1 S,5R)-1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of binge eating.
18. (1 S,5R)-1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1 ,3-oxa- zol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of premature ejaculation.
PCT/EP2006/008314 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives WO2007022980A1 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
MX2008002564A MX2008002564A (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives.
EA200800655A EA016084B1 (en) 2005-08-22 2006-08-21 New use of azabicyclo hexane derivatives
BRPI0614929-4A BRPI0614929A2 (en) 2005-08-22 2006-08-21 use of azabicycloexane derivatives
DE602006020589T DE602006020589D1 (en) 2005-08-22 2006-08-21 USE OF AZABICYCLOHEXAN DERIVATIVES
EP06777058A EP1917013B1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives
JP2008527394A JP5166267B2 (en) 2005-08-22 2006-08-21 Use of azabicyclohexane derivatives
AT06777058T ATE500826T1 (en) 2005-08-22 2006-08-21 USE OF AZABICYCLOHEXANE DERIVATIVES
CN2006800389371A CN101291669B (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives
CA002620090A CA2620090A1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives
AU2006284077A AU2006284077B2 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives
US12/064,119 US20090036461A1 (en) 2005-08-22 2006-08-21 Use of Azabicyclo Hexane Derivatives
KR1020087006993A KR101363090B1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives
PE2007001117A PE20080609A1 (en) 2006-08-21 2007-08-17 1- [2-FLUORO-4- (TRIFLUOROMETIL) PHENYL] -3- (3 - {[4-METHYL-5- (4-METHYL-1,3-OXAZOL-5-IL) -4H-1, 2,4-TRIAZOL-3-IL] THIO} PROPYL) -3-AZABICYCLO [3.1.0] -HEXANE AS D3 MODULATORS
EA200970211A EA017917B1 (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives
TW096130644A TW200825074A (en) 2006-08-21 2007-08-20 Compounds
BRPI0716454-8A2A BRPI0716454A2 (en) 2006-08-21 2007-08-20 USE OF HEXAN AZABICYCLE DERIVATIVES
CL200702422A CL2007002422A1 (en) 2006-08-21 2007-08-20 TARTRATO 1- [2-FLUORO-4- (TRIFLUOROMETIL) PHENYLE] 3- (3 - {[4-METHYL-5- (4-METHYL-1,3-OXAZOL-5-IL) -4H-1,2 , 4-TRIAZOL-3-IL] TIO} PROPIL) -3-AZABICICLO [3,1,0] -HEXAN, SOLVATOS, HYDRATS AND CRYSTAL FORM; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND;
US11/841,015 US20080058398A1 (en) 2006-08-21 2007-08-20 Compounds
EP07788490A EP2054054A1 (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives
PCT/EP2007/058636 WO2008022994A1 (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives
KR1020097003484A KR101495362B1 (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives
CA002661437A CA2661437A1 (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives
MX2009001941A MX2009001941A (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives.
AU2007287527A AU2007287527B2 (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives
CN2007800392082A CN101528221B (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives
ARP070103715A AR062471A1 (en) 2006-08-21 2007-08-21 CRYSTAL SESQUIHYDRATE OF THE TARTRATE OF 1- [2-FLUORO-4- (TRIFLUOROMETIL) -3- (3 - {[4-METHYL-5- (4-METHYL-1, 3-OXAZOL-5-IL) -4H-1 , 2, 4-TRIAZOL-3-IL] TIO} PROPIL) -3-AZABICICLO [3.1.0] HEXANE (1S, 5R) or (2R, 3R), ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE MODU
ZA2008/01352A ZA200801352B (en) 2005-08-22 2008-02-08 Use of azabicyclo hexane derivatives
IL189435A IL189435A0 (en) 2005-08-22 2008-02-11 Use of azabicyclo hexane derivatives
NO20081314A NO20081314L (en) 2005-08-22 2008-03-12 Use of azabicyclohexane derivatives
ZA2009/00886A ZA200900886B (en) 2006-08-21 2009-02-06 Use of azabicyclo hexane derivatives
IL196976A IL196976A0 (en) 2006-08-21 2009-02-09 Use of azabicyclo hexane derivatives
CO09017330A CO6150139A2 (en) 2006-08-21 2009-02-20 TARTRATE SALT OF 1- [2- FLUORIDE-4- (TRIFLUOROMETIL) PHENYL] -3- (3 - {[4-METHYL-5- (4-METHYL-1,3 OXAZOL-5-IL) -4H-1 , 2,4-TRIAZOL-3 IL] UNCLE} PROPIL) -3-AZABICICLO [3.1.0] -HEXAN AND ITS SOLVATES, PHARMACEUTICAL FORMULATIONS, PROCEDURES FOR THEIR PREPARATION AND THEIR
NO20090834A NO20090834L (en) 2006-08-21 2009-02-23 Use of azabicyclohexane derivatives
CR10638A CR10638A (en) 2006-08-21 2009-02-25 USE OF HEXAN AZIBICICLO DERIVATIVES
MA31673A MA30672B1 (en) 2006-08-21 2009-02-27 USE OF AZABICYCLO HEXANE DERIVATIVES
US13/432,359 US20120196910A1 (en) 2005-08-22 2012-03-28 Use of azabicyclo hexane derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517193.9A GB0517193D0 (en) 2005-08-22 2005-08-22 Novel use
GB0517193.9 2005-08-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/432,359 Division US20120196910A1 (en) 2005-08-22 2012-03-28 Use of azabicyclo hexane derivatives

Publications (1)

Publication Number Publication Date
WO2007022980A1 true WO2007022980A1 (en) 2007-03-01

Family

ID=35098098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008314 WO2007022980A1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives

Country Status (20)

Country Link
US (2) US20090036461A1 (en)
EP (1) EP1917013B1 (en)
JP (1) JP5166267B2 (en)
KR (1) KR101363090B1 (en)
CN (1) CN101291669B (en)
AT (1) ATE500826T1 (en)
AU (1) AU2006284077B2 (en)
BR (1) BRPI0614929A2 (en)
CA (1) CA2620090A1 (en)
CR (1) CR9807A (en)
DE (1) DE602006020589D1 (en)
EA (1) EA016084B1 (en)
ES (1) ES2361933T3 (en)
GB (1) GB0517193D0 (en)
IL (1) IL189435A0 (en)
MA (1) MA29774B1 (en)
MX (1) MX2008002564A (en)
NO (1) NO20081314L (en)
WO (1) WO2007022980A1 (en)
ZA (1) ZA200801352B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1915146A2 (en) * 2005-07-27 2008-04-30 DOV Pharmaceutical, Inc. Novel 1-aryl-3-azabicycloý3.1.0¨hexanes: preparation and use to treat neuropsychiatric disorders
WO2008153937A3 (en) * 2007-06-06 2009-02-19 Dov Pharmaceutical Inc Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US7838680B2 (en) 2006-04-03 2010-11-23 Glaxo Group Limited Process for preparing heterocyclic derivatives
WO2010150281A3 (en) * 2009-06-26 2011-04-21 Panacea Biotec Ltd. Novel azabicyclohexanes
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
AU2007287527B2 (en) * 2006-08-21 2013-01-31 Glaxo Group Limited Use of azabicyclo hexane derivatives
US8765801B2 (en) 2004-08-18 2014-07-01 Euthymics Bioscience, Inc. Polymorphs of azabicyclohexane
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9527813B2 (en) 2006-04-28 2016-12-27 Euthymics Bioscience, Inc. Process for the synthesis of (+) and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
US12042481B2 (en) 2011-07-30 2024-07-23 Otsuka America Pharmaceutical, Inc. Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070922B1 (en) * 2004-02-23 2011-08-17 Glaxo Group Limited Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
US7807698B2 (en) * 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
DE602006018152D1 (en) * 2005-08-22 2010-12-23 Glaxo Group Ltd TRIAZONE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
DE602007012531D1 (en) * 2006-04-03 2011-03-31 Glaxo Group Ltd AZABICYCLOA3.1.0 OXIDE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
US8222266B2 (en) * 2006-04-03 2012-07-17 Glaxo Group Limited Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors
WO2012033956A1 (en) * 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9314600B2 (en) 2012-04-15 2016-04-19 Bioconnect Systems, Inc. Delivery system for implantable flow connector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080832A1 (en) * 2004-02-24 2005-09-01 Kongsberg Automotive As Gearshift transmission

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
EP2070922B1 (en) * 2004-02-23 2011-08-17 Glaxo Group Limited Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors
JP5049134B2 (en) * 2004-12-02 2012-10-17 アボット ゲーエムベーハー ウント カンパニー カーゲー Triazole compounds suitable for the treatment of disorders responsive to modulation of dopamine D3 receptors
GB0507601D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
US7807698B2 (en) * 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
DE602006018152D1 (en) * 2005-08-22 2010-12-23 Glaxo Group Ltd TRIAZONE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
US7727988B2 (en) * 2006-04-03 2010-06-01 Glaxo Group Limited Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080832A1 (en) * 2004-02-24 2005-09-01 Kongsberg Automotive As Gearshift transmission

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770436B2 (en) 2004-08-18 2017-09-26 Euthymics Bioscience, Inc. Polymorphs of azabicyclohexane
US9139521B2 (en) 2004-08-18 2015-09-22 Euthymics Bioscience, Inc. Polymorphs of azabicyclohexane
US8765801B2 (en) 2004-08-18 2014-07-01 Euthymics Bioscience, Inc. Polymorphs of azabicyclohexane
US9737506B2 (en) 2005-07-27 2017-08-22 Neurovance, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
EP1915146A2 (en) * 2005-07-27 2008-04-30 DOV Pharmaceutical, Inc. Novel 1-aryl-3-azabicycloý3.1.0¨hexanes: preparation and use to treat neuropsychiatric disorders
US9205074B2 (en) 2005-07-27 2015-12-08 Neurovance, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
EP1915146A4 (en) * 2005-07-27 2010-06-02 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US8877798B2 (en) 2005-07-27 2014-11-04 Neurovance, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US10039746B2 (en) 2005-07-27 2018-08-07 Otsuka America Pharmaceutical, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US7838680B2 (en) 2006-04-03 2010-11-23 Glaxo Group Limited Process for preparing heterocyclic derivatives
US9527813B2 (en) 2006-04-28 2016-12-27 Euthymics Bioscience, Inc. Process for the synthesis of (+) and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
AU2007287527B2 (en) * 2006-08-21 2013-01-31 Glaxo Group Limited Use of azabicyclo hexane derivatives
CN101528221B (en) * 2006-08-21 2013-05-08 葛兰素集团有限公司 Use of azabicyclo hexane derivatives
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9597315B2 (en) 2007-06-06 2017-03-21 Euthymics Bioscience, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2008153937A3 (en) * 2007-06-06 2009-02-19 Dov Pharmaceutical Inc Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
CN102803224A (en) * 2009-06-26 2012-11-28 万能药生物有限公司 Novel azabicyclohexanes
WO2010150281A3 (en) * 2009-06-26 2011-04-21 Panacea Biotec Ltd. Novel azabicyclohexanes
US12042481B2 (en) 2011-07-30 2024-07-23 Otsuka America Pharmaceutical, Inc. Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect

Also Published As

Publication number Publication date
KR101363090B1 (en) 2014-02-13
BRPI0614929A2 (en) 2011-04-19
ATE500826T1 (en) 2011-03-15
CR9807A (en) 2008-07-29
CN101291669A (en) 2008-10-22
KR20080040022A (en) 2008-05-07
EA200800655A1 (en) 2008-08-29
ES2361933T3 (en) 2011-06-24
MX2008002564A (en) 2008-03-18
JP2009506989A (en) 2009-02-19
NO20081314L (en) 2008-03-17
US20090036461A1 (en) 2009-02-05
CA2620090A1 (en) 2007-03-01
DE602006020589D1 (en) 2011-04-21
JP5166267B2 (en) 2013-03-21
EA016084B1 (en) 2012-02-28
ZA200801352B (en) 2009-01-28
IL189435A0 (en) 2008-08-07
EP1917013A1 (en) 2008-05-07
AU2006284077B2 (en) 2012-05-17
AU2006284077A1 (en) 2007-03-01
CN101291669B (en) 2012-09-26
US20120196910A1 (en) 2012-08-02
EP1917013B1 (en) 2011-03-09
MA29774B1 (en) 2008-09-01
GB0517193D0 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
AU2006284077B2 (en) Use of azabicyclo hexane derivatives
CN105407888B (en) New bicyclic bromine structural domain inhibitor
CN105492439B (en) Substituted dicyclic compound as bromine structural domain inhibitor
CN102834393B (en) Apoptosis signal-regulating kinase 1 inhibitors
AU2005215918B2 (en) Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors
JP5832524B2 (en) Pyridone and azapyridone compounds and methods for their use
RU2665036C2 (en) Heteroaromatic compounds as phosphatidylinositol 3-kinase modulators and methods of use
JP6162130B2 (en) Heterocyclic compounds and modulators thereof as modulators of type III receptor tyrosine kinases
RU2672910C2 (en) Heteroaromatic compounds as phosphatidylinositol 3-kinase modulators
TW201036958A (en) Pyridazinone compounds
JP2017527604A (en) sGC stimulant
TW201306842A (en) Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of PI3K/MTOR with bendamustine and/or rituximab
MXPA02009817A (en) A pharmaceutical composition for treatment of acute, chronic pain and or neuropathic pain and migraines.
TW201024297A (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
JP2012521428A (en) P2X3 receptor antagonist for the treatment of pain
AU2013331070A1 (en) Treating polycystic kidney disease with HSP90 inhibitory compounds
KR20210003764A (en) Imidazopiperazine inhibitors of transcription-activated proteins
AU2002247059A1 (en) Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
EP1363993A2 (en) METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)
CN116615430A (en) Heterocyclic GLP-1 agonists
CZ2004524A3 (en) Agonists of nicotine acetylcholine receptor useful for the treatment of restless legs
EP4183415A1 (en) Trpv4 inhibitor as therapeutic drug for eye disease
RU2258506C2 (en) Medicinal agents used for prophylaxis and treatment of neurodegenerative diseases
CN116368140A (en) Heterocyclic GLP-1 agonists
JP2000344667A (en) Combination therapy for treating migraine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680038937.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 565784

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12008500369

Country of ref document: PH

Ref document number: 189435

Country of ref document: IL

Ref document number: 2006777058

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1195/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006284077

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008020296

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2620090

Country of ref document: CA

Ref document number: 2008527394

Country of ref document: JP

Ref document number: 08018676

Country of ref document: CO

Ref document number: MX/a/2008/002564

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2008-009807

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: DZP2008000174

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2006284077

Country of ref document: AU

Date of ref document: 20060821

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006284077

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200800655

Country of ref document: EA

Ref document number: 1020087006993

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2006777058

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12064119

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0614929

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080220